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Introduction
The intestine is equipped with villi and crypts to harbour the entire 300 
square meters of epithelium in just 8 meters of GI tract. Gastro- and intestinal 
epithelial cells (IEC) form a single cell layer covering the gastrointestinal 
tract (GI tract). These cells have the important and difficult task to protect 
the host from harmful luminal content while enabling the uptake of nutrients 
and water. One way the IEC deal with this dual task is to have IEC witch are 
specialized for certain task; e.g. Goblet cells that produce mucus, Paneth cells 
producing defensins, enterocytes that absorb water and nutrients, and the 
enteroendocrine cells that produce hormones. At a molecular level intracellular 
receptors, membrane bound transporters, and degradation enzymes play an 
additional but very important role in host-protection mechanisms1. 
Inflammatory bowel disease
Inflammatory bowel disease (IBD) has two major distinct phenotypes: 
Crohn’s disease (CD) and ulcerative colitis (UC). CD is characterized by 
trans-mural and patchy inflammation that can occur the entire GI tract but 
mostly involves the terminal ileum and colon, while UC is characterized by 
superficial inflammation involving the large bowel only. Colorectal cancer 
(CRC) is a serious and life-threatening complication of longstanding IBD 
with a poor prognosis compared to sporadic CRC. This is demonstrated by 
the fact that, although IBD-associated-CRC represents on 1-2% of all CRC, it 
account for 15% of all CRC-related deaths2, 3. 
IBD is a multifactorial disease in which the onset of disease and also 
the progression to IBD related CRC is determined by the interplay of 
multiple factors such as, genetics, the microbiome, immunity, and unfavorable 
environmental triggers4. All these factors partly but often directly affect the 
IEC function. As such, the IEC play a crucial role in the gut homeostasis and 
the deregulation as seen in IBD (Chapter II Figure 1B). 
Immunity and IEC
In this thesis we focus in particular on the NF-kB signaling pathway, 
which is one of the key regulators in innate immune responses. Reduced 
mucus production reduces the IEC-barrier function, allowing pathogens 
and commensal microbe to directly contact the IEC. Subsequently, bacterial 
components are able to reach and membrane receptors such as the Toll Like 
Receptors (TLR’s), which activate the NF-kB signaling pathway. Two decades 
ago NF-kB was discovered as an enhancer-binding protein5, now known as 
the classical (canonical) NF-kB signaling pathway. Once activated, NF-kB 
is able to translocate to the nucleus, where it binds DNA and subsequently 
activates gene expression6. Recently a second NF-kB signaling pathway or so 
called alternative or non-canonical NF-kB signaling pathway was described7. 
The classical NF-kB pathway is activated by different receptors such as TLR’s, 
TNF-R, Interleukin receptors and even UV light8. The triggered receptors 
are activating the IkB kinase (IKK) complex. The most common form of this 
complex consists of IKKa and IKKb catalytic subunits where IKKg is the 
regulatory (NEMO) subunit of the IKK complex. Active IKK phosphorylates 
the NF-kB inhibitory complex IkB. Phosphorylated IkB is detached form 
the NF-kB complex, ubiquitinated, and proteosomal degraded. Tumour 
necrosis ligand superfamily members like lymphotoxins, B-cell activating 
factors (BAFF) and RANKL activate the alternative pathway. Ligand-bound 
receptors activate a specific IKKa homodimer complex that partly degrades 
p100 till the P52 subunit is formed. P52 then binds RelB and translocate 
to the nucleus to induce gene transcription7 (reviewed in9). Both signalling 
pathways induce transcription of genes involved in IBD i.e. IL-6, IL-8 IL-
1b, IL-10, TNFa, ICAM and ELC. The effect of several drugs used for IBD 
medications may exert their effects via the inhibitory effect on the NF-kB 
pathway10. 
Xenobiotic pathways in IEC 
IEC utilize advanced molecular mechanisms to maintain the host integrity 
to face toxic compound (xenobiotics) challenges. Appropriate cellular-
responses to xenobiotic stress are coordinated through a specific subfamily 
of the steroid-thyroid superfamily of nuclear hormone receptors (NR). Upon 
ligand specific binding to the receptor, the NR homo- or heterodimerizes 
with another NR-family member. Thereafter a pro-transcription factor 
forms, that by virtue loss of hsp90 binding exposes the nuclear localization 
signal to the cytoplasmic machinery leading to nuclear translocation11. In 
the nucleus, the complex binds to specific palindromic promoter regions and 
directs transcription of genes involved in executing the appropriate response 
to the xenobiotic challenge. A large number of nuclear hormone receptors 
appears to be involved in orchestrating the transcriptional response to IEC 
xenobiotic challenges, including the Pregnane X Receptor (PXR/ SXR/ 
NR2L1), Farnesoid X Receptor (FXR/ NR1H4), the Vitamin D Receptor 
(VDR/ NR1L1), the Constitutive Androstane Receptor (CAR) and the 
Retinoid X Receptor (RXR/ NR2B2), and there is clear evidence that PXR 
is a master xenobiotic sensor12.  
NR activation induces transcription of xenobiotic degradation enzymes 
such as the Cytochrome p450 (CYP) superfamily and membrane xenobiotic 
transporters such as the ABC transporters. Degradation enzymes such 
as CYP3a4 and Sult1a are neutralizing the xenobiotics by oxidation13. 
Whereupon transporters such as, ABCG2 (BCRP, breast cancer resistant 
protein), MDR1 (multi drug resistant protein) and BSEP (bile salt excretion 
pump), export the xenobiotics out of the cell and back into the gut lumen14. 
Proper cellular responses to toxic insults go beyond the simple induction of 
detoxification enzymes15 and also include the inhibition of pathways associated 
with further damage (e.g. the generation of reactive oxygen species) and the 
facilitation of regenerative responses to repair tissue damage. A reflection 
of these processes can be found in the thought that activation of PXR 
down-regulates the transcriptional activity of NF-kB and thereby reduces 
intestinal inflammation16-19. By contrast, these detoxification pathways are 
down regulated in patients with active IBD20-23. Giving rise to the thought 
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that this is a mutual interaction between the xenobiotic and NF-kB signalling 
pathways16. To go even further, there is also contradictory literature about 
the function of PXR in intestinal cancer cell proliferation and apoptosis24-26. 
In conclusion, the function of the xenobiotic pathways goes far beyond their 
detoxification properties and includes controlling inflammatory reactions, 
and cell growth and apoptosis. 
Genetics and endoplasmic reticulum stress in IEC
In general, membrane-bound and secreted proteins undergo a folding 
quality check before they are released from the endoplasmic reticulum (ER). 
Un- or misfolded proteins are extracted from the ER and degraded. This 
process is called ER-associated degradation (ERAD). Engulfing a part of the 
ER (autophagy) is an element of the ERAD. However, when unfolded proteins 
accumulate inside the ER the unfolded protein response (UPR) is activated. 
Upon UPR three major ER stress pathways are activated, IRE1, PERK and 
ATF6 (Figure 1). All three proximal UPR effectors start transcription of 
genes that are involved in reducing the unfolded protein load in the ER, e.g. 
ERAD. The mechanism of these three pathways were described previously27. 
Intestinal inflammation is associated with difficulties in ER-dependent 
protein folding (ER stress)22, 28-31. However, the question whether uncontrolled 
ER stress leads to active IBD or whether active IBD leads to ER stress still 
remains unanswered. A possible explanation for the ER stress in IBD can 
be found in genome wide associated studies (GWAS)32. Identifying single 
nucleotide polymorphisms (SNPs) associated with an increased risk for 
developing IBD largely uncovered the genetic basis of IBD. Outcome of this 
research revealed in more than 99 possibly involved genetic variations in the 
human genome related to IBD33-35. A distinct group of IBD associated SNP 
is found in genes involved in the ER stress (XBP128) and ERAD (NOD236, 
37, ATG16L138, IRGM39, ) pathways. Functional studies are majorly lacking, 
but it can be assumed that IBD can originate in an ER associated genetic 
susceptible host. Other inflammation related factors that can impede the ER 
dependent protein folding are discussed in this thesis. 
Figure 1: Schematic overview of ER stress pathway. Upon accumulation of unfolded proteins inside 
the ER the chaperone GRP78 is detached from the signal molecules, e.g. ATF6, Ire1, and PERK, to assist 
the protein folding. Detachment activates these signal molecules, which initiate ER stress associated 
pathways to overcome the excessive protein load. 
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Aim and Thesis outline
The mucosal inflammation in patients with IBD originates from an 
overactive immune response against the (commensal) luminal bacteria with the 
IEC in a crucial position between these interactions. Moreover, the question 
whether dysfunctions in IEC can lead to IBD or whether IBD provokes IEC 
dysfunction is still unanswered. In this thesis we aim to discuss the function 
of IEC on the IBD aetiology by investigating multiple molecular pathways, 
protein folding difficulties, neoplastic progression and genetic associations in 
IBD. 
The importance of IEC in the IBD disease aetiology is pointed out 
in Chapter II. In this chapter we will summarise recent literature on the 
cellular implication of IEC in the multifactorial IBD pathogenesis. We want 
to emphasize the importance of IEC on disease-associated mediators and the 
possibility to improve IEC functioning as therapy for IBD patients. 
In Chapter III we hypothesised that the activation of PXR inhibits NF-
kB activity, to implicate a possible novel therapeutic approach. We tested this 
hypothesis by activating PXR in freshly isolated human biopsies, and further 
exploring the mechanism of action using PXR specific knock down cell lines. 
In Chapter IV we emphasized on the role of PXR in intestinal cancer 
cells as inhibitor of cell growth and cell survival by measuring the intestinal 
PXR expression in (non-)IBD related CRC, and investigating the role of PXR 
expression on the growth of intestinal cancer cells. 
In Chapter V we will discuss the possible effect of locally produced ROS 
on ER-depending protein folding, in IBD patients with active inflammation. 
This concept will be further investigated in Chapter VI measuring the 
ABCG2 expression in biopsies from IBD patients and their functionality 
using in vitro cell line experiments. 
Several IBD related SNPs are found in the ER stress or autophagy 
pathways, however experimental evidence for a possible causal relation is still 
lacking. In Chapter VII we explored the functional effect of these SNPs on 
high-secretory IEC, such as Paneth cells.
Innate immune activation is accompanied with the production of ROS. 
As a result of the dramatic effect of ER depending proteins upon excessive 
ROS production (Chapter V and VI) we investigated the consequence of 
a mutation in the NCF4 gene on the ROS production in our final chapter 
(Chapter VIII). 
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Abstract
The epithelial layer of our intestines must meet two opposing 
requirements. On one hand it must allow for efficient uptake of nutrients 
and fluids, on the other hand it is a vital defence barrier between the milieu 
interior and the milieu exterior. Different from the lung that by virtue of 
cilia movement is kept virtually sterile, the gut epithelium is confronted by 
a stupendous microbiological load and a substantial xenobiotic challenge. 
The efficiency by which our intestinal epithelium manages to deal with the 
challenge of efficient nutrient absorption while simultaneously fulfilling its 
barrier function is testimony to what the forces of evolution can accomplish. 
Importantly, our understanding as to how our gut epithelial compartment 
manages this balancing act is now rapidly emerging, answering one of the 
oldest questions in cell biology. Importantly, when aberrations in this balance 
occur, for instance as a consequence genetic polymorphisms, increased 
propensity to develop chronic inflammation and inflammatory bowel disease 
is the result. Thus the knowledge on intestinal cell biology and biochemistry 
is not only of academic interest but may also aid design of novel avenues for 
the rational treatment of mucosal disease.
Introduction
A single cell layer of intestinal epithelial cells (IEC) is the first line of 
defence against the luminal content and the host. IEC are challenged by 
the complex task of on the one hand to adsorb water and nutrients from the 
lumen but on the other hand to protect the host from pathogenic microbes 
and toxic compounds. To deal with this challenge, the cells are equipped 
with sophisticated protection mechanisms (Figure 1A). Inflammatory bowel 
disease (IBD) is a chronic inflammatory disorder affecting the gastrointestinal 
tract with an apparently ever-increasing incidence and tendency to more 
severe clinical phenotypes. The disease is characterised by an exaggerated 
immune response to the luminal flora, suggesting that deficiencies in barrier 
function of intestinal flora may be involved, and recent studies support this 
notion1-4. IBD can be classified into two main groups, Crohn’s disease (CD) 
and ulcerative colitis (UC). CD patients can have inflammatory lesions in 
their entire gastrointestinal tract, whereas the inflammation in UC patients 
is restricted to the colon. Apart from the misery inflicted by the life-long 
chronic intestinal inflammation, patients with long-standing IBD are also 
substantially at risk for developing colorectal cancer. In the case of UC in 
combination with primary sclerosing cholangitis the risk for developing 
colorectal cancer approaches that 100 times as high as the risk for developing 
colon cancer in the population at large. In addition, IBD related cancers 
account for 15% of all the intestinal cancer-related deaths5, 6. The prevailing 
view is that defective IEC function in IBD has a multi-factorial background 
and involves the interplay between genetics, microbiome, immunity and 
environmental triggers (Figure 1B). In this review we shall attempt to link 
these factors to IEC cellular physiology.
The single cell layer: intestinal epithelium
Although the IEC compartment constitutes a single layer of cells, a fair 
number of different specialised cell types can be discerned including the 
crypt-located stem cells that bear the proliferative burden associated with the 
constant cell renewal in the intestinal epithelium; goblet cells that produce 
mucus which has a protective function with respect to the mechanical, 
xenobiotic and also microbiological load to which this compartment is 
exposed; crypt-restricted paneth cells that produce anti-microbial defensins 
and trophic factors and protect and nurture the stem cells; enterocytes 
that mediate the absorption of water and nutrients and constitute the most 
abundant cell type in this compartment, M cells that execute specialised 
tolerogenic antigen-presenting functions to prevent intestinal inflammation 
and enteroendocrine cells which produce and secrete a variety of hormones 
and bioactive peptides (schematic overview of small intestinal specialised IEC 
see Figure 2). The morphogenetic processes, which involve amongst others 
the concerted action of Wnt, Notch, FGF, Hedgehog and BMP pathways 
that maintain homeostasis of histology in this organ have now to a large 
extent be delineated7. The resulting epithelial surface forms an impregnable 
barrier for the in potential harmful luminal intestinal content. The various 
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Figure 1: Schematic overview of the intestinal epithelial cells and their function by inflammatory 
bowel disease. 
A) Three at a subsequent simplified schemes that increase in magnification from intestinal organ to 
intestinal epithelial cell. The upper left corner is a cross section of the intestine with the luminal and 
mucosal side indicated. The enlarged section beneath schematically indicates a crypt villus structure 
as can be found in the small intestine. The bacteria and other luminal content are separated from the 
intestinal epithelial cells by the mucus layer. The intestinal wall is covered with a layer of intestinal 
epithelial cells, indicated in the enlarged section on the right side. 
B) The involvement of intestinal epithelial cells in the inflammatory bowel disease aetiology. 
Inflammatory bowel disease is a multi factorial disease that includes four main contributors. As such 
an overaggressive immune response against the commensal bacteria in a genetic susceptible host with 
favourable environmental factors is needed to give onset to the disease. Important mediators between 
these four factors are intestinal epithelial cells. The arrows indicate the causal relationship between 
these factors. The genetic background of a patient can modulate the microbial composition and the 
outcome of the host immune response. At the same time, the host environment can also modulates 
these factors, irrespective of genetic background. Whereas the mucosal inflammation and the bacterial 
composition are counter interactive. IEC = intestinal epithelial cell, IBD = inflammatory bowel disease. 
C) Hampered intestinal epithelial cell function in patients with active inflammatory bowel disease. 
This scheme emphasises the dramatic changes in the intestinal epithelial cell function during active 
inflammatory bowel disease. Basically all cellular functions are impeded during an inflammatory insult, 
which also decreases the basic function of the intestine such as nutrient and water absorption. 
components involve from the luminal side, a thick mucus layer made up from 
heavy glycosylated mucins excreted by the goblet cells which prevents many 
luminal microbes to IEC, although other bacterial species actually find their 
ecological habitat in this layer protein and sugar rich layer (e.g. Akkermansia 
muciniphila)8. In evolutionary adaptation, goblet cells continuously produce 
new mucus. The mucus layer also operates as a lubricant so that, together 
with the peristaltic movement of the bowel, the luminal content including the 
microbes are transported trough the intestinal tract9. Secondly, the Paneth 
cells produce and secrete defensins and lysozyme to prevent the invasion of 
the microbes into the mucus layer2. However, their spatial restriction to the 
crypt base suggests that they mainly function to protect the stem cells from 
bacterium-induced genotoxic damage, a view supported by the production of 
indispensable trophic factors for the intestinal stem cells by the Paneth cell 
compartment, suggesting that their main function is in the support of stem 
cells rather as in the control of microbiological challenge to the epithelial 
layer10. The IEC compartment in toto forms a non-penetrable layer of cells by 
generating cell-to-cell tight-junctions independent of the various cell types 
present11. This barrier is tight enough for active ion-transport to generate an 
electrolyte potential between the mucosa and the lumen. This subsequent ion 
flux is needed to absorb water from the intestinal lumen into the mucosa12. 
Deregulation in this system lead to diarrhoea and in the worst cases to 
dehydration13. In addition, the IEC are equipped with pathogen receptors that 
mediate immune responses once other barriers fail to repel invading bacteria15, 
16.  Many of the risk genes for IBD are involved in IEC defence against the 
luminal microbiological onslaught, examples will be discussed later in this 
review, but it has not been demonstrated convincingly demonstrated that the 
polymorphisms involved are directly linked to reduced intestinal immunity. 
Next to the microbes, another major challenge to the IEC are the toxic 
compounds present in the intestinal lumen, which include secondary bile 
acids, food derived toxic compounds, and toxins produced by microbes. These 
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Figure 2: Schematic overview of 
different specialised IEC in the small 
intestine
Schematic overview of specialised 
IEC present in the small intestine. 
The intestinal epithelium forms an 
impregnable barrier for bacteria and 
toxins where water and nutrients are 
taken up. The small intestine consists 
of villi that point towards the lumen 
and crypts that are surrounded by the 
mucosa. The Paneth cells are located 
at the crypt base, which produce 
antimicrobial peptides, lysozyme and 
indispensable growth factors for its 
companying stem cells. Stem cells 
together with the trans amplifying cells 
are responsible for the regeneration 
of the entire intestinal epithelium 
layer every five to six days. Death and 
redundant cells are shed on the top of the villi where newborn cells arise from the crypt base. Goblet cells, 
M cells and enterocytes can be found throughout the crypt and villi. Goblet cells continuously produce 
mucus as lubricant for the bowel movements and to prevent direct contact of the luminal microbes 
to the epithelium. M cells are the main intestinal hormone producers and important mediators in the 
adaptive immune system, because these cells can present microbial antigens to activate leukocytes. 
Enterocytes mainly absorb water and nutrients from the lumen.  
non-host produced toxins are called xenobiotics. IEC adapt their physiology 
to the level of xenobiotic stress to which they are exposed. The first step in 
this response the recognition of the xenobiotics is their detection by a nuclear 
receptor (NR) family member17. Important NRs in IEC are the Pregnane X 
receptor (PXR/ SXR/ NR2L1), the Farnesoid X receptor (FXR/ NR1H4), 
the Vitamin D receptor (VDR/ NR1L1), the constitutive androstane receptor 
(CAR), the Retinoid X receptor (RXR/ NR2B2) and the Hepatocyte Nuclear 
Factor 4 a (HNF4a/ NR2A21)18. Each receptor has its own specific (xenobiotic) 
ligands. Once activated, the NR dimerise and translocate to the nucleus and 
initiate gene expression of degradation enzymes and membrane transporters. 
Xenobiotic-degrading enzymes such as, the cytochrome P450 family, 
neutralise xenobiotics via oxidation19. Membrane bound transporters such as, 
ABCG2, MDR1 and BSEP, export the xenobiotics out of the cell back into the 
lumen20. It is known that the xenobiotic clearing system is impaired during 
active intestinal inflammation21-23 (Figure 1C). Thus overall, the intestinal 
epithelium has specialised cells and molecular intracellular mechanisms to 
protect the host from potential harmful luminal content (Figure 1), but this 
system dramatically disturbed during active mucosal inflammation. 
1: IEC and genetics in IBD
Genome-wide associated studies (GWAS) found more than 163 genomic 
loci that are associated with IBD, 90 with CD, 73 with UC, and 110 for both 
diseases1, 24, 25. These single nucleotide polymorphisms (SNPs) are located 
throughout the entire human genome. An important milestone in IBD genetics 
was the discovery of rare mutations (SNPs) in the NOD2 receptor26, 27. By 
using classical linkage analysis technique, these authors described in 1996 the 
first genetic variants that are associated with a higher susceptibility to CD, in 
casu the NOD2 gene. NOD2 is an intracellular pattern recognition receptor 
that can detect intracellular microbial compounds and activates an immune 
response26, 27. The discovery that genetic variants of this receptor predispose 
to IBD thus provided a first rational explanation for the observation that 
IBD involves an interaction of immunological, microbiological and genetic 
factors. Functional studies reveal that mutations in NOD2 have functional 
consequences for Paneth cells28, reduced Toll like receptor (TLR) signalling29, 
and impaired ability to trigger autophagy30, 31 and thus a link between genetic 
background and reduced immune functionality in the IEC compartment is 
now firmly established. 
More recent, large GWA studies have and still do identify an increasing 
number of distinct susceptibility loci in the genome that are associated with 
IBD and IEC function1, 32. Thus far, only a small percentage of all SNPs 
associated with IBD are linked to a clear functional or clinical phenotype, 
but those that do manifest their influence on physiology largely in the 
IEC compartment. For example, a mutation in ATG16L1 (rs22441880) 
revealed a clear phenotype in Paneth cells of patients with Crohn’s disease33 
and (Deuring et al. manuscript in preparation). In addition, a rare variant 
in the XBP1 gene is associated with increased susceptibility for IBD. IEC 
specific XBP1 knock out mice have spontaneous ileitis due to malfunctioning 
endoplasmic reticulum (ER) stress signal pathways34 in the secretory lineages 
of the IEC compartment. Also various other genetic variations in or near 
genes with a link to IEC functionality are associated with IBD such as, IL-
10, IL-23R, JAK2, DNMT3a, NDFIP1, and FADS224, 25. Thus the genetics 
of IBD suggests that the hereditary component of this disease is at least to a 
certain extent due to innate deficiencies in IEC functionality. 
Interestingly, genetics does not only point to a role of IEC microbial 
immunity in the development of IBD by also to genes involved in IEC defence 
against xenotoxic challenge are linked to increased propensity to contract this 
disease. Especially various SNPs in NR genes are linked to IBD, including 
the FXR35, HNF4a36, the PXR37 and the LXR38.  However, although these 
findings further focus attention on the IEC compartment as the structure 
that manifests hereditary susceptibility to contracting IBD, in the absence 
of the functional work it is difficult to make definitive statements. A further 
complicating factor here is that the constant increase in loci mediating 
susceptibility to IBD makes selecting worthwhile avenues for functional 
studies more difficult.
2: IEC and gut micro flora in IBD
The intestinal tract is loaded with bacteria, which are indispensable for a 
normal gut homeostasis39. Misbalance in the intestinal bacterial composition 
is associated with IBD40, 41. Directly after birth the young sterile intestine is 
colonised by bacteria. The mucosa has together with the IEC become tolerant 
against the commensal microbes where possible pathogens need to be 
eliminated. The establishment of the micro flora is essential for a normal IEC 
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development and homeostatic gut mucosa42-44. In the first few years of life the 
gut microbiome composition is highly dynamic due to major changes in diet45, 
46. It is generally assumed that gut microbial ecosystems show wild swings 
depending on diet and other life style factors47, 48, although individual-specific 
core elements of microbial composition are evidently present as well. It has 
been suggested that a  ‘Western’ micro-flora also resulting from a ‘Western’ 
diet might underlie the increasing incidence of IBD in the western countries47. 
Also in the Western world, however, local diets vary wildly and in general IBD 
appears more correlated with wealth per se rather as cultural background and 
thus it remains uncertain to which extent diet-induced changes in microbiota 
are implicated in the increasing incidence of IBD. Hampering investigations 
in this area is that gut microbes are mostly anaerobic bacteria that are 
challenging to cultivate in vitro, making it problematic to profile the entire 
gut microbiome. Over the past decade, high throughput 16s rRNA sequencing 
now allows researchers to assess complex microbiome compositions49. Much 
effort is put on finding potential pathogens that may provoke flares or 
disease onset in IBD patients50-52. Until now no distinct pathogen or group 
of pathogens has been found52, leading to speculation that the IBD should be 
considered primarily an overactive immune response against the commensal 
micro-flora50. Indeed, viral infection of the IEC compartment may actually 
be more important in developing chronic mucosal disease as compared to 
the microbial challenge:  mice with humanised T300A ATG16L1 expression, 
an important gene in the autophagic process and an important locus in the 
genetic risk factors for contracting IBD, are more prone to developing CD-
like colitic symptoms, but exclusively in the presence of Noroviral infection53. 
As a consequence, next to microbiome profiling, investigation of the virome 
possibly associated with IBD is now taking off 54.  
The first line of defence against microbiological and viral challenge is 
the mucus layer, as discussed before. This layer is imbued with antimicrobial 
peptides produced by Paneth (crypts of the small intestine only) and Goblet 
cells. When microorganisms overcome this barrier, specific transcriptional 
responses in the IEC compartment help to repel the possible breach of the 
integrity of the milieu interior-protecting barrier. Especially TLR-mediated 
NF-kB activation is important for mediating transcriptional responses after 
detection such threats, but other receptors (especially NODs) are important 
in this respect as well. An integral component of the barrier are the tight 
junctions between the IECs11 and diminished tight junctional functionality 
is a strong trigger for fulminant mucosal immunity. As tight barrier 
functionality is compromised in IBD patients55 an genetic or environmental 
deficiency in tight junctional barrier formation may contribute to IBD, but as 
inflammation per se is associated with reduced tight junction function cause 
and effect is difficult to distinguish.
Next to the microbes themselves, these organisms can also produce 
metabolites that harm the IEC. Microbes digest the food components and 
primary bile acids, which are present in the gut lumen. The human liver cells 
originally produce two types of primary bile acids namely cholic acid and 
chenodeoxycholic acid from cholesterol. The bile acids are secreted in the 
intestine where after bacteria dehydroxylate a portion of these two bile acids 
to deoxycholic acid and lithocholic acid, secondary bile acids. These four bile 
acids are reabsorbed and directed to the liver. The liver cells can conjugate them 
to eight different conjugated bile salts and redirected to the intestinal tract56. 
Bile is needed to solubilize lipids and fat-soluble vitamins for a better uptake 
by IEC. High concentrations of bile acids, however, especially of the secondary 
monohydroxic bile acid lithocholic acid can be toxic and also carcinogenic to 
IECs57. Next to bile acids, bacteria produce toxins that hamper the function 
of IEC58-60. These intestinal bile acids and toxins are detected by IEC specific 
NR (FXR, PXR, RXR) and transported by IEC membrane transporters 
(ABCG2, BSEP, MDR1). Active inflammation in IBD patients is associated 
with reduced function and expression of these receptors and transporters 21, 
61-63. Hence, the bile acids can build up in the cells and can exert their (geno)
toxic damage57 and devising strategies to limit the deleterious effects of flora-
derived metabolites in the IEC compartment represents an important frontier 
in experimental gastrointestinal biology. Next to these harmful compounds, 
the microbiota also produces essential vitamins and breakdown indigestible 
fibers into short-chain fatty acids and digestible carbohydrates for more 
efficient uptake by IEC. Short chain fatty acids, which include propionate and 
butyrate, are essential for the energy production in IEC64, 65 and can protect 
against colorectal cancer66.  Dietary components, like fructans favour bacteria 
associated with beneficial metabolites67 and are thus called prebiotics and can 
contribute to healthy life through the microbiome. 
In conclusion, direct contact of bacteria to IEC and the toxic metabolites 
produced by bacteria do harm the intestinal epithelium. This is, under normal 
circumstances, not necessarily a problem for the IEC. On the other hand, as a 
result of malfunctioning IEC, bacteria and xenobiotics can almost unchecked 
enter the gut mucosa and provoke inflammation and intestinal damage. In 
addition, the micro flora produces essential compounds for a healthy gut. 
Hence, IEC play an indispensable role in maintaining a healthy gut micro-
flora homeostasis, conversely IEC are depending on a homeostatic commensal 
microflora for optimal functionality. 
3: IEC and intestinal immune response
The IEC are constantly exposed to non-human microbial and also food 
antigens. Receptors on the IEC can detect these antigens and thereafter 
provoke an immune response. Overactive intestinal immune response is found 
in many gastrointestinal disorders such as, coeliac disease, IBS, necrotizing 
enterocolitis, and IBD.  In the classical interpretation of immunology, detection 
of such antigens is limited to professional immune cells, In the past decades, 
however, it has become clear that also IEC can exert a wide variety of innate 
immune functions and under certain circumstances even function as antigen-
presenting cells (in particular the so-called M cells). The key transcriptional 
mediator evoking immune relevant gene transcription in IEC is nuclear 
factor kB (NF-kB). Three decades ago NF-kB was discovered as an enhancer-
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binding protein68. Once activated, NF-kB translocates to the nucleus, binds 
DNA and subsequently activates gene expression69. The classical, canonical, 
NF-kB pathway is activated by different receptors, such as TLRs, the TNFa 
receptors, Interleukin (IL) receptors and importantly, NOD like receptors70. 
When engaged with their cognate ligand, these receptors trigger activation 
of the IkB kinase (IKK) complex. In its most common form, this complex 
consists of IKKa en IKKb catalytic subunits where IKKg is the regulatory 
(NEMO) subunit of the IKK complex. Activation of the IKK complex results 
in phosphorylation of IkB, thereby targeting it for proteosomal degradation. 
This in turn releases the inhibitory binding of IkB to the NF-kB complex 
(p50/p65), allowing NF-kB translocation to the nucleus. Recently a second 
NF-kB signalling pathway was described71, now denominated as the non-
canonical alternative NF-kB pathway. TNFa-like molecules, except TNFa 
itself, activate this alternative pathway such as, lymphotoxins and B-cell 
activating factors (BAFF). The activated receptors subsequently activate 
a specific IKKa homodimer complex that partly degrade p100 till the P52 
subunit is formed binds Rel-b and translocates to the nucleus71 (reviewed in72). 
Both signalling pathways induce transcription of genes involved in mucosal 
inflammation including cytokines as IL-6, IL-8 IL-1b, IL-10, TNFa, ICAM 
and ELC. Several drugs that are commonly used for treatment in IBD, e.g. 
steroids, are thought to act via the inhibitory effect of the NF-kB pathway, 
in particular in IEC73. But also other bona-fide anti-inflammatory processes 
appear to act through NF-kB inhibition. For instance, the anti-inflammatory 
action of NR is mainly mediated through NF-kB inhibition, at least in murine 
liver22 and intestine74-76 and thus activation of FXR and PXR is a potential 
therapeutic target for intestinal inflammation22, 74 and (Deuring et al. DDW 
2012 abstract no. 1291342). Probably, this pathway exists to limit inflammatory 
responses to xenobiotic agents. This indirectly links the xenobiotic pathways 
to innate immune responses in IEC. However, caution has to be taken in the 
complete inhibition of NF-kB, since IEC specific NEMO knock out mice 
suffer from severe spontaneous colitis77 and we do not completely understand 
all interactions involved.
Important innate immune receptors are the family or Toll like Receptors 
(TLRs), which includes TLR1-916, 78-82. On IEC of healthy individuals TLR4 
and TLR2 protein is detected at low levels although, mRNA of all TLRs 
could be measured in colon and small intestine (reviewed in79). However in 
patients with IBD the IEC decrease the expression of TRLs, except for TLR4 
that is significantly increased16. It is suggested that the cytokines present 
during active inflammation up-regulate the expression of TLR4 in IEC79. 
Since activated TLRs initiate the NF-kB pathway, the increased expression 
may prolong the mucosal inflammation. Next to the innate immune responses, 
IEC also participate in the adaptive immune responses. As such, IEC express 
the antigen presenting molecule histocompatibility complex (MHC) class I83 
and class II84, 85. The IEC can process and present antigens on these molecules 
of microbial products or total bacteria. Although, the gut lumen is filled with 
commensal bacteria the IEC need to distinguish between commensal and 
pathogen. The expression of MHC molecules in IEC is regulated by stress 
signals86, particular microbial strains87 and viral infection88. In addition 
patients with IBD have increased T-cell meditated cytotoxicity due to 
modulated MHC class I and class II expression84. That can lead to increased 
IEC apoptosis. This indicates that IEC also play an important role in the 
adaptive immune system. 
In conclusion, the intestinal epithelium detect, react, engulf, process, and 
present pathogenic microorganisms and thereby initiate and strong innate 
and adaptive immune response. Hence, IEC are pronounced mediators in the 
gut immune response during IBD. 
4: IEC and environmental factors in IBD
The gut lumen is a constantly chancing environment, its nature being 
changed due to food intake, intoxication and even mental conditions. Prandial 
food intake results in many different antigens to pass the IEC layer and 
thus it is tempting to relate changes in IBD incidence to dietary differences, 
especially as other chronic inflammatory conditions of the intestine, e.g. celiac 
disease can be directly related to specific dietary components. Apart from 
directly supplying antigens, food intake majorly influences gut microfloral 
composition. However just a few and unpersuasive dietary studies suggest 
a link between IBD and diet, mostly because they just provide indirect 
evidence of possible cause-and-effect between these two factors. Excessive 
refined sugar consumption might be a risk factor for CD but not for UC89, fat 
intake has been positively correlated to UC whereas high fiber consumption 
(e.g. fruit and vegetables) were reported to decrease the risk of IBD90. In 
particular children but also adult IBD patients can remain in remission using 
a well-defined high fiber diet91. However, these results should be carefully 
interpreted, by its small patient number and since diet-studies are an easy 
subject for experimental bias, due to the difficulties of obtaining the dietary 
histories. Certain specific food components can modulate the function of IEC, 
e.g. potato glycoalkaloids can permeabilize the cholesterol containing cellular 
membranes in turn causing disruption of the epithelial barrier92. Frying 
potatoes increases the concentration glycoalkaloids even more which might 
be consistent with an observation that a high fat diet contributes to risk for 
IBD92, at bay with this notion is that observation of very high consumption of 
potato-based food (as e.g. occurs in the former Soviet Union) does not translate 
in increased epidemiological risk for IBD. Likewise, meat is considered part 
of the modern ‘western diet’ and includes a high fatty acid intake with an 
unfavourable w-6/ w-3 ratio93. Although increased w-6/ w-3 fatty acid ratio 
has been reported to increase the risk for IBD patients to get a relapse93, 
94. Thus although changing the diet of IBD patients is suggested to be an 
additional or even a primary therapeutic strategy targeting IEC physiology95, 
the value of such strategies remain largely unproven. A complicating factor 
might be that certain fatty acids can bind to the IEC NR PPARg and thus 
mediate mucosal healing96 through induction of genes involved in the 
metabolisation and transport of fatty acids97. 
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Smoking has a dichotomous role in both diseases98. Whereas smoking 
is a risk factor for getting CD and for having relapses in CD patients99. Can 
smoking be protective in UC, but smoking cessation increases the risk for 
UC100.  However, although the exact function of cigarette-smoke on the IBD 
aetiology is still largely unknown, smoking augments intestinal macrophage 
phagocytosis via nicotinic acetylcholine receptor a4b2101, which in turn 
may combat deficiencies in innate immunity common to CD102. Moreover, 
cigarette-smoke in general also modulates genes involved in apoptosis and 
membrane transporters of heavy metal ions through the IEC layer103. It 
also will be of great interest to investigate the change in micro flora due 
to cigarette-smoke, since the micro flora play an indispensable role in the 
normal gut homeostasis. 
Another surprising factor that negatively affects the IEC barrier 
permeability are chronic mental-stress conditions104, 105. Intestinal nerve-
fibers interact with the immune cells present in the intestinal mucosal. As 
such mucosal mast cells can get activated upon neural stimulation. Activated 
mast cell produce high amounts of cytokines and tryptase initially to recruit 
more mast cells106-108. However, elevated cytokine and tryptase expression 
can also modulate the IEC barrier function. Enhanced IEC macromolecule 
permeability is observed in conditions with high concentrations of cytokines 
and tryptase, moreover blocking the tryptase prevents experimental colitis109. 
Many environmental factors can modulate the normal function of IEC. Diet, 
smoking, and mental stresses play an indispensable role in the function of 
these cells and can provide clues for designing treatment.
IEC as therapeutic target 
Various IEC-mediated treatment modalities for IBD patients exist. 
An important therapeutic goal in the treatment of IBD patients is fast 
mucosal healing, in particular in UC patients110, 111 and reviewed in112. Rapid 
restoration of the intestinal barrier functionality appears beneficial for IBD 
patients and reduces the change of a relapse. Molecular pathways in IEC and 
IEC proliferation are key processes in the resealing of the gut mucosa113 and 
explain the interest in for instance Lactococcus-driven local mucosal trefoil 
factor (a trophic factor for IECs) application for the treatment of IBD 114 and 
has been proven successful in rodent models of chronic inflammation115. 
According the European guidelines is 5-aminosalicylates (5-ASA) one of 
the first given medications for UC patients116. Interestingly, IEC have an 
important function in the metabolism and mechanism of action of 5-ASA, 
when 5-ASA enters the IEC it is acetylated where after it can bind to PPARg, 
which is an important intestinal NR117. This binding initiates transcription 
of genes that reduce the NF-kB activity118, enhances cyto-protection by 
reducing production of chemo-attractants119, and inhibits oxidative stress 
induced apoptosis120. The most likely mechanism of action of 5-ASA on IEC 
immunity is through phospholipase D and mTOR inhibition121. Hence, 5-ASA 
reduces the overactive innate immune response in IEC and provokes IEC 
proliferation and thus epithelium resealing. 
A second line in the therapeutic strategy for IBD patients is corticoid-
steroids, for UC and CD patients116, 122. Also these compounds have a 
pronounced effect on IEC. Steroids reduce the NF-kB activity in IEC and they 
are involved in the epithelium repair mechanism123, 124. However, the working 
mechanism of steroids is different between CD and UC patients125-129. CD 
patients do benefit from steroid therapy by reducing the disease symptoms, 
but do not exhibit increased epithelial barrier functionality128, 129. Conversely, 
steroid therapy in UC patients does ameliorate the IEC barrier function 
and thereby counteracts mucosal inflammation125-127. Major drawbacks of 
long turn steroids use are the severe side effects130, therefore steroids are 
mostly used as induction therapy. The popularity of topical steroid therapy 
for remission maintenance is testimony of the importance of the IEC as a 
therapeutical target in IBD. 
Azathioprine is a strong chemical immunomodulator, which is used for 
CD and UC patients with moderate to severe inflammation116, 122. Azathioprine 
is a DNA synthesis modulator that impedes the T- and B-cell proliferation to 
diminish the activated adaptive immune responses131. Moreover, azathioprine 
also has a pronounced function in the IEC homeostasis of IBD patients132, 133. 
Although, classically the action of azathioprine is attributed to its capacity 
to impede DNA synthesis, the compound provokes fast mucosal healing132, 
133. The insight that the compound works through Rac inhibition rather as 
on DNA synthesis provides rational explanations here131, 134. Certainly, Rac 
is abundantly expressed in the IEC compartment and has been identified 
as a relevant target for anti-inflammatory drugs135 and thus the notion that 
the IEC represents a relevant compartment for azathioprine in IBD is not 
unreasonable. 
The last decade the strong anti-inflammatory biological agent anti-TNFa 
appears to be highly effective for immunological diseases such as IBD136, 137. 
Although the exact working mechanism of anti-TNFa is still unknown, there 
is a clinical link between anti-TNFa and mucosal healing138-141. Besides, anti-
TNFa ameliorates the functions of IEC during active intestinal inflammation 
by reducing p53-mediated apoptosis142, 143 and reducing IL-33 cytokine 
expression144. By contrast, anti-TNFa also can be detrimental for the tight 
junctions strength between IEC145. This together indicates that IEC have a 
pronounced function in anti-TNFa therapy but still much research is needed 
before the precise mechanisms of action are unravelled. 
To date there is an established treatment strategy for IBD patients116, 
122. Since not all patients do respond well to these therapies, there is always 
room for novel therapeutic approaches. As such, NR can also inhibit the 
NF-kB activity in IEC. Although this described inhibition needs further 
investigation, the first results appear to be promising22, 74 and (Deuring et 
al. DDW 2012 abstract no 1291342). Hence, it is evident that the IEC are 
important mediators in the current therapeutic strategies for IBD patients, 
but there is still much research needed to uncover the exact details of IEC 
physiology and their potential usefulness for therapy. 
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Abstract
The Pregnane X Receptor (PXR) is a principal signal transducer in 
mucosal responses to xenobiotic stress. To facilitate regenerative responses 
PXR impedes activity of Nuclear Factor-κB (NF-kB), the main transcription 
factor controlling inflammatory responses. Although it is well-recognised 
that IBD (inflammatory bowel disease) is accompanied by xenobiotic stress, 
the importance of PXR in limiting inflammatory responses in IBD has not 
been investigated.
In total 106 colonic biopsies from 19 CD (Crohn’s disease) patients and 36 
colonic biopsies from 8 control patients were stimulated with the PXR ligand 
rifampicin or vehicle. As a readout for NF-kB activity, levels of IL-8 and IL-
1b mRNA and protein were employed, whereas PXR levels were assessed 
using its mRNA expression. In-vitro PXR and NF-kB interactions in colon 
cells were investigated using the PXR knockdown LS174t (siPXR) and its 
PXR-expressing counterpart LS174t (nt).  
PXR levels show a strict inverse correlation with NF-kB target gene 
expression in biopsies from CD patients with active disease. Furthermore, 
treatment with rifampicin reduces NF-kB activity showing that PXR activity 
is a rate-limiting step with respect to CD-associated NF-kB activity. These 
effects were verified in-vitro, showing that LS174t (siPXR) cells have higher 
NF-kB activity.  
Our data suggest that the presence of PXR is the main mechanism 
counteracting and limiting the epithelial NF-kB activity in patients with 
active IBD. Modulation of PXR activity thus holds therapeutic promise in the 
clinical management of CD. 
Introduction
Intestinal epithelial cells (IEC) form the physical barrier between the gut 
luminal content and the mucosa. The function of IEC is multifold: nutrients 
and water are absorbed, and simultaneously these cells are responsible for 
the detection1 and form a first line of defence against both microbial as well 
as xenobiotic challenges to the body2, 3. Appropriate responses to xenobiotic 
stress are complex but are coordinated through a specific subfamily of the 
steroid-thyroid superfamily of nuclear hormone receptors (NR). When specific 
ligands engage such receptors, either homodimerisation or heterodimerisation 
with other nuclear hormone receptor family members ensues and a pro-
transcription factor forms, that by virtue loss of hsp90 binding exposes the 
nuclear localisation signal to the cytoplasmic machinery leading to nuclear 
translocation4. In the nucleus, the complex binds to specific palindromic 
promoter regions and directs transcription of genes involved in executing the 
appropriate response to the xenobiotic challenge. A large number of nuclear 
hormone receptors appears to be involved in orchestrating the transcriptional 
response to IEC xenobiotic challenges, including the Pregnane X receptor 
(PXR/ SXR/ NR2L1), Farnesoid X receptor (FXR/ NR1H4), the Vitamin D 
receptor (VDR/ NR1L1), the constitutive androstane receptor (CAR) and the 
Retinoid X receptor (RXR/ NR2B2), but the evidence that PXR is a master 
xenobiotic sensor is especially strong5.
Proper cellular responses to toxic insult go beyond the simple induction of 
detoxification enzymes6 but also include the inhibition of pathways associated 
with further damage (e.g. the generation of reactive oxygen species) and the 
facilitation of regenerative responses to repair tissue damage. A reflection of 
these processes can be found in the association of PXR activity with foetal 
liver development7 and cancer cell growth in endodermally-derived tissues8. 
Also inhibition of inflammatory responses plays an important part in fostering 
a regeneration-permissive environment. Activation of PXR down-regulates 
the transcriptional activity of NF-kB (the master regulator of genomic 
inflammatory responses) and thereby reduces intestinal inflammation9-12. 
Conversely, NF-kB activation represses activity of the PXR pathway9, 13. 
Evidence has been provided that activated PXR physically binds the NF-kB 
subunit p65 and thereby inhibits the NF-kB signalling pathway9. The mutual 
repression of the NF-kB and PXR pathways raises obvious questions as to 
the importance of these interactions in pathological intestinal inflammation.
Indeed, increasing evidence suggests that PXR is also involved in the 
pathogenesis of inflammatory bowel disease (IBD) probably via its interaction 
with NF-kB9, 12, 14-19. A single nucleotide polymorphism near the PXR locus 
is associated with an increased susceptibility to IBD14, 16. Furthermore, 
PXR deficient mice display more severe NF-kB-driven small intestinal 
inflammation than their non-mutant littermates9. Conversely, in patients with 
active IBD and strong NF-kB activation the transcriptional-activity of PXR is 
reduced13, suggesting that the negative reciprocal relationship between PXR 
and NF-kB is also relevant in the context of human chronic inflammatory 
intestinal pathology. The importance of PXR activity in human IBD has 
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not been investigated and rodent results cannot be directly extrapolated to 
human, as PXR ligands are different for rodents than for humans20. Thus the 
importance of PXR in human IBD prompts urgent clarification. 
PXR is also known as a bile acid receptor. High concentrations of bile 
acids especially of the secondary monohydroxic bile acid lithocholic acid can 
be toxic and even carcinogenic for the IEC21. Next to the toxic effects of bile, 
it also can have a positive effect on the disease progression. For example, 
tauroursodeoxicholic acid (TUDCA) can work as a chemical chaperone to 
diminish endoplasmic reticulum (ER) stress and also may contribute as an 
immunomodulator22-25. This effect was investigated in human intestinal 
biopsies as described in Addendum I (page 53). 
In the present study we show that PXR activity is the major rate-limiting 
pathway constraining mucosal NF-kB activity in active IBD and thus reveal 
that PXR signals are much more important in pathology as previously 
thought. Furthermore, our results imply that modulation of PXR activity 
holds significant clinical promise in the management of IBD.  
Methods
Cell lines and ligands
To study the NF-kB inhibiting potential of PXR activation, the PXR 
expressing colon cancer cell line LS174t a PXR knockdown LS174t cell 
line was created to test the specificity of PXR. The LS174t cell line was 
transduced with a lenti-virus, containing small interference RNA for PXR 
(siPXR), as described before21. The transduced cells were cultured with 
100 mM puromycin (Sigma-Aldrich) for three weeks to select for cells that 
harbour the siPXR. The hepatocyte cancer cell line HepG2 and colon cancer 
cell lines CACO2 and LS174t were used to investigate the effect of HNF4a on 
PXR expression. All cell lines needed two passages a week and were cultured 
according standard culture conditions. NF-kB was in-vitro activated by 2 
mL E. coli lysate (ELI), a centrifuged 50 mL o/n E. coli (DH5a, Invitrogen) 
culture taken up in 500 mL dH2O. PXR was activated by 100 mM rifampicin 
(Rif, Sigma-Aldrich) and HNF4a was activated by 240 mM linoleic acid (LA, 
Sigma-Aldrich). 
Biopsies
This study was conducted with approval of the Institutional Review 
Board of the Erasmus MC University Medical Centre in Rotterdam. All 
patients gave written informed consent. During endoscopy biopsies were 
taken from patients with a known history at least 6 months of CD and from 
patients referred for colonoscopy but without intestinal abnormalities, further 
described as control patients. Also patients were asked for additional blood 
samples. CD was diagnosed according to international guidelines and only 
the results of the control biopsies were used if there were no abnormalities on 
pathology, when there was no history of IBD, and no familiar history of IBD. 
For each patient the biopsies were taken from the ascending colon (n=3), the 
transversum (n=3) and the descending colon (n=3), if applicable. 
Histology
One biopsy from each location was fixed in 4% formalin, dehydrated 
and embedded in paraffin for histological scoring. Four mM slices from the 
formalin fixed paraffin embedded (FFPE) tissue specimens were stained 
with hematoxylin and eosin (Sigma-Aldrich) according standard procedure. 
Three observers have independently examined each biopsy, in a blinded 
fashion. Discrepancies were reassessed to reach agreement. 
Stimulation of the biopsies
The freshly taken biopsies were immediately placed in ice-cold regular 
culture medium (DMEM) for transport. Before stimulating the biopsies, 
they were washed three times with ice-cold PBS containing antibiotics to 
prevent infection. The biopsies were then stimulated for 18 h at 37oC with 100 
mM Rifamcipin (Sigma-Aldrich), 10 mM Linoleic Acid (LA, Sigma-Aldrich) 
and or solvent. Stimulated biopsies were directly lysed in Tripure (Roche, 
Switzerland) for RNA and protein extraction, according manufacturer’s 
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protocol. After the Tripure extraction, the RNA samples were purified 
using the RNA II extract kit from Macherey Nagel (Bioke) according to 
manufacturer’s protocol.  
Peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were isolated from fresh 
blood using Ficoll (Gibco) according standard procedures. The isolated 
PBMC were stimulated with 100 mM rifampicin for 18 h at 37oC followed by 
lysing of the PBMC in Tripure (Roche) for RNA isolation. 
RT-PCR
Gene expression of GapdH, Ywaz, IL8, IL1b, Cyp3a4, Sult1a, and PXR 
were measured using quantitative PCR (qPCR, IQ5, Bio-Rad). The primer 
sequences are shown in Table S1. All genes were analysed using the same 
qPCR program as described before 22. Gene expression is plotted as fold 
change using the DCt method23. The data from patients with multiple colonic 
biopsies where averaged. All qPCR reactions where at least performed in 
duplo. 
Protein analysis
The p-p65 (catalogue no. 3037, Cell Signaling Technology) and p-Akt 
(catalogue no. 11055-2, Signalway Antibody) protein expression was measured 
using conventional western blot as described before 22. The IL-8 protein 
expression in the protein solution isolated from the TriPure fraction was 
measured using ELISA, Human IL-8 ELISA Ready-SET-Go! (eBioscience). 
Statistics and software
All the graphs and the statistical analyses were performed using the 
Graphpad Prism 5.0 software package for Windows. Data from the paired 
biopsies were non-parametric statistically analysed using the Wilcoxon 
matched pairs test. Correlations were determined using the Spearman’s rank 
correlation coefficient. A two-tailed p value <0.05 was accepted as statistically 
significant. Images were composed using Adobe Photoshop CS5. 
Table S1: Primer sequences 
Primer name Sequence from 5’ to 3’
GapdH_fw GCATTGCCCTCAACGACCAC
GapdH_rev CCACCACCCTGTTGCTGTAG
YWHAS_fw ACTTTTGGTACATTGTGGCTTCAA
YWHAS_rev CCGCCAGGACAAACCAGTAT
IL8_fw CACTGCGCCAACACAGAAATTA
IL8_rev ACTTCTCCACAACCCTCTGCAC
IL1b_fw CCCTAAACAGATGAAGTGCTCCTT
IL1b_rev GTAGCTGGATGCCGCCAT
Cyp3a4_fw CAGGAGGAAATTGATGCAGTTTT
Cyp3a4_rev GTCAAGATACTCCATCTGTAGCACAGT
HNF4a_fw ACATGGACATGGCCGACTAC
HNF4a _rev TGCCTCAATCTGGCGAGACG
Claudin-15_fw TGAGGTGGGTGGATTACTTG
Claudin-15_rev TGTTGAAGGCGTACCAGGAG
Mep1a_fw TCAAGCCCTATGAAGGAGAG
Mep1a_rev CCTTATAGGCACATCCTTGG
Sult1a_fw GCACCCACCCTGTTCTCTAC
Sult1a_rev ACCACGAAGTCCACGGTCTC
PXR_fw ATGGCAGTGTCTGGAACTAC
PXR_rev CAGTTGACACAGCTCGAAAG
Table S2: Baseline characteristics of patients treated with rifampicin
CD Control
Total number of patients 19 8
Mean age, yr (SD) 44 (16.6) 62 (3.5)*
Gender (M/F) 5/14 3/4
Mean duration of disease, yr (SD) 13 (8.8) -
# Smoking (%Yes) 4 (25) 2(33)
# Familiar IBD (%Yes) 5 (36) -
Concomitant medication:
- none 1 -
- aminosalicylates 3 -
- corticosteroids 4 -
- immunosuppressives 9 -
- biological 5 -
# Biopsies colon 106 36
* The healthy controls are significantly older than the CD patients. p=0.002 
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Results 
Tissue samples
In total we obtained 106 biopsies from 19 CD patients and 36 biopsies 
from 8 controls are used for rifampicin stimulation. In total 36 other biopsies 
are stimulated with linoleic acid (4 CD patients and 6 controls). Demographic 
patient characteristics are presented in Tables S2 and S3. Five additional 
patients with quiescent CD and 4 controls agreed to donate blood samples. 
Mutual repression of PXR and NF-kB signalling in IBD.
We first determined the expression of NF-kB the target genes IL-8 
and IL-1b in non-stimulated biopsies. As expected, the expression of both 
these cytokines was higher in biopsies of patients with active inflammation 
compared to biopsies from controls or CD patients with quiescent disease 
(Figures 1A and B). To clarify the relationship between intestinal PXR 
expression and the corresponding NF-kB activity both were determined in 
our patient cohort (Figure 2A). The expression of PXR is similar in control 
biopsies and in biopsies from quiescent CD patients. However, although not 
significant (p=0.15) the PXR expression levels seemed to be reduced in 
biopsies from active CD patients (Figure 2A). The reduced PXR expression 
negatively correlates (r=-0.6, p<0.01) with increased inflammation and 
NF-kB activity as judged by IL-8 and IL-1b expression (Figure 2B). The 
negative correlation between PXR and NF-kB pathway activity suggests that 
the activation status of xenobiotic and inflammatory pathways is mutually 
exclusive and constitutes an important regulatory circuit in IBD.
Table S3: Baseline characteristics of patients treated with linoleic acid
Linoleic acid
Linoleic acid +/- 
Rifampicin
CD Control CD Control
Total number of patients 2 3 2 3
Mean age, yr (SD) 38(7.7) 49(12.9) 50(0.7) 45(6.4)
Gender (M/F) 1/1 2/1 1/1 2/1
Mean duration of disease, yr (SD) 17(7.1) - 5.5(0.7) -
# Smoking (%Yes) 0(0) 0(0) 0(0) 1(33)
# with familiar link to IBD (%Yes) 0(0) - 1(50) -
Concomitant medication:
- none 0 - 1 -
- aminosalicylates 1 - 1 -
- corticosteroids 0 - 0 -
- immunosuppressives 0 - 0 -
- biological 1 - 0 -
# Biopsies colon 10 8 10 8
PXR activation is rate limiting for mucosal NF-kB activation in IBD
A prediction, from the notion that the negative regulation of NF-kB 
signalling through PXR is functionally relevant, is that hyper stimulation 
of the PXR pathway reduces the inflammatory aspect of gene expression in 
biopsies of IBD patients. Thus we challenged biopsies with the human PXR 
ligand rifampicin. Such treatment did not significantly reduce the IL-8 or IL-
1b mRNA expression in the biopsies from control and quiescent CD patients 
(Figures 1A and B), demonstrating that outside the context of active IBD, 
PXR activity is not a rate-limiting factor with respect to NF-kB-directed gene 
expression. Importantly, however, rifampicin stimulation also caused a 35 fold 
reduction of IL-1b mRNA expression in the biopsies with active inflammation 
(p<0.01, Figure 1B). Also at the protein level the IL-8 expression is reduced 
following rifampicin treatment in CD patients with active disease (-750pg/
mL, p<0.01), compared to the untreated biopsies (Figure 1C). Thus at least 
in active IBD it appears that level of PXR activation is the dominant NF-kB 
pathway activity controlling mechanism. 
Figure 1: Cytokine expression in human intestinal biopsies with rifampicin treatment. 
A) IL-8 mRNA expression in human intestinal biopsies. The graph represents the mean IL-8 mRNA expression 
on log scale from biopsies stimulated with solvent only (0.1% (v/v) DMSO) or 100 mM rifampicin for 18 h 
at 37oC. Ctr are the biopsies from control patients (n=36), iaCD are the biopsies from CD patients without 
active intestinal inflammation (n=66), and aCD are the biopsies from CD patients with active intestinal 
inflammation (n=40). The error bar is SEM, ** p<0.01.
B) IL-1b mRNA expression in human intestinal biopsies. For this graph the same methodology as in A) was 
used. The error bar is SEM, ** p<0.01. 
C) IL-8 protein expression in human intestinal biopsies. ELISA was used to measure the IL-8 protein 
concentration from biopsy homogenates. The same biopsies were used as for the mRNA expression 
analysis in A) and B). The error bar is SEM, ** p<0.01, *** p<0.001.
D) IL-8 mRNA and protein expression correlation. The IL-8 mRNA expression is plotted against the IL-8 
protein (pg/mL) expression per biopsy. Spearman correlation is calculated, r=0.72, p<0.0001. 
Chapter III |   51 50   | Chapter III
PXR constrains mucosal NF-kB activity during active IBD
III
Back to Index
Figure 2: Non-activated PXR and reduced NF-kB activity.
A) PXR mRNA expression in human intestinal biopsies. The same methodology as in Figure 1A was used. 
The error bar is SEM. 
B) Correlation coefficient between IL-8 and PXR from non-stimulated biopsies. The IL-8 and PXR mRNA 
expression difference with and without rifampicin was calculated and plotted in this graph. For this graph 
only the non-stimulated biopsies from CD patients were used. Both axes are in log scale. Spearman r = 
-0.6, p<0.01. 
C) Flowchart dividing CD patients into groups based on PXR expression. The CD patients were divided in 
three groups; group 1 do not have increased PXR expression after rifampicin treatment, group 2 that do 
have increased PXR expression with rifampicin treatment, and group 3 that have equal PXR expression.
D) The difference in IL-8 mRNA expression with and without rifampicin treatment. For each patient the 
mean of the difference between non-rifampicin stimulated and rifampicin stimulated biopsies in IL-8 
expression is presented in this graph. The error bar is SEM, * p<0.05.
E) PXR expression in biopsies with and without Rifampicin stimulation. The mean PXR mRNA expression 
of all biopsies, control and CD patients, with or without Rifampicin stimulation is presented in this graph. 
The error bar is SEM, p=0.056.
To further investigate this relationship between PXR expression and 
NF-kB signalling the CD patients were stratified into two groups (flowchart 
in Figure 2C); patients that do not have higher PXR expression (n=5) and 
patients that do have higher PXR expression (n=10) in the biopsies with 
rifampicin treatment. Four patients had equal or undeterminable PXR levels. 
Indeed, the IL-8 expression in biopsies from the patients that have high 
PXR expression following rifampicin is 6 fold lower (p<0.05) as compared 
to biopsies of patients in the patients that do not show high PXR expression 
following rifampicin treatment (Figure 2D). In the same way, grouping 
all the biopsies (controls and CD patients) it becomes clear that rifampicin 
stimulation increases the overall PXR expression by 3 fold (p=0.056; Figure 
2E), consistent with a scheme in which PXR activity constrains NF-kB 
activity and vice versa. It thus appears that the level of PXR activity is the 
rate-limiting factor with respect to NF-kB-directed gene expression in active 
IBD and conversely the amount of NF-kB activity is an important negative 
regulator for PXR expression.
PXR activity is restricted to the epithelial compartment 
Since the biopsies, especially those of patients with active CD, contain a 
large number of lymphocytes we wanted to determine if these cells contribute 
to the observed PXR-mediated reduction of NF-kB signalling. Therefore, 
we investigated the effect of rifampicin on PBMC isolated from blood. No 
PXR mRNA can be detected in any of the PBMC fractions (data not shown). 
Rifampicin stimulation does not influence the IL-8 mRNA expression 
in PBMC from controls and CD patients (Figure S1A). Furthermore the 
expression of PXR target gene Sult1a is not altered (Figure S1B). Hence, 
mononuclear cells such as, stromal cells do not seem to interfere in the PXR-
mediated inhibition of NF-kB in human intestinal biopsies. 
Figure S1: The effect of rifampicin on PBMC. 
A) IL-8 mRNA expression in PBMC. PBMC isolated from peripheral blood samples of CD patients and 
healthy individuals were stimulated for 18 h at 37oC with solvent (0.1% (v/v) DMSO) or 100 mM rifampicin. 
Ctr is the mean IL-8 expression of the healthy individuals (n=4) and ia CD is the mean IL-8 expression of the 
inactive CD patients (n=5). The error bar is SD. 
B) Sult1a mRNA expression in PBMC. Same methodology as used in A) was used. 
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Figure 3: NF-kB signalling in the PXR knock down cell line. 
A) LS174t cell line stably transduced with non-target siRNA LS174t (nt) or a siRNA for PXR LS174t (siPXR). 
The graph represents PXR mRNA expression in LS174t cells from three independent experiments. The 
error bar is SD, *p<0.05. 
B) LS174t (nt) and LS174t (siPXR) cells stimulated with rifampicin. Both cell lines were stimulated with 
100 mM rifampicin (Rif) for 16 h at 37oC. The relative mRNA expression of the PXR target gene, Cyp3a4, 
is presented in this graph. Data is from two in duplo performed independent experiments, the error bar 
is SD, *** p<0.001. 
C) IL-8 mRNA expression in LS174t cells. Both cell lines were stimulated with 2 mL E. Coli lysate (ELI). The 
graph represents the IL-8 mRNA expression from two in duplo performed independent experiments. The 
error bar is SD, *p<0.05. 
D) Activated NF-kB subunit p65 protein (p-p65) expression in LS174t cells. The same stimulation conditions 
as in C) were used. Actin protein expression is shown as loading control. This blot is a representative of two 
independent experiments. 
E) Activated Akt (p-Akt) protein expression in LS174t cells. Same methodology as in D) was used. 
F) PXR mRNA expression in LS174t cells. Same methodology as in C) was used. The error bar is SD, 
**p<0.01. 
In vitro non-activated PXR mediated NF-kB inhibition
Direct support for the notion that PXR is important for restricting NF-
kB activation in the epithelial compartment came from experiments in which 
we investigated the effect of PXR expression per se on NF-kB inhibition. We 
used the LS174t cells, a generally used model for colonic epithelial cells that 
recapitulates many aspects of normal enterocyte physiology and generated 
two derivatives, the LS174t (siPXR) clone that lacks PXR expression and 
LS174t (nt) as a transfection control (Figure 3A). Consistently, induction 
of the PXR target gene CYP3a4 is corrupted in the LS174t (siPXR) cells 
(Figure 3B) but not in the other cells. Following stimulation with E. Coli 
lysate, IL-8 expression is enhanced two fold in the cells lacking PXR (p<0.05; 
Figure 3C). We confirmed this difference by showing a decreased p-p65 
and p-Akt protein expression in the LS174t (nt) cell line (Figures 3D and 
E), demonstrating that also in this model cell line, PXR activity constitutes 
the rate-limiting step in NF-kB-dependent gene expression. Conversely, 
stimulation with E. Coli lysate and thus activating NF-kB signalling reduces 
PXR levels in LS174t (nt) cells (Figure 3F). Thus these in vitro experiments 
show that the negative relationship between NF-kB and PXR signalling is 
cell-autonomous and provide strong support for the notion that the presence 
of PXR represents an important mechanism constraining NF-kB signalling 
in the mucosal epithelial compartment.
HNF4a induced PXR expression
As it becomes increasingly clear from our data that PXR expression per 
se is already sufficient to inhibit the NF-kB activity, we investigated whether 
stimulating the HNF4a nuclear receptor could increase the PXR expression 
as published previously for murine hepatocytes7. Linoleic acid stimulation in 
a hepatocyte cancer cell line, HepG2, increases the expression of HNF4a 
target gene Claudin-15 (p<0.001) but not in colon cancer cell lines, LS174t 
and CACO2 (Figure S2A). Notwithstanding that, all cell lines have detectable 
mRNA expression of HNF4a (Figure S2B). Furthermore, the PXR expression 
is also not increased in any of the cell lines (Figure 4A). Besides, stimulated 
biopsies do also not have increased PXR mRNA expression after linoleic acid 
stimulation (Figure 4B). In line with this observation, the expression of IL-8 
was also not altered after stimulation of the cells with Linoleic acid (Figure 
4C). The biopsies do express the HNF4a receptor and induction of HNF4a 
target gene (Mep1A) was found in the control biopsies (p<0.05, Figures S2C 
and D). In addition, adding rifampicin to the linoleic acid stimulated biopsies 
did not further change the mRNA expression of PXR or IL-8 (Figures 4D and 
E). These data show that linoleic acid is not able to enhance PXR expression 
or activity in human intestinal biopsies as well as cell lines. 
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Figure 4: HNF4a stimulation to increase the PXR expression. 
A) Cancer cell lines stimulated with HNF4a ligand. Hepatocyte cancer cell line HepG2 and colon cancer cell 
line CACO2 and LS174t were stimulated with 240 mM linoleic acid for 18 h at 37oC. The graph represents 
the mean relative PXR expression per cell lines and with and without linoleic acid stimulation line, from 
two independent in duplo performed experiments. The error bar is SD. 
B) PXR mRNA expression in biopsies stimulated with linoleic acid. Biopsies from two CD patients and three 
healthy individuals were stimulated with solvent (1% (v/v) PBS) or 240 mM Linoleic acid for 18 h at 37oC. 
The graph represents the mean PXR expression per group. CTR are the controls and iaCD are CD patients 
with quiescent disease.  The error bar is SD. 
C) IL-8 mRNA expression in biopsies stimulated with linoleic acid. Same methodology as in B) was used. 
The graph represents the mean IL-8 expression per group. The error bar is SD.
D) PXR mRNA expression in biopsies stimulated with rifampicin and linoleic acid. Biopsies from two 
different CD patients and three different healthy individuals were stimulated with 100 mM rifampicin and 
together with solvent (1% (v/v) PBS) or 240 mM linoleic acid for 18 h at 37oC. CTR are the controls and 
iaCD are CD patients with quiescent disease.  The graph represents the mean PXR expression per group. 
The error bar is SD.
E) IL-8 mRNA expression in biopsies stimulated with rifampicin and linoleic acid. Same methodology as in 
D) was used. The graph represents the mean IL-8 expression per group. The error bar is SD.
Discussion
Active IBD is associated with an impaired immune response against 
microbial activation but concomitantly the increased bacterial load elicits a 
substantial xenobiotic challenge. As xenobiotic and inflammatory signalling 
are to a certain extent mutually exclusive9, 11, this raises important questions 
as how the relative activities of the two pathways are fine-tuned during 
fulminate inflammation, especially in IBD. Here we demonstrate that both 
signalling pathways restrain each other’s activity and that in the context of 
active IBD the PXR pathway is the rate-limiting factor for NF-kB dependent 
epithelial gene expression. As it is becoming clear that especially ileal IBD 
might largely be an epithelial disease, our observations have substantial 
consequences in our thinking of IBD and open the possibility that by 
targeting PXR signalling therapeutic benefit may be achieved in those 
patients in epithelial hyper activation of NF-kB signalling is an important 
factor for pathogenesis.
Earlier studies already demonstrated multiple links between the xenobiotic 
metabolism and inflammatory pathways9-12, 15, 24, but did not address the 
importance of PXR signalling in limiting NF-kB-dependent signalling in 
IBD. As down modulation of NF-kB-dependent gene expression is probably 
a secondary response to xenobiotic stress, likely to facilitate regenerative 
responses. We were surprised to see that PXR emerged as the major rate-
limiting step for epithelial NF-kB activation in active CD. Nevertheless, a 
recent study done in six CD patients with quiescent disease showed that 
PXR activation can reduce LPS-induced NF-kB activity in human IEC10. As 
such artificial inflammation induced by LPS stimulation may not necessarily 
relate to NF-kB signalling in active IBD, we assessed PXR effects in active 
IBD directly. As PXR levels directly negatively correlate with NF-kB, and 
rifampicin further reduces pro-inflammatory cytokine mRNA and protein 
expression, we conclude that PXR activity is the rate-limiting step for NF-kB 
activity in the epithelial compartment in IBD.  
Consistent with a critical role for PXR in constraining epithelial 
inflammatory responses are the genetic studies that link genomic variation 
in PXR in susceptibility to IBD14, 16. Although no functional data is available, 
Dring et al. and Martinez et al. showed significant associations of two 
PXR promoter SNPs with Crohn’s disease and ulcerative colitis14, 16. Two 
other SNPs were associated with Crohn’s disease but not with ulcerative 
colitis. Although replication studies in different cohorts failed to show these 
associations25. Lack of association of the pregnane X receptor (PXR/NR1I2, 
based on the data obtained in the present study it is tempting to suggest 
that in certain patient populations aberrant PXR induction fails to control 
epithelial NF-kB induction predisposing to disease. Larger studies in other 
cohorts are essential to clarify the association between PXR polymorphisms 
and susceptibility to IBD. In addition, with advent of microbiome profiling, 
it should prove interesting to correlate our findings with certain variations 
of the microbiome. Understanding the exact interactions between patient 
genetics, microbiome may however be necessary to exploit our findings for 
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devising rational therapy for IBD based on modulation of PXR activity. 
Nevertheless, keeping this caveat in mind, the present study has shown that 
PXR activity is the major rate-limiting pathway constraining epithelial NF-
kB activity in active IBD and implying modulation of PXR activity holds 
significant clinical promise in the management of IBD.
Figure  S2: Expression and effect of HNF4a stimulation. 
A) HNF4a target gene Claudin-15 expression in cancer cell lines. Hepatocyte cancer cell line HepG2 and 
colon cancer cell line CACO2 and LS174t were stimulated with 240 mM linoleic acid for 18 h at 37oC. The 
graph represents the mean relative Claudin-15 expression per cell lines and with and without linoleic acid 
stimulation line, from two independent in duplo performed experiments. The error bar is SD, * p<0.05. 
B) HNF4a expression in cancer cell lines. Same methodology as in A) was used. The graph represents the 
mean expression of HNF4a per cell line. The error bar is SD. 
C) HNF4a target gene Mep1a expression in biopsies. Biopsies from two CD patients and three healthy 
individuals were stimulated with solvent (1% (v/v) PBS) or 240 mM Linoleic acid for 18 h at 37oC. The graph 
represents the mean Mep1a expression per group. CTR are the controls and iaCD are CD patients with 
quiescent disease. The error bas is SD.
D) HNF4a expression in biopsies. Same methodology as in C) was used. The graph represents the mean 
HNF4a expression per group. The error bas is SD. 
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Addendum I: Bile salt and intestinal immunomodulation 
Nuclear receptors such as the Pregnane X receptor (PXR/ SXR/ NR2L1), 
Farnesoid X receptor (FXR/ NR1H4), and the Retinoid X receptor (RXR/ 
NR2B2) are responsible for the detection of  bile acids in the intestinal tract. 
High concentrations of  bile acids especially of  the secondary monohydroxic 
bile acid lithocholic acid can be toxic and even carcinogenic for the IEC1. 
Bile acid malabsorbtion is a common feature in patients with inflammatory 
bowel disease (IBD)2. Next to the toxic effects of  bile, it also can have a 
positive effect on the disease progression. For example, tauroursodeoxicholic 
acid (TUDCA) can work as a chemical chaperone to diminish endoplasmic 
reticulum (ER) stress and also may contribute as an immunomodulator3-6. 
The aim of  this additional study was to investigate the immunomodulation 
and the ER stress reducing capacity of  TUDCA on human IEC and whether 
this effect is mediated by the presence of  PXR. Firstly, we chemically induced 
ER stress in LS174t (siPXR) cells and their PXR expressing counterparts 
with tunicamycin. TUDCA was added to evaluate its ER stress modulating 
effect. The GRP78 and CHOP(primer sequences Table Ad S1) expression 
is 10 fold higher in both cell lines stimulated with tunicamyin, irrespective 
of  the presence of  TUDCA (Figure Ad.1A). In addition, the GRP78 and 
p-EIF2a protein expression is not different with TUDCA stimulation (Figure 
Ad.1B). Hence, in contrast to previous findings6, the chemical-induced ER 
stress could not be reduced by TUDCA in LS174t cells, independent of  the 
presence of  PXR. IEC have membrane-bound receptors which are able to 
detect microbes and initiate an innate immune response7, 8. In vitro, a lysate 
of  E. Coli (ELY) is able to induce transcription of  NF-kB related, innate 
immunity key regulator, genes such as IL-8 and IL1b (Figure Ad.1C). There 
is no immune-modulating effect detected with TUDCA co-stimulation 
(Figure Ad.1C), irrespective of  the presence of  PXR. Thus, TUDCA has 
no ER stress- or immune-modulating effect on LS174t cells, without a 
significant role for PXR. Of  note, the expression of  IL-8 and IL-1b (NF-kB 
target genes) is again higher in the LS174t (siPXR) cells (Figure Ad.1C and 
Figure 3).  
Table Ad S1: Primer sequences 
Primer name Sequence from 5’ to 3’
GRP78_fw ACCATCCCGTGGCATAAACC
GRP78_rev CCTCCCACAGTTTCAATACC
CHOP_fw GGAGCTGGAAGCCTGGTATG
CHOP_rev CCTCAGTCAGCCAAGCCAGAG
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IEC from IBD patients with active inflammation have an activated innate-
immune system9-11 and have activated ER stress pathways12-14. To investigate 
the immune modulating and ER stress reducing effect of  TUDCA on human 
IEC, we stimulated freshly isolated intestinal biopsies from nine IBD (6 CD 
and 3 UC) patients and 4 healthy individuals with TUDCA (Table Ad S2). 
Biopsies from IBD patients with active disease have higher GRP78, IL-8 and 
IL-1b expression than the biopsies from inactive IBD patients and healthy 
individuals (Figure Ad.2A and Ad.2B). The GRP78 higher expression is not 
modulated in the accompanying biopsies stimulated with TUDCA (Figure 
Ad.2A). However, although not significant, the expression of  the cytokines 
IL-8 and IL-1b is slightly reduced in the TUDCA stimulated biopsies. In 
conclusion, the ER stress signals are not impeded in the biopsies stimulated 
with TUDCA, however there is a trend in immune modulation by TUDCA 
in the freshly isolated biopsies. These findings needs further exploration, but 
already give new insights in the possible implication of  conjugated bile acids 
in current therapy for IBD patients.
Table Ad S2: Baseline characteristics of patients treated with rifampicin
CD Control
Total number of patients 19 8
Mean age, yr (SD) 44 (16.6) 62 (3.5)*
Gender (M/F) 5/14 3/4
Mean duration of disease, yr (SD) 13 (8.8) -
# Smoking (%Yes) 4 (25) 2(33)
# Familiar IBD (%Yes) 5 (36) -
Concomitant medication:
- none 1 -
- aminosalicylates 3 -
- corticosteroids 4 -
- immunosuppressives 9 -
- biological 5 -
# Biopsies colon 106 36
* The healthy controls are significantly older than the CD patients. p=0.002
Figure Ad1: Effect of TUDCA on ER stress and innate immune signals in cell lines.
A) ER stress related mRNA expression. LS174t(nt) and LS174t(siPXR) cells where stimulated with 
tunicamycin (16 h) with or without TUDCA (18 h). The relative mRNA expression of GRP78 and CHOP from 
two independently in-duplo performed experiments is presented in these graphs. The error bar is SD. 
B) ER stress related protein expression. Representative blots of GRP78 and p-EIF2a are presented. Similar 
methodology as is A) was used. 
C) Cytokine mRNA expression. LS174t(nt) and LS174t(siPXR) cells where stimulated with E. Coli lysate (ELY, 
16 h) with or without TUDCA (18 h). ELY is derived from a centrifuged 50 mL o/n E. Coli culture, where after 
the bacteria pallet was lysed in 500 mL dH
2
O using five freezing-thawing cycles and sonication. The relative 
mRNA expression of IL-8 and IL-1b from two independently in-duplo performed experiments is presented 
in these graphs. The error bar is SD.
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Figure Ad2: Effect of TUDCA in freshly isolated biopsies 
A) mRNA ER stress signals in biopsies. Freshly isolated biopsies from healthy individuals (CTR), IBD patients 
with quiescent disease (iaIBD), and IBD patients with active disease where stimulated with TUDCA or 
solvent (18 h). The average relative mRNA expression of GRP78 and CHOP is presented in these graphs. 
The error bar is SD.
B) mRNA cytokine expression in biopsies. Similar methodology as is A) was used. The average relative 
mRNA expression of IL-8 and IL-1b is presented in these graphs. The error bar is SD.
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Abstract
Patients with long standing inflammatory bowel disease (IBD) are 
known with an increased risk for developing neoplastic progression. 
Nuclear receptors such as, the Pregnane X Receptor (PXR) are involved 
in detoxification and chemotherapy resistance processes in intestinal 
epithelial cell (IEC). In addition, PXR expression also mediates cancer cell 
proliferation and survival. In this study we investigated the expression of 
PXR during neoplastic progression in patients with IBD, and studied the 
function of PXR in intestinal cancer cell proliferation and survival. PXR was 
assessed immunohistochemically (IHC) in colonic tissue samples of; 9 healthy 
individuals, 61 IBD patients, 10 IBD patients with low-grade dysplasia, 8 IBD 
patients with high-grade dysplasia, 15 IBD related colorectal cancer (CRC) 
patients, 5 patient with sporadic polyps, and 14 with sporadic CRC. Similar 
PXR IHC was performed in small bowel tissue specimens of; 17 healthy 
individuals, 29 Crohn’s disease patients, and 7 patients with Crohn’s disease 
related adenocarcinoma. PXR dependent cell growth and chemotherapy 
sensitivity was investigated in vitro using a PXR knockdown CRC cell line 
LS174t (siPXR) and its PXR-expressing counterpart LS174t (nt). High PXR 
expression was found in neoplastic IEC but not in normal or inflamed IEC, 
which was not related to the presence of IBD or intestinal location. Loss 
of PXR expression in LS174t (siPXR) cells increases the proliferation and 
decreases high cell-density survival, but the chemotherapeutic sensitivity 
was independent of PXR expression. PXR is abundantly present in human 
intestinal cancers, irrespective of the cancer origin or intestinal location. 
High PXR expression reduces the cancer cell proliferation, but improves 
high cell-density survival in vitro. As such, PXR expression in cancer cells 
is sustaining 
Introduction
Intestinal epithelial cells (IEC) are well equipped with a variety of 
protection mechanisms against toxic luminal contents. When toxins enter 
the cell, they are detected by xenobiotic specific nuclear receptors (NR) such 
as, the Pregnane X Receptor (PXR)1, 2. After binding a specific ligand, PXR 
hetro-dimerizes with the Retinoid X Receptor and translocate to the nucleus 
to promote transcription of genes involved in the xenobiotic metabolisation 
and clearance2. Conversely, this efficient process of cellular clearing could also 
be detrimental i.e. for patients with cancer, where increased PXR activity is 
related to chemotherapy resistance3, 4. Proteins involved in chemotherapeutic 
agent transport (MDR1, ABCG2) and metabolisation (CYP3a4, Sult1A) are 
directly regulated by PXR5, 6. 
Deregulation in de PXR mediated xenobiotic metabolism and clearance 
are described during inflammatory lesions such as in IEC of patients with 
active inflammatory bowel disease (IBD)7, 8. Patients with IBD suffer from 
chronic intestinal inflammation, which comprises of two main groups; 
Crohn’s disease (CD) and ulcerative colitis (UC). The loss of PXR-mediated 
detoxification during active inflammation could enhance the cellular 
sensitivity to, lethal build-up of xenobiotic compounds, which undoubtedly 
increases change of DNA damage and even neoplastic progression8. Moreover, 
IBD is associated with an increased risk of developing colorectal cancer 
(CRC). The risk for developing CRC is increasing by 0.5-1% every 8-10 years 
after IBD diagnosis and is depending on the age of onset9. Whereas only 
1.5% of all CRC-cases are caused by IBD, the mortality rate of patients with 
IBD related CRC is dramatically higher than in sporadic CRC10. There are 
clear etiologic differences between sporadic CRC and IBD-CRC. Sporadic 
CRC arise from earlier formed polyps where IBD-CRC is raised from flat 
intestinal epithelium. Typical IBD-CRC originates from long standing 
IBD with normal looking IEC which can transform to low-grade dysplastic 
(LGD) epithelium, that can further evolve to high-grade dysplasia (HGD) and 
ultimately in a carcinoma11. 
Recent studies describe that non-activated PXR is also directly involved 
in other cellular processes such as, proliferation12, 13, survival14, and inhibition 
of inflammatory pathways15. However, there are contradictory results about 
the exact function of PXR in cancer cell proliferation and survival. PXR is 
described to be anti-apoptotic16 and increases cancer cell growth17 in human 
and experimental colorectal cancers, whereas other studies have found that 
PXR induces apoptosis in breast cancer cells14 and is inhibiting the cancer cell 
proliferation13. Since PXR is involved in cancer cell chemotherapy resistance, 
survival and proliferation, it is important to determine the exact expression 
and function of PXR in human inflammation-related and non-inflammation 
related CRC. Since chemotherapy is focused on high proliferative cells, it is also 
important to examine the function of PXR expression during chemotherapy. 
In this study we investigated the involvement of PXR in the proliferation and 
survival of IEC during neoplastic progression in IBD patients. We measured 
the expression of PXR in human intestinal non-neoplastic and neoplastic 
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tissue. In addition, we evaluated the cellular involvement of PXR expression 
in proliferation and chemotherapeutic agent resistance. 
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Methods
Patient selection
Formalin fixed paraffin embedded (FFPE) colonic tissue specimens were 
collected from nine healthy controls and 108 patients: 30 with inactive IBD 
(iaIBD), 31 with active IBD (aIBD), 10 with low grade dysplasia (LGD), 8 
with high grade dysplasia (HGD), 15 with IBD related CRC (IBD-CRC), 
5 with sporadic polyps, and 14 with sporadic CRC. FFPE small bowel 
tissue specimens were collected from 17 different healthy individuals and 
36 different patients: four with inactive CD, 25 with active CD, and 7 with 
adenocarcinoma. The demographic patient characteristics are described in 
Tables S1 and S2. 
Histology 
An expert pathologist assessed the inflammation and dysplasia score for all 
selected tissue specimens. The FFPE tissue sections were immunohistological 
stained for PXR (Biolegend) as described before18. The expression of PXR in 
IEC was determined by the immune reactivity intensity of the staining by 
two independent observers. Slides with intense staining in >80% of the IEC 
was scored as positive, staining in 20-80% was scored as mild and <20% 
positive IEC was scored as negative. 
Cell lines and siRNA
Colon carcinoma cell line LS174t was used in all experiments. The cells 
were cultured using standard culturing conditions and needed two passages 
a week. To assess PXR involvement in cell growth a PXR knock down cell-
line was created using siRNA constructs against PXR (LS174t (siPXR)), as 
described before19. LS174t cells transfected with non-target siRNA (LS174t 
(nt)) were used as control. 
Table S2: Baseline characteristics small bowel tissue specimens
Controls
Inactive Crohn’s 
disease
Active Crohn’s 
disease
Adeno-
carcinoma
Total number of patients 17 4 25 7
Mean age, yr (SD) 45 (15) 41 (19) 42 (17) 61 (9)**
Sex (M/F) 8/9 3/1 10/15 5/2
Mean duration disease, yr (SD) - 17 (14) 10 (8)* -
Concomitant medication:
- none - 1 5 -
- aminosalicylates - - 1 -
- corticosteroids - - 7 -
- immunosuppressives - 1 10 -
- biologicals - 3 8 -
* CD patients in the group with active disease had a significantly shorter duration of disease at the 
time the biopsies were collected compared to the group of inactive colitis. p=0.01
** Patients with a sporadic small bowel adenocarcinoma are significantly older that the controls, 
inactive CD, and active CD patients. 
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Growth assays
The LS174t(nt) and LS174t(siPXR) cells were seeded in a 96 well plate, 
with identical concentrations, and cultured for indicated time points using 
normal culture conditions. Cell viability was measured by incubating the cells 
for 3 hours with 4 mG/mL MTT (Sigma-Aldrich), there after the formed 
crystals were dissolved in 100 mL DMSO (Sigma-Aldrich). The colour 
intensity of the DMSO solution was measured using an ELISA plate reader 
at 490nm and 595nm (BioRad). The soft agar culturing technique was used 
to assess the colony-forming capacity. Sterile electrophoresis grade agarose 
was dissolved in warm standard culture medium in a final concentration of 
1.5% and 0.5% (w/v). In a 6 well plate, a single cell suspension (3000 cells 
per well) was taken up in a liquid 0.5% agarose solution and directly poured 
on the already solidified 1.5% bottom layer. After cooling down to RT 2 mL 
standard culture medium was added to cover the agarose layers. Every other 
day the liquid medium was refreshed. Either 100 mM rifampicin or solvent 
(DMSO 0.1% v/v) was added to the medium for this assay. Starting from day 
6 after seeding, images where taken and the colony diameter (pixels) were 
measured using the Nikon Nis Elements® for windows software.
Chemotherapeutic agent resistance assay
To test chemotherapy resistance the LS174t (nt) and LS174t (siPXR) cells 
were stimulated with different concentrations 5-Fluoroacil (5-FU). The cells 
were seeded in a 96 well plate with 10000 cells per well in four different 
wells per 5-FU concentration. At four time points after adding 5-FU (24, 
48, 72 and 96 h) the cell viability was measured using the MTT assay as 
described before. The mRNA expression of genes involved in PXR mediated 
detoxification-pathways was measured in both cell lines cells seeded in a 12 
well plate stimulated with 15 mM 5-FU for 72 h. 
Table S3: Primer sequences
Primer name Sequence from 5’ to 3’
GapdH_fw GCATTGCCCTCAACGACCAC
GapdH_rev CCACCACCCTGTTGCTGTAG
Cyp3a4_fw CAGGAGGAAATTGATGCAGTTTT
Cyp3a4_rev GTCAAGATACTCCATCTGTAGCACAGT
Sult1a_fw GCACCCACCCTGTTCTCTAC
Sult1a_rev ACCACGAAGTCCACGGTCTC
ABCG2_fw CAGCCGTGGAACTCTTTGTG
ABCG2_rev CACTCTGACCTGCTGCTATG
MDR1_fw TTTGGCCATCAGTCCTGTTC
MDR1_rev CTAATTGCTGCCAAGACCTC
PXR_fw ATGGCAGTGTCTGGAACTAC
PXR_rev CAGTTGACACAGCTCGAAAG
RNA isolation and RT-PCR
For mRNA isolation the cultured cells were lysed in TriPure (Roche) 
and mRNA was isolated as described by manufactures protocol. cDNA was 
created using the iScript cDNA synthesis kit (BioRad) according manufactures 
description. Quantitative PCR was performed, as described before20, for the 
genes as described in the figure legends. Primer sequences are described in 
Supplementary Table 3. 
Statistics and software
All the graphs and the statistical analyses were performed using the 
Graphpad Prism 5.0 software package for Windows. Data on different patient 
groups were compared using the Mann-Witney U test with Kruskal-Wallis 
post test and the cell viability assays were compared using a students T-test. 
A two-tailed p value <0.05 was accepted as statistically significant. Images 
were composed using Adobe Photoshop CS6.  
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Results 
Increased PXR expression in neoplastic intestinal tissue
To evaluate the PXR expression in human intestinal biopsies we stained 
the tissue samples for PXR expression. The tissue specimens from healthy 
individuals and patients with inactive IBD, active IBD and LGD do not have 
detectable PXR protein expression in their IEC. Similarly, no PXR expression 
was detected in the biopsy samples taken from the small bowel from healthy 
individuals or CD patients with inactive or active inflammation (Figure 
1A). The absence of PXR expression was unrelated to disease phenotype, 
disease location, duration of disease, or gender. Patients with HGD, IBD-
CRC, sporadic polys and sporadic CRC show abundant PXR expression 
in their IEC, irrespective of intestinal location (Figure 1A). In colonic 
biopsies 80-90% of the specimens with no dysplasia or LGD where scored as 
negative for PXR, whereas 60% of the biopsies with HGD or polyp biopsies 
where scored with mild PXR expression (p<0.01) and even 70-90% of the 
colonic cancer tissue specimens where scores with positive PXR expression 
(p<0.001, Figure 1B). Similar to these results, 90-100% of the non-neoplastic 
small bowel tissue specimens were graded as negative, whereas 60% of the 
slides with small bowel located adenocarcinoma were scored as positive for 
PXR (p<0.001, Figure 1C). Thus, PXR expression is undetectable in non-
neoplastic intestinal tissue but is detectable in pre-neoplastic and intestinal 
cancer tissue independent of cancer etiology. 
PXR impedes cancer cell proliferation in-vitro
To investigate the effect of PXR expression on the proliferation rate and 
survival in IEC, a stable PXR knock down (siPXR), was created using the 
LS174t cell line. From day 11 the number of cells was significantly higher 
in the LS174t (siPXR) compared to the LS174t (nt) cells (p<0.001, Figure 
2A), suggesting enhanced proliferation of the siPXR cells. To examine to 
role of PXR in a high cell-density setting, we seeded the cells at a 16x higher 
concentration. Although the LS174t (siPXR) cells still grew faster, they 
also had a strongly reduced survival from day 13 (p<0.001, Figure 2B). The 
LS174t (siPXR) colony size, measured during the soft agar growth assay, 
was bigger than the LS174t (nt) cells at day 6 and 7 after seeding the cells 
(p<0.05, Figure 2C). This growth advantage was diminished and from day 
18 the colonies of the LS174t (nt) cells were bigger than the LS174t (siPXR) 
cells (p<0.001, Figure 2C). An identical growth pattern was found in the cells 
stimulated with rifampicin (Figure 2D). Only in the PXR expressing cells, 
LS174t (nt), stimulated with rifampicin form bigger colonies than the non-
stimulated cells at day 22 (p<0.01, Figure 2E). In total, the LS174t (siPXR) 
cells formed approximately 100 colonies per well more than the LS174t (nt) 
cells (p<0.01, Figure 2F). Representative images of the formed colonies, per 
analysed day, are presented in Figure S1. 
So, although the expression of PXR is impeding the cancer cell proliferation, 
it is increasing the high cell-density survival of these cells. 
Figure 1: PXR expression in intestinal tissue specimens
A) FFPE Intestinal tissue specimens immunohistochemically stained for PXR. Red-orange immune-
precipitate indicates PXR expression. These images are representative images of intestinal tissue specimens 
from the colon and small bowel. Ctr are controls, iaIBD are quiescent IBD patients, aIBD are IBD patients 
with active disease, LGD are biopsies with low-grade dysplesia, HGD are biopsies with high-grade dysplasia, 
IBD-CRC are biopsies with an IBD related colorectal cancer, Polyp are biopsies from sporadic polyps, CRC 
are biopsies with sporadic colorectal cancer, SB ctr are biopsies from the small bowel of controls, SB iaCD 
are small bowel biopsies from quiescent CD patients, SB aCD are small bowel biopsies from CD patients 
with active disease, SB AC are small bowel biopsies from sporadic small bowel adenocarcinomas. Original 
magnification 200x. 
B) PXR expression score per group of colonic tissue specimens. Ctr n=9, iaIBD n=30, aIBD n=31, LGD n=10, 
HGD n=8, IBD-CRC n=15, polyps n=5, sporadic CRC = 14. 
C) PXR expression score per group of small bowel tissue specimens. Ctr n=17, iaCD n=4, aCD n=25, 
adenocarcinoma n=7. 
B) and C) All tissue specimens were scored for PXR expression by two independent observers in a blinded 
fashion. If 0-20% of the IEC where positive for PXR the slide was scores as negative, 20- 80% was scored 
as mild and 80-100% was scored as positive. The increase in PXR expression was compared using the 
organ specific controls. Mann–Whitney U tests was used for statistical analysis. (*p<0.05, **p < 0.01, 
***p<0.001).
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Chemotherapeutic agent resistance
We measured the cell viability in LS174t (nt) and LS174t (siPXR) cells 
after 5-FU stimulation to investigate the involvement of PXR on chemo 
resistance in IEC. In both cell lines the metabolic activity was decreased by 
50%, compared with the control 72 h after stimulation with 60 mM 5-FU 
(Figure 3A). There was no difference in survival between the two cell lines in 
any of the used concentrations (Figure 3A). Besides, chemotherapeutic agents 
are known to increase the expression of detoxification genes. As shown in 
Figure 3B, 5-FU increases the expression of detoxification-associated genes 
such as Cyp3a4 (p<0.001), ABCG2 (p<0.001), Sult1a (p<0.05) independent 
of PXR. The only difference that could be detected was the expression of 
MDR1, which was only upregulated in LS174t (nt) cells (p<0.01). Our finding 
that Cyp3a4 mRNA expression was not increased in the LS174t (siPXR) cells 
after the stimulation with the specific PXR ligand rifampicin (Figure 3D) 
further confirms that the 5-FU-mediated upregulation is PXR independent. 
Hence explaining why there are no detectable differences in chemotherapeutic 
agent resistance between the PXR expression and non-PXR expressing cells 
in vitro. 
Figure 2: PXR mediated cell proliferation 
A) MTT assay on LS174t (nt) and LS174t (siPXR) cells. For both cell lines a 100 mL cell suspension of 1.6E4 cells 
per mL was added in a 96 well plate. At indicated time points the cell viability was measured by incubating 
the cells for 3 hours with 4 mG/mL MTT. The formed crystals were dissolved in 100 mL DMSO. An ELISA 
reader using the wavelengths 490nm and 595nm measured the colour intensity of the DMSO solution. 
This graph represents the average of four wells per experiment of three independent experiments. Error 
bar is SD,  **p < 0.01, ***p<0.001. 
B) MTT assay on LS174t (nt) and LS174t (siPXR) cells. Similar methodology was used as in A), only this time 
100 mL cell suspension of 2.5E5 cells per mL were used. This graph represents the average of four wells per 
experiment of three independent experiments. Error bar is SD,  *p < 0.05, ***p<0.001.
C) Soft agar growth assay. LS174t (nt) and LS174t (siPXR) cells were single cells seeded in a 6 well plate 
embedded in 0.5% agarose dissolved using standard culture medium with 0.1% (v/v) solvent (DMSO) and 
incubated for in total 22 days using standard culturing conditions. Each time point, at the exact same spot, 
one picture per well was taken and the colony diameter was measured (pixels). The graph represents an 
average diameter of the 4 largest colonies per picture, three wells per cell line per experiment and three 
independent experiments. Error bar is SEM, *p < 0.05, **p<0.01, ***p<0.001. 
D) Soft agar growth assay with rifampicin. Similar methodology as in C) was used, only now 100mM 
rifampicin was added. Error bar is SEM, *p < 0.05, ***p<0.001.
E) Soft agar growth colony size after 22 days. The average colony diameter (pixels) per cell line, per 
condition is presented in this graph. Error bar is SEM, **p<0.01, ***p<0.001. 
F) Total amount of formed colonies. For the LS174t (nt) and LS174t (siPXR) cells the total amount of formed 
colonies per well was counted. The graph represents an average amount of colonies per well, three wells 
per cell line per experiment and three independent experiments. Error bar is SEM, **p<0.01. 
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Figure 3: Chemotherapeutic agent resistance 
A) MTT assay on 5-FU stimulated LS174t (nt) and LS174t (siPXR) cells. Both cell lines were seeded in a 96 
well plate in 10000 cells per well. The cells were stimulated with different concentrations of 5-FU for 72 
h. Ctr is the control were nothing was added to these cells, DMSO is the control for the condition with the 
highest solvent concentration (0.5% v/v). This graph represents the average of six wells per experiment of 
two independent experiments. Error bar is SD. 
B) The expression of multi drug resistant associated genes. The mRNA expression of the indicated genes 
was measured in the LS174t (nt) cells and the LS174t (siPXR) cells stimulated with 15 mM 5-FU for 72 h. 
These graphs represent the average of two independent experiments. Error bar is SD. The increase in 
expression was compared per cell line to the un-stimulated cells using a non-parametric t-test, *p < 0.05, 
** p<0.01 and ***p<0.001. 
C) PXR specific stimulation by rifampicin. LS174t (nt) and LS174t (siPXR) cells were stimulated with 100 
mM rifampicin to test the specificity of the PXR knock down. This graph represents the average, of two 
independent experiments performed in duplo, mRNA expression of Cyp3a4. Error bar is SD, *** p<0.001. 
Figure S1: soft agar growth assay images. 
LS174t (nt) and LS174t (siPXR) cells (3000 per well) were seeded in a 6 well plate using a 0.5% agarose 
medium solution on top of a 1.5% agarose in medium base layer. At indicated time points (number left 
upper-corner each image, days) an image was taken. The medium contains either 0.1% (v/v) DMSO or 100 
mM rifampicin.
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Discussion
There is no consistent literature concerning the expression and the 
function of PXR in human cancers12-14, 16. Therefore we investigated the 
expression and function of PXR in IBD related and non-IBD related CRC. 
In this study we are able to show that the PXR expression is increased in 
human neoplastic intestinal tissue specimens. In addition we found that 
although the cells that express PXR grow slower, they had increased high 
cell density survival. In addition, PXR expression does not play a role in the 
5-FU chemotherapy resistance in vitro. 
In a recent study by Ouyang et al., the authors concluded that the 
expression of PXR is absent in intestinal cancers and that the presence of 
PXR is inhibits the cell growth13. We also find decreased cell growth in PXR 
expressing cells in our study, but by contrast we detected high PXR expression 
in the neoplastic tissue samples. We cannot rule out that this difference is due 
to different antibodies used for the IHC staining. However, in line with our 
results another study also showed an abundant PXR mRNA expression in 
IEC of patients with CRC3. Moreover, we used the same antibody as was used 
for another study in our lab18 showing that the used antibody is specific for 
the detection of PXR. 
Cancer cells proliferate quickly and unlimited, but even more important 
is that the cancer cells survive longer than normal IEC, which can lead to 
tumour progression and metastasis21. The MTT and soft agar growth assay 
show that the LS174t (nt) cells seem to survive longer than the LS174t (siPXR) 
cells. This indicates that the PXR expression in cancer cells might be beneficial 
for the tumour. Stimulating PXR expressing cells with rifampicin increases 
the growth and likely prolongs survival of the cells even further, which is in 
line with earlier observations16, 17. Further research is needed to examine the 
exact role of PXR in cancer cell survival. Of more interest, actively reducing 
the PXR expression in cancer can be a promising therapeutic approach for 
patients with CRC. 
PXR is also described to be a biomarker for neoplastic progression in 
patients with barrettes oesophagus18. In the biopsies with HGD, a precursor 
of IBD-CRC, already a mild increased PXR expression could be detected. 
Next to that, similar results were found in the polyp tissue-specimens, a 
precursor for sporadic cancer. We can conclude from this that PXR could 
also be a marker for neoplastic progression in intestinal tissue specimens. 
Despite of the nuclear PXR expression that was observed before18, we could 
not detect nuclear expression of PXR in IEC. Probably the different luminal 
ligand composition of the various organs will influence the localisation of 
PXR. Besides, PXR also has a distinct cytoplasmic function, since that the 
cytoplasmic presence of PXR is already sufficient to execute PXR mediated 
cellular effects15, 16. In general, PXR expression in IEC is increased in 
neoplastic intestinal tissues and affects the proliferation and survival of these 
cells. 
A chemotherapeutic agent such as 5-FU is a common therapy in patients 
with CRC. 5-FU inhibits the DNA replication of proliferating cells22. Despite 
the specificity of 5-FU, the response rate to this compound, if given as first 
line therapy, is just 10-15% and decreases even further in severe metastatic 
disease22. This lack of treatment response may be contributed by induced 
expression of multi-drug resistance proteins such as, ABCG223 which 
expression is correlated with PXR expression24. From our study we know 
that neoplastic IEC express PXR, PXR expression inhibits cell growth 
but prolongs cell survival. Hence, we hypothesised that the cancer cells 
without PXR expression respond better to the 5-FU treatment, since highly 
proliferative cells are more sensitive to 5-FU22. However, there is no difference 
in survival between the LS174t (siPXR) and LS174t (nt) cells by using 5-FU 
stimulation. The expression of genes associated with multi-drug resistance 
23 was increased in both cell lines after 5-FU stimulation, suggesting that 
PXR is not the only NR involved in multi drug resistance, and not involved 
in 5-FU resistance25. Thus, solely reducing the PXR expression, in respect to 
chemotherapy resistance, might not be sufficient for intestinal cancer patients. 
In conclusion, PXR is abundantly expressed in human intestinal cancers 
irrespective of the cancer origin or intestinal location. High PXR expression 
reduces the cancer cell proliferation, improves high cell density survival, but 
PXR expression is not influencing the chemotherapy resistance. In respect 
to the PXR mediated reduced cell survival, a therapeutically approach to 
inhibit the PXR expression in intestinal cancer is a promising area for further 
investigation.
Chapter IV |   81 80   | Chapter IV
PXR expression in intestinal neoplastic progression
IV
Back to Index
References
1. Kliewer SA, Goodwin B, Willson TM. 
The nuclear pregnane X receptor: a key 
regulator of xenobiotic metabolism. 
Endocr Rev 2002;23:687-702.
2. Blumberg B, Sabbagh W, Jr., Juguilon 
H, et al. SXR, a novel steroid and 
xenobiotic-sensing nuclear receptor. 
Genes Dev 1998;12:3195-205.
3. Raynal C, Pascussi JM, Leguelinel 
G, et al. Pregnane X Receptor 
(PXR) expression in colorectal 
cancer cells restricts irinotecan 
chemosensitivity through enhanced 
SN-38 glucuronidation. Mol Cancer 
2010;9:46.
4. Chen Y, Tang Y, Wang MT, et al. 
Human pregnane X receptor and 
resistance to chemotherapy in prostate 
cancer. Cancer Res 2007;67:10361-7.
5. Kast HR, Goodwin B, Tarr PT, et al. 
Regulation of multidrug resistance-
associated protein 2 (ABCC2) by the 
nuclear receptors pregnane X receptor, 
farnesoid X-activated receptor, and 
constitutive androstane receptor. J 
Biol Chem 2002;277:2908-15.
6. Pfrunder A, Gutmann H, Beglinger 
C, et al. Gene expression of CYP3A4, 
ABC-transporters (MDR1 and 
MRP1-MRP5) and hPXR in three 
different human colon carcinoma cell 
lines. J Pharm Pharmacol 2003;55:59-
66.
7. Langmann T, Moehle C, Mauerer 
R, et al. Loss of detoxification 
in inflammatory bowel disease: 
dysregulation of pregnane X receptor 
target genes. Gastroenterology 
2004;127:26-40.
8. Blokzijl H, Vander Borght S, Bok LI, et 
al. Decreased P-glycoprotein (P-gp/
MDR1) expression in inflamed human 
intestinal epithelium is independent of 
PXR protein levels. Inflamm Bowel 
Dis 2007;13:710-20.
9. Baars JE, Kuipers EJ, van Haastert M, 
et al. Age at diagnosis of inflammatory 
bowel disease influences early 
development of colorectal cancer in 
inflammatory bowel disease patients: a 
nationwide, long-term survey. Journal 
of gastroenterology 2012.
10. Eaden J. Review article: colorectal 
carcinoma and inflammatory bowel 
disease. Alimentary pharmacology & 
 
 therapeutics 2004;20 Suppl 4:24-30.
11. Riddell RH, Goldman H, Ransohoff 
DF, et al. Dysplasia in inflammatory 
bowel disease: standardized 
classification with provisional clinical 
applications. Hum Pathol 1983;14:931-
68.
12. Gupta D, Venkatesh M, Wang H, et 
al. Expanding the roles for pregnane 
X receptor in cancer: proliferation and 
drug resistance in ovarian cancer. Clin 
Cancer Res 2008;14:5332-40.
13. Ouyang N, Ke S, Eagleton N, et al. 
Pregnane X receptor suppresses 
proliferation and tumourigenicity 
of colon cancer cells. Br J Cancer 
2010;102:1753-61.
14. Verma S, Tabb MM, Blumberg 
B. Activation of the steroid and 
xenobiotic receptor, SXR, induces 
apoptosis in breast cancer cells. BMC 
Cancer 2009;9:3.
15. Zhou C, Tabb MM, Nelson EL, et al. 
Mutual repression between steroid and 
xenobiotic receptor and NF-kappaB 
signaling pathways links xenobiotic 
metabolism and inflammation. J Clin 
Invest 2006;116:2280-2289.
16. Zhou J, Liu M, Zhai Y, et al. The 
antiapoptotic role of pregnane X 
receptor in human colon cancer cells. 
Mol Endocrinol 2008;22:868-80.
17. Wang H, Venkatesh M, Li H, et 
al. Pregnane X receptor activation 
induces FGF19-dependent tumor 
aggressiveness in humans and mice. J 
Clin Invest 2011;121:3220-32.
18. van de Winkel A, van Zoest KP, van 
Dekken H, et al. Differential expression 
of the nuclear receptors farnesoid 
X receptor (FXR) and pregnane X 
receptor (PXR) for grading dysplasia 
in patients with Barrett’s oesophagus. 
Histopathology 2011;58:246-53.
19. Henry SD, Pan Q, van der Laan LJ. 
Production of multicopy shRNA 
lentiviral vectors for antiviral therapy. 
Methods in molecular biology 
2011;721:313-32.
20. Deuring JJ, de Haar C, Koelewijn CL, 
et al. Absence of ABCG2-mediated 
mucosal detoxification in patients with 
active inflammatory bowel disease 
is due to impeded protein folding. 
Biochem J 2011.
21. Lowe SW, Lin AW. Apoptosis in 
cancer. Carcinogenesis 2000;21:485-
95.
22. Longley DB, Harkin DP, Johnston PG. 
5-fluorouracil: mechanisms of action 
and clinical strategies. Nature reviews. 
Cancer 2003;3:330-8.
23. Yuan JH, Cheng JQ, Jiang LY, et 
al. Breast cancer resistance protein 
expression and 5-fluorouracil 
resistance. Biomedical and 
environmental sciences : BES 
2008;21:290-5.
24. Naspinski C, Gu X, Zhou GD, et al. 
Pregnane X receptor protects HepG2 
cells from BaP-induced DNA damage. 
Toxicological sciences : an official 
journal of the Society of Toxicology 
2008;104:67-73.
25. Urquhart BL, Tirona RG, Kim RB. 
Nuclear receptors and the regulation 
of drug-metabolizing enzymes and 
drug transporters: implications 
for interindividual variability in 
response to drugs. J Clin Pharmacol 
2007;47:566-78.
V
Impeded Protein Folding and 
Function in Active 
Inflammatory Bowel Disease 
J. Jasper Deuring 
Maikel P. Peppelenbosch
 Ernst J. Kuipers
C. Janneke van der Woude+
Colin de Haar+
+ CvdW and CdH share senior authorship
Biochemical Society Transactions, (2011) 39, 1107–1111
Chapter V |   85 84   | Chapter V
Impeded protein folding during active IBD
V
Back to Index
Abstract
An area of 300 square meters of intestinal epithelial cells (IEC) is covering 
the entire intestinal mucosa. The IEC are equipped with membrane-bound 
and secreted proteins for protection against luminal xenobiotics, pathogens 
and commensal microbes. In patients with active inflammatory bowel disease 
the expression of these proteins, e.g. defensins and ABC-transporters like 
ABCG2 in IEC is decreased, leaving the underlining tissue less protected 
against luminal threats. 
Correct endoplasmic reticulum (ER)-dependent protein folding is essential 
for the location and function of secreted and membrane-bound proteins. 
Inflammatory triggers, like cytokines and nitric oxide can impede protein 
folding causing unfolded proteins to accumulate inside the ER. As a result, 
the unfolded protein response is activated which than leads to ER stress. This 
protein-folding impairment affects several proteins with great importance 
in cellular protection against xenobiotics. In this review we discuss how 
inflammation may affect the protein folding leading to IEC malfunction. 
Introduction
IECs (intestinal epithelial cells) and their products form a physical barrier 
between the host and the luminal content. They have to deal with the complex 
situation where they absorb nutrients and water, and also protect the host 
from commensal microbes, pathogens and toxic compounds. Various specific 
adaptations, such as tight junctions and microfolds, as well as specialized 
IECs such as goblet cells and Paneth cells, enable these cells to carry out 
their complex task1. 
To protect themselves from toxic compounds, such as xenobiotics, IECs 
are able to sense, degrade and actively transport various toxic compound out 
of the cell by specific membrane-bound exporters2. Mucosal disorders such 
as IBD (inflammatory bowel disease) are associated with a disturbance of 
this well-regulated intestinal homoeostasis3. One of the cellular processes 
that seem to be affected by inflammation is ER (endoplasmic reticulum)-
dependent protein folding. The present review focuses on how inflammation 
may affect protein folding and function leading to ER stress followed by IEC 
malfunction.
ER stress
Secreted and membrane-bound proteins undergo a folding quality check 
before they are released from the ER. Un- or mis-folded proteins are extracted 
from the ER and degraded. This process is called ERAD (ER-associated 
degradation). However, when un- and mis-folded proteins accumulate 
inside the ER, the UPR (unfolded protein response) is activated. Upon UPR 
activation, three major intracellular pathways are activated, namely IRE1 
(inositol-requiring enzyme 1), PERK PKR (double-stranded-RNA-dependent 
protein kinase)-like ER kinase and ATF6 (activating transcription factor 
6). All three proximal UPR effectors start transcription of genes that are 
involved in reducing the unfolded protein load in the ER, e.g. ERAD. The 
mechanism of these three pathways have been described previously4. 
A proportion of proteins, translated in the ER, will always be misfolded 
due to the complexity of the protein folding process and in the case of high 
protein production demand. As such, cells with a high secretory activity, 
e.g. intestinal goblet and Paneth cells, have a constitutively activated ER- 
stress response. Hence, these cells are extremely sensitive to environmental 
changes, such as inflammation, which could affect protein synthesis or 
folding5. Interestingly, mutations in genes involved in the ER-stress response 
are associated with an increased risk for developing IBD6. Genetic defects in 
the ER-stress pathway may therefore contribute to a malfunction of these 
highly active secretory cells that play a crucial role in intestinal homoeostasis.
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Intestinal inflammation, protein folding and ER stress 
Patients with IBD, which includes Crohn’s disease and ulcerative colitis, 
are at risk for a chronically inflamed intestinal tract. Active intestinal 
inflammation is associated with an increased intestinal levels of cytokines, 
chemokines7,8 and nitric oxide (NO)9. These innate inflammatory responses, 
such as TNFα (tumour necrosis factor α) and ROS (reactive oxygen species), 
can directly affect protein folding10. At the same time, IEC stimulation is 
provoked by inflammatory cytokines11, microbial product recognition by 
IECs12 and secreted growth factors13, which all may increase cellular protein 
synthesis. These triggers increase the protein production, which can be 
catastrophic for normal goblet and Paneth cells14, leading to intestinal 
inflammation. A large number of high-impact research papers and reviews 
have been published on the molecular pathogenesis of inflammation provoked 
by ER stress, genetic predisposition for ER stress and the ability of ER stress 
to aggravate inflammation4–6,14–16. However, the effect of ER stress on protein 
expression and function in cells is less well known.
Inflammatory triggers that can provoke ER stress 
Chaperones and heat-shock proteins mediate protein folding inside the 
ER. For example, GRP78 (glucose-regulated protein 78) binds and secures 
unfolded proteins inside the ER until they are properly folded17. The PDI 
(protein disulfide-isomerase) family catalyses the obligatory disulfide bonds 
within or between proteins18. These helper proteins are crucial for the ER to 
deal with the high protein concentration. A disturbance in the function of 
these helper proteins can cause unfolded proteins to accumulate and activate 
ER-stress pathways. 
Interestingly, NO inhibits the function of PDI by S- nitrosylation of 
its catalytic domains, which leads to the accumulation of unfolded proteins 
inside the ER and subsequently activates ER stress19,20. Furthermore, NO 
is a small and reactive molecule that can affect protein folding through 
different approaches as well21. Activated innate immune cells in active IBD 
are associated with an increased NO concentration9. The inhibitory effect of 
high concentrations of NO on protein folding is considered to affect protein 
folding in IECs during IBD. Other inflammatory triggers such as bacterial 
cytotoxins can also affect protein folding and thereby induce ER stress22. 
As discussed above, protein synthesis in general is stim- ulated by 
chemokines, cytokines and bacterial compounds11–13. It is conceivable that this 
increased protein synthesis leads to the accumulation of unfolded proteins 
whereupon ER stress signals are activated. 
Other well-described factors that can provoke proteins to misfold are 
glucose and oxygen depravation. N-glycosylation of proteins inside the ER 
is an important post-translational protein modification. N-glycosylation 
increases the stability and solubility of proteins and protects them from 
proteases. Before ER-dependent proteins pass through the ER quality check, 
a large group of linked sugar molecules are added to specific amino acids23. 
Active mucosal inflammation increases the need for nutrients and oxygen as 
activated immune cells are in considerable need of oxygen and nutrients to 
defend the mucosa from invading microbes24. The increased proliferation of 
IECs25 also requires a significant amount of energy. As such, inflammation 
limits the amount of glucose thereby affecting correct protein folding26. 
In addition to this, intestinal inflammation results in oxygen deprivation, 
e.g. hypoxia and production of ROS such as NO. The epithelium is protected 
against inflammation- induced hypoxia by activating the transcription factor 
HIF1 (hypoxia-inducible factor 1)27. Nonetheless, in patients with active IBD, 
HIF1 is abundantly expressed28, indicating that actively inflamed intestinal 
lesions are under severe hypoxia. The exact molecular role of hypoxia during 
inflammation has been described previously24,29. Protein folding inside the 
ER is dependent on an electron-relay system that requires oxygen as electron 
acceptor. Folding proteins such as PDI are dependent on oxygen as a terminal 
electron acceptor in the formation of protein disulfide bonds30. Interestingly, 
HIF1 induces the expression of proteins in the relay of protein disulfide bond 
formation, providing a link between hypoxia and UPR. 
In summary, there are several inflammation-associated triggers that 
provoke impeded protein folding and eventually lead to UPR and ER stress 
and these can be found in Figure 1. 
Effect of inflammation-induced ER stress
As mentioned above, different specialized proteins protect IECs from 
toxins present in luminal content. The function and expression of the 
membrane-bound exporters are depending on proper N-glycosylation and 
disulfide bonds31,32. It has been described previously that the expression 
of xenobiotic and bile acid transporters, such as P- glycoprotein MDR1 
(multidrug-resistance 1)/ABCB1 (ATP-binding cassette transporter B1)33 
and ABCG2 (ATP-binding cassette transporter G2) BCRP (breast cancer 
resistance protein)34,35, are decreased in mucosal biopsies from patients 
with active IBD. This process is linked to a decreased mRNA expression. 
Despite these findings, the reduced mRNA expression is unlikely to be 
sufficient to explain the complete loss of protein expression as was seen using 
immunohistological staining34,35. Inflammation-induced protein misfolding 
Figure 1. Schematic overview of inflammation-associated triggers which can provoke protein misfolding 
ER-dependent protein folding in IECs of patients with active IBD is affected by several inflammatory triggers.
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(ER stress) provides a possible additional mechanism. As the creation of 
disulfide bonds is inhibited by NO20,21 and these disulfide bonds are essential 
for the function of xenobiotic transporters, such as ABCG231,32, it can be 
assumed that these proteins are not properly folded and therefore reduced 
in expression during inflammation. A schematic overview of ABCG2 folding 
and misfolding is shown in Figure 2. 
This reduction in transporter protein expression indicates that IECs with 
inflammation-induced ER stress are impeded in their protection from toxic 
bile acids and other luminal toxic compounds. As a result, the risk for genomic 
DNA damages and thus eventually neoplastic progression is increased. 
In addition to the inflammation-associated decrease in xenobiotic 
transporter expression, other proteins are also decreased during inflammation. 
Two non-intestinal examples of affected protein folding induced by NO have 
been found. Insulin, a small excreted protein with at least three disulfide 
bonds, is reduced in expression by an increased NO concentration triggered 
by inflammation36. A similar reduced protein excretion of vascular endothelial 
growth factor, a protein with at least five disulfide bonds, has been described 
under the influence of high NO concentrations37. Both unrelated excreted 
proteins are reduced in expression because of impeded protein folding in the 
presence of a high NO concentration. 
Diarrhoea can be a symptom of patients with IBD, and is caused by changes 
in electrolyte transport during intestinal inflammation. This is underlined 
by the fact that membrane- bound sodium transporters and their regulating 
proteins are decreased in expression during active IBD38. Moreover, these 
sodium transporters, e.g. Na+/H+ exchangers and epithelial Na+ channel, 
require multiple aminoacid modifications such as N-glycosylation. Nutrition 
deprivation in the intestinal inflammatory lesions apparently reduces the 
ability to undergo N-glycosylation of ER-dependent proteins, whereupon 
unfolded proteins accumulate and ER stress is activated26. Thus, upon glucose 
deprivation, these sodium transporters are likely to be misfolded and degraded 
from the ER. The inflammation-associated decrease in protein expression of 
Toll-like receptor 539 and monocarboxylate transporter 140 could be explained 
by the same mechanism. 
Highly active secretory cells, e.g. Paneth cells, are sensitive to changes 
in protein folding mechanisms because of their constitutive ER stress 
activation14. In addition to the production of mucus-soluble defensins and 
lysozymes, Paneth cells have important functions in maintaining the stem 
cell niche in intestinal crypts41. Consequently, inflammation-induced protein 
folding issues inhibit the regular function of Paneth cells and probably 
diminish intestinal stem cell homoeostasis. This will reduce the ability of a 
fast regenerative IEC seal in covering the inflamed intestinal mucosa, leaving 
the lamina propria exposed.
ER stress as therapeutic target for intestinal inflammation 
Studies in metabolic diseases discuss different approaches to regulate ER 
stress42. In the management of IBD, however, there are almost no ER stress-
regulating strategies proposed. From studies in metabolic diseases, chemical 
chaperones, such as 4-phenylbutyric acid, DMSO and bile acid conjugates 
of ursodeoxycholic acid, are found to provide protein stability and improve 
the ER protein folding capacity43. Inhibition of phosphorylation of the UPR 
downstream target eIF2α (eukaryotic initiation factor 2a) by a small molecule 
named salubrinal protects cells from ER stress- associated apoptosis44. 
Although these approaches are promising, their molecular effect on human 
disease remains unclear. In contrast, conventional therapy for IBD aims to 
get IBD patients in inflammatory remission. As such, it can be argued that, 
as a result of reducing inflammatory activity, fewer proteins will misfold and 
the stress inside the ER is diminished. Thus the question remains whether it 
is necessary to investigate the possibilities of reducing protein misfolding in 
IECs specifically for patients with IBD not suffering from a genetic defect in 
their ER-stress response.
Conclusions
Current knowledge provides insight into the substantial effects of impeded 
protein folding in inflammatory intestinal disease. Xenobiotic transporters 
such as ABCG2, but also excreted proteins such as lysosyme, are reduced in 
expression in IECs due to impeded protein folding. 
Overall, much more research is needed to fully understand the 
consequence of impeded protein folding during active IBD. Questions such 
as why are proteins prone to misfold by high concentrations of NO and which 
other proteins are affected in expression by misfolding are interesting areas 
of research.
Figure 2. ABCG2 protein folding and misfolding
The function and cellular location of ABCG2 is dependent on proper protein folding. Protein modifications 
such as inter- and intra-molecular disulfide bonds and N-glycosylation are executed before ABCG2 is 
localized on the membrane. During active inflammation, the increased NO concentrations and low sugar 
concentrations affect ABCG2 protein folding whereupon improper folded ABCG2 will be degraded.
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Abstract 
Xenotoxic damage in inflammatory diseases, including IBD (inflammatory 
bowel disease), is compounded by reduced activity of the xenobiotic 
transporter ABCG2 (ATP-binding-cassette G2) during the inflammatory 
state. An association between the activation of the unfolded protein response 
pathway and inflammation prompted us to investigate the possibility that 
reduced ABCG2 activity is causally linked to this response. To this end, we 
correlated expression of ABCG2 and the unfolded protein response marker 
GRP78 (glucose-regulated protein of 78 kDa) in colon biopsies from healthy 
individuals (n = 9) and patients with inactive (n = 67) or active (n = 55) IBD, 
ischaemic colitis (n = 10) or infectious colitis (n = 14). In addition, tissue 
specimens throughout the small bowel from healthy individuals (n = 27) and 
from patients with inactive (n = 9) or active (n = 25) Crohn’s disease were 
co-stained for ABCG2 and GRP78. In all biopsies from patients with active 
inflammation, irrespective of the underlying disease, an absolute negative 
correlation was observed between epithelial ABCG2 expression and GRP78 
expression, suggesting that inflammation-dependent activation of the 
unfolded protein response is responsible for suppression of ABCG2 function. 
The link between the unfolded protein response and functional ABCG2 
expression was further corroborated by live imaging of ABCG2-expressing 
cells, which showed that various inflammatory mediators, including nitric 
oxide, activate the unfolded protein response and concomitantly reduce plasma 
membrane localization as well as transport function of ABCG2. Thus a novel 
mechanism for explaining xenobiotic stress during inflammation emerges 
in which intestinal inflammation activates the unfolded protein response, in 
turn abrogating defences against xenobiotic challenge by impairing ABCG2 
expression and function.
Introduction
The intestinal epithelium is a single cell physical barrier between the gut 
luminal content and mucosa, important for detection1 and defence2,3 against 
microbes. IECs (intestinal epithelial cells) are constantly exposed to a large 
variety of xenobiotic substances, including microbes and their products, as 
well as exogenous (e.g. drugs or food) and endogenous (e.g. bile acids) toxic 
substances present in the luminal content. IECs utilize various mechanisms 
to maintain epithelial integrity in the face of a xenobiotic challenge. They are 
protected against exogenous and endogenous toxic compounds by, among 
others, proteins from the ABC (ATP-binding-cassette) transporter family. 
This family includes P-glycoprotein/MDR1 (multidrug resistance 1)/ABCB1, 
MRP1 (multidrug-resistance protein-1)/ABCC1, MRP2/ABCC2 and BCRP 
(breast cancer resistance protein)/ABCG24,5. In particular, the homodimeric 
xenobiotic transporter ABCG2, which specifically localizes to the IEC apical 
membrane, is widely considered to be especially important in combating 
luminal- derived xenobiotic stress6,7.
Disruption of IEC integrity leads to inflammatory lesions, which are a 
hallmark of active inflammation in patients with IBD (inflammatory bowel 
disease). The appropriate response to such a disruption requires rapid mucosal 
healing by cell division, differentiation and maturation to restore barrier 
function8,9. Active inflammation in patients with IBD has been associated 
with a dramatically reduced expression of ABC transporters in IECs and the 
resulting diminished capacity to deal with luminal xenobiotic challenge is 
thought to interfere with the efficiency of regenerative responses7,10–12. Further 
compounding this problem is that several medications used in IBD are specific 
substrates of ABCG2. Hence understanding the mechanisms governing 
ABCG2 expression is highly relevant for devising improved therapy13,14. 
Nevertheless, the molecular mechanisms driving ABCG2 expression during 
inflammatory responses remain obscure at best.
Generally, excreted and membrane-bound proteins are translated in 
the ER (endoplasmic reticulum). If ER function is disrupted, proteins can 
accumulate inside the ER, and this can initiate a specific ER stress syndrome 
known as the unfolded protein response. Abnormalities in the ER stress 
response pathways have been associated with the pathogenesis of IBD15–17. 
Proper function of the ABCG2 protein depends on N-glycosylation and the 
formation of inter-/intra-molecular disulfide bonds18,19. These bonds are 
formed inside the ER by PDIs (protein disulfide-isomerases). Inflammatory 
conditions, such as increased nitric oxide production, can dramatically reduce 
the efficiency of these PDIs, which can initiate misfolding of various proteins, 
leading to ER stress20,21. As correct ABCG2 protein folding is necessary for 
its functionality, we hypothesized that mucosal inflammation in the setting 
of IBD alters proper ABCG2 protein folding and thereby reduces its apical 
expression. In the present study we describe a novel mechanism by which 
ABCG2 protein expression is decreased during active inflammation.
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Methods
Patient samples
The present study was conducted with the approval of the Ethics 
Committee of Erasmus MC University Medical Centre, Rotterdam. Consent 
was obtained from all patients participating in the study.
Patient materials
FFPE (formalin-fixed paraffin-embedded) colonic biopsies were collected 
from nine healthy individuals and from 76 patients: 25 with CD (Crohn’s 
disease), 36 with UC (ulcerative colitis), ten with ischaemic colitis and five 
with infectious colitis. Biopsies throughout the small intestine were collected 
from 17 other healthy individuals and 34 CD patients. For mRNA isolation, 
freshly frozen biopsies were collected from six healthy individuals and from 
15 patients: eight with inactive IBD and seven with active IBD. To compare 
the ABCG2 protein expression throughout the large bowel of IBD patients, 
two samples per patient were selected from the right and left hemi-colon. 
To investigate whether the ABCG2 expression pattern was specific for IBD, 
biopsies from patients with ischaemic and infectious colitis were included. As 
controls, we obtained colon and small bowel biopsy specimens from patients 
without IBD or any other underlying disease. The demographic characteristics, 
number of biopsies per group, duration of disease and medication use are 
described in Tables S1–S3. 
Immunohistochemistry and scoring
FFPE sections were immunohistologically stained using the primary 
antibodies BXP-21 anti-ABCG2 (1:300, Santa Cruz Biotechnology) and BiP 
(1:400, immunoglobulin heavy-chain-binding protein) anti-GRP78 (glucose-
regulated protein of 78 kDa; Cell Signaling Technology) according to the 
manufacturers’ protocol. The expression of ABCG2 and GRP78 in IECs was 
scored by the intensity over the whole slide by two independent observers, 
and discrepancies were re-assessed to come to a final agreement. Individual 
scores were used for statistical analyses, whereas they were combined into 
three subgroups for graphic representation. ABCG2-positive staining at the 
apical membrane of the epithelial cells was defined as positive if >50 % of the 
IECs were positive, mild if 15–50 % or negative if <15 %. Immunoreactivity 
for GRP78 was also defined in terms of positive IECs, but now the percentages 
were: >70 % defined as positive, 20–70 % as mild and <20 % as negative.
mRNA isolation and qPCR (quantitative PCR)
mRNA was isolated from colonic biopsies, which were taken from CD 
and UC patients, using the NucleoSpin Extract II mRNA isolation kit 
(Macherey Nagel). Gene expression of GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase), IL8 (interleukin 8), IL1β, ABCG2, villin and the ER-
stress- associated gene CHOP C/EBP (CCAAT/enhancer binding protein) 
homologous protein20 were measured using qPCR (IQ5, Bio-Rad). Villin and 
ABCG2 are both IEC-specific, thus ABCG2 mRNA was corrected for villin 
Table S1: Baseline characteristics of healthy individuals, patients with inactive IBD, 
active IBD, ischemic- and infectious colitis. 
Controls
Inactive 
colitis
Active 
colitis
Ischemic 
colitis
Infectious 
colitis
Total number of patients 9 30 31 10 5
Crohn’s disease (n) - 12 13a - -
Ulcerative colitis (n) - 18 18b - -
Mean age, yr (SD) 41 (16) 53 (16) 43 (16)* 61 (23)† 59 (18)
Sex (M/F) 4/5 12/18 17/14 3/7 3/2
Mean duration of 
disease, yr (SD)
- 22 (10) 15 (11)* - -
Concomitant medication:
- none - 6 5 - -
- aminosalicylates - 16 18 - -
- corticosteroids - 5 11 - -
- immunosuppressives - 9 9 - -
- biologicals - 2 2 - -
Total number of tissue 
samples 9 67 55 10 14
a Includes 3 patients with only right-sided colitis
b Includes 4 patients with only left-sided colitis
* IBD patients in the group of active colitis were significantly younger and had a shorter duration of 
disease at the time the biopsies were collected compared to the group of inactive colitis. p=0.001 and 
p=0.001, respectively
† Ischemic colitis patients are significantly older than all other patients groups. p<0.05
Table S2: Baseline characteristics of small bowel biopsies of healthy individuals, patients 
with inactive- and active Crohn’s disease
Controls
Inactive 
Crohn’s disease
Active Crohn’s 
disease
Total number of patients 17 4 25
Mean age, yr (SD) 45 (15) 41 (19) 42 (17)
Sex (M/F) 8/9 3/1 10/15
Mean duration of disease, yr (SD) - 17 (14) 10 (8)*
Concomitant medication:
- none - 1 5
- aminosalicylates - - 1
- corticosteroids - - 7
- immunosuppressives - 1 10
- biologicals - 3 8
Total number of tissue samples 27 9 25
* CD patients in the group with active disease had a significantly shorter duration of disease at the time 
the biopsies were collected compared to the group of inactive colitis . p=0.01
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Table S3: Baseline characteristics of healthy individuals, patients with inactive IBD and 
active IBD, for mRNA isolation. 
Controls Inactive colitis Active colitis
Total number of patients 6 8 7
Crohn’s disease (n) - 4 4
Ulcerative colitis (n) - 4 3
Mean age, yr (SD) 38 (19) 40 (21) 34 (10)
Sex (M/F) 2/4 3/5 5/2
Mean duration of disease, yr (SD) - 10 (5) 13 (6)
Concomitant medication:
- none - 1 3
- aminosalicylates - 2 3
- corticosteroids - 4 1
- immunosuppressives - 1 1
- biologicals - 2 -
Total number of tissue samples 6 8 7
Table S4: Primer sequences 
Primer name Sequence from 5’ to 3’
ABCG2_Fw(XhoI)
CTCGAGCTGGTGCCGGCGCAGGAGCGGGTGCAGGCGCTG-
GAATGTCTTCCAGTAATGTCGAAG
ABCG2_Rev(SalI) GTCGACTTAAGAATATTTTTTAAGAAATAAC 
XBP-1 splicing fw AAACAGAGTAGCAGCTCAGACTGC
XBP-1 splicing rev TCCTTCTGGGTAGACCTCTGGGAG
GapdH_fw_qPCR GCATTGCCCTCAACGACCAC
GapdH_rev_qPCR CCACCACCCTGTTGCTGTAG
IL-8_fw_qPCR CACTGCGCCAACACAGAAATTA
IL-8_rev_qPCR ACTTCTCCACAACCCTCTGCAC
ABCG2_fw_qPCR CAGCCGTGGAACTCTTTGTG
ABCG2_rev_qPCR CACTCTGACCTGCTGCTATG
IL-1b_fw_qPCR CCCTAAACAGATGAAGTGCTCCTT
IL-1b_rev_qPCR GTAGCTGGATGCCGCCAT
CHOP_fw_qPCR GGAGCTGGAAGCCTGGTATG
CHOP_rev_qPCR CCTCAGTCAGCCAAGCCAGAG
Villin_fw_qPCR GAGCCACCTCATCTTATGTC
Villin_rev_qPCR CCCGGTCTCCAAGTTGTTAG
to prevent underestimation in biopsies with fewer IECs. From each sample, 
1 μg of isolated mRNA was reverse- transcribed to cDNA using the cDNA 
synthase kit iScript (Bio- Rad). Gene expression was measured using 50 
ng of cDNA together with 10 pM gene-specific primer in a 25 μl real-time 
qPCR mixture (SensiMix; Bioline). Duplicate samples were run three times 
independently, and the average gene expression was normalized to GAPDH 
(for IL8, IL1β and CHOP) and villin (for ABCG2) using the ΔΔCt method. 
The primers used are described in Table S4.
Cell culture
HEK-293T human embryonic kidney-293 cells expressing the large 
T-antigen of SV40 (simian virus 40); A.T.C.C.; CRL-1573 cells were cultured 
according to routine procedures. Transient transfection was performed 
using polyethylenimine (Polysciences). SNAP (S-nitroso-N-acetyl-DL-
penicillamine; Sigma–Aldrich) was used as a nitric oxide donor. Tunicamycin 
from Streptomyces sp. (Sigma–Aldrich) was used as a positive control for 
ER stress induction. The cell culture supernatant nitrate concentrations 
were measured using Griess reagents (Cayman Chemical), according to the 
manufacturer’s protocol. 
XBP1 splicing
ER stress and unfolded protein response activity was assessed by 
identifying mature XBP1 mRNA and its spliced variant as described 
previously16. In short, mRNA was isolated using TriReagent (Sigma–Aldrich), 
according to the manufacturer’s instructions. cDNA was created using the 
iScript cDNA synthesis kit (Bio-Rad) using 1 μg of RNA. Standard PCR 
was performed on diluted cDNA. The PCR conditions were 95◦C for 5 min, 
30 s at 95◦C, 30 s at 63◦C and 30 s at 72◦C for 30 cycles, and 72◦C for 8 
min. For primer sequences, see Table S4. We analysed the PCR products by 
electrophoresis on a 3% agarose gel. Images were created and band intensities 
were measured with ChemiDoc XRS and accompanying software (Bio-Rad).
Construct cloning
To investigate ABCG2 functionality, we created a GFP–ABCG2 fusion 
construct by inserting the ABCG2 cDNA sequence into the pEGFP-C1 
vector (Clontech). In brief, ABCG2 cDNA was obtained using PCR with 
primers that flank the cloning sites, XhoI was used for the forward primer 
and SalI was used for the reverse primer. The forward primer also contains a 
6×Ala-Gly repeat as a flexible linker between GFP and ABCG2 (for primer 
sequences, see Table S4.) We cloned the PCR product directly into a pGEMt-
easy cloning vector, after which we used the cloning enzymes as described 
above, and ABCG2 cDNA was cloned into the pEGFP-C1 vector. Cloning 
enzymes were used as described by Promega. The GFP–ABCG2 construct 
was checked for the correct insertion by sequencing. GFP-β-catenin and 
GFP–H2B were provided by Dr R. Smits.
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Fluorescence microscopy
The GFP-tagged proteins were examined using a confocal microscope 
(LSM510META, Zeiss). For the transport assay, nuclear Hoechst 33342 (4 
μM, Sigma-Aldrich) accumulation was determined at 30 s intervals over a 
total of 12 min. The ER was stained with ER–RFP (red fluorescent protein) 
using ER-Tracker (Molecular Probes), according to the manufacturer’s 
instructions. We analysed the GFP-tagged proteins with a 488nm laser, 
Hoechst with a 405 nm laser and the ER–RFP with 543 nm laser. A specific 
ABCG2 transport inhibitor, Ko143 (2 μM, Sigma–Aldrich), was used to 
identify ABCG2 transport specificity.
SDS/PAGE and fluorescent immunoblotting
To examine the GFP–ABCG2 fusion protein, whole cell lysates were 
created using 2× SDS sample buffer containing 120 mM Tris/HCl, pH6.8, 
4% (w/v) SDS, 20% (v/v) glycerol, 0.01% Bromophenol Blue and freshly 
added 0.1 M dithiothreitol. The proteins were separated by SDS/PAGE (8 
% gels; pH 8.8) with a stacking gel (pH6.8). After electrophoresis, proteins 
were electrophoretically transferred on to a PVDF membrane (Millipore, 
Immobilon-FL) at 200 mA for 90 min. The membrane was blocked with 
1 vol. of Odyssey blocking buffer (LI-COR) and 1 vol. of PBS for 1 h at 
room temperature (21◦C). Then the membrane was incubated with primary 
antibody: 1:1000 anti- GFP (polyclonal, rabbit IgG, Invitrogen) or 1:100 
anti-ABCG2 (monoclonal, mouse IgG2a, BXP-21, Solvo) in blocking buffer 
overnight at 4◦C. The membranes were incubated together with a reference 
protein antibody, 1:2500 β-actin (monoclonal, mouse IgG1, Santa Cruz 
Biotechnology) for GFP or 1:5000 tubulin (polyclonal, rabbit IgG, Abcam) 
for ABCG2. We washed the membrane three times in PBS-T (PBS with 
0.05 % Tween 20) at room temperature. Directly thereafter, the secondary 
antibody GaM IgG IRDye 680 and GaR IgG IRDye 800 CW, both 1:5000 
in blocking buffer, were incubated for 1h at room temperature. We washed the 
membrane twice again with PBS-T and twice with PBS. Then the membrane 
was scanned for red and green fluorescent bands using an Odyssey scanner 
(LI-COR).
Statistics and software
Statistical analyses were performed using the SPSS 11.0 software package 
for Windows. Data on different patient groups were compared using the 
Mann–Whitney U test with a Kruskal–Wallis post-hoc test. Using univariate 
and multivariate multinomial logistic regression analysis, we examined the 
association between colitis and GRP78 and ABCG2 expression, adjusting for 
age and duration of disease. A two-tailed P value of <0.05 was accepted as 
statistically significant. Images were composed using Adobe Photoshop CS3.
 
Results
Colonic inflammation reduces apical ABCG2 expression in IECs
To investigate ABCG2 expression during human intestinal inflammation, 
ABCG2 expression in colonic biopsies was qualitatively assessed employing 
immunohistochemistry. As expected, IECs in biopsies of control subjects as 
well as of IBD patients in remission (with no active inflammation) showed 
strong specific staining for ABCG2 at the apical surface (Figure 1A). In 
contrast, apical IEC ABCG2 staining was dramatically reduced in patients 
with active IBD, in the colon as well as in the small intestine, and also in 
biopsies from ischaemic colitis and infectious colitis patients (Figure 1A). 
Thus diverse colonic inflammatory responses are uniformly characterized 
by the down-regulation of apical ABCG2 levels, suggesting that processes 
common to these alternative modes of inflammation underlie the absence of 
apical ABCG2 during intestinal inflammation.
In apparent agreement, a quantitative study of ABCG2 levels in the 
human colon revealed significantly less ABCG2 expression in active colitis 
(24% positive expression, 13 out of 54), ischaemic colitis (10% positive 
staining, one out of ten) and infectious colitis (0% positive staining, zero out 
of 14) as compared with either inactive colitis (80 % positive expression, 53 
out of 67) or control tissues (100 % positive expression, nine out of nine) (all 
P < 0.001; see Figure 1B). There was no significant difference in ABCG2 
levels between active CD (27%, six out of 22) compared with active UC (22%, 
seven out of 32) and inactive CD (67%, 18 out of 27) compared with inactive 
UC (88%, 35 out of 40). As a control, we examined left- and right- sided 
biopsies from IBD patients and controls to investigate a confounding possible 
differential expression of ABCG2 based on position in the colon, but this 
analysis demonstrated that only the degree of inflammation is an important 
factor guiding apical ABCG2 levels. Thus inflammation itself is associated 
with a marked reduction in apical ABCG2 expression in the human colon.
Small bowel inflammation is associated with down-regulation of apical 
ABCG2 expression
Mirroring the findings obtained in the human colon, small bowel biopsy 
specimens obtained from CD patients with active disease by double balloon 
endoscopy exhibit markedly less ABCG2 staining when compared with biopsies 
obtained from patients with inactive disease or no intestinal inflammatory 
phenomena (see Figure 1A). In active CD, there was significantly less small 
bowel ABCG2 staining (75 % negative staining, 19 out of 25) as compared 
with inactive CD (11% negative staining, one out of nine) and controls (8% 
negative staining, two out of 25) (both P<0.05; see Figure 1C). We found 
no significant differences between inactive CD and controls. In all cases, 
current drug use did not influence the expression of ABCG2. We conclude 
that human intestinal inflammation is accompanied by reduced expression of 
the xenobiotic transporter ABCG2 and experiments were initiated to identify 
the underlying molecular mechanisms.
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Figure 1. Reduced ABCG2 expression in actively inflamed intestinal biopsies
(A) Representative images of intestinal biopsies stained for ABCG2. Colon, ctr: colon biopsy from healthy 
individual. Colon, IA: colon biopsy from an IBD patient in remission. Colon, A: colon biopsy from an IBD 
patient with active inflammation. Colon, ISC: colon biopsy from a patient with ischaemic colitis. Colon, IFC: 
colon biopsy from a patient with infectious colitis. SB, Ctr: small bowel biopsy from a healthy individual. 
SB, IA: small bowel biopsy from a CD patient in remission. SB, A: small bowel biopsy from a CD patient with 
active inflammation. The ABCG2 expression is represented by red/brown staining on the apical membrane 
of IECs. Original magnification is ×400. (B) Decrease in the IEC fraction of colonic biopsies with ABCG2 
expression during active inflammation. (C) Actively inflamed small bowel displays a reduced expression of 
ABCG2. (B and C) All intestinal biopsies were double blindly examined as negative, moderate or positive 
for ABCG2 membrane immune reactivity. Mann–Whitney U tests and Kruskal–Wallis tests were used for 
statistical analysis. (*P < 0.001).
Intestinal inflammation acts to reduce ABCG2 via a post-transcriptional 
mechanism
To delineate the molecular events reducing the capacity of the intestine 
to cope with xenobiotic challenge, we first determined whether genomic or 
post-transcriptional processes are involved in this effect. To this end, we 
measured ABCG2 mRNA levels in freshly frozen colon biopsies from healthy 
individuals, and inactive and active IBD patients. Importantly, ABCG2 mRNA 
levels in IECs did not differ between these three groups (all P > 0.8). The 
expression, however, of the pro-inflammatory cytokines IL8 and IL1β were 
10- and 8-fold higher (P < 0.05) in biopsies with active mucosal inflammation 
(Figure 2), and thus technical issues do not underlie the absence of intestinal 
inflammation-induced effects on apical ABCG2 expression. Hence we are 
forced to conclude that down-modulation of ABCG2 in human intestinal 
inflammation is brought about by a post-transcriptional process.
Figure 2. mRNA 
expression from 
intestinal biopsies
(A) No difference 
in ABCG2 mRNA 
expression in colonic 
biopsies. Relative 
mRNA (ΔΔCt) 
expression corrected 
for villin. Villin and 
ABCG2 are both IEC-
specific, thus ABCG2 
mRNA was corrected 
for villin to prevent 
underestimation 
in biopsies with 
fewer IECs. N.S., 
not significant. 
(B) Increased pro-
inflammatory 
cytokine expression 
in colonic biopsies 
from patients with 
active inflammation. 
Relative mRNA 
expression (ΔΔCt) 
corrected for GAPDH. 
IL8 and IL1β (IL1b) are 
pro-inflammatory cytokines and CHOP is an ER-stress-related gene. *P < 0.05. (A and B) Controls are 
healthy individuals (n = 6), ia IBD are biopsies with inactive inflammation (n = 8) and a IBD are biopsies 
with active inflammation (n = 7). Mann–Whitney U tests and Kruskal–Wallis tests were used for 
statistical analysis. (C) XBP1 mRNA splicing. Agarose gel image of XBP1 splicing PCR products. Spliced 
XBP1 is an indicator of increased ER stress. A is active IBD, IA is inactive IBD and H is healthy control.
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Activation of the unfolded protein response accompanies human 
intestinal inflammation
As it is becoming increasingly clear that activation of the unfolded 
protein response accompanies inflammatory processes and that ER stress 
may interfere with proper production of complexly folded proteins (the ‘half ’ 
transporter ABCG2 transverses the membrane six times), we examined 
whether the ER stress path- way is activated in intestinal inflammation 
and to which extent this activation mirrors the down-regulation of ABCG2. 
To this end, we employed the expression of the bona fide ER stress marker 
GRP78. Representative images of the GRP78 immunohistochemical analyses 
of the same biopsies as stained for ABCG2 are shown in Figure 3(A). There 
was a significant increase in GRP78 expression in active colitis (32% positive 
expression, 16 out of 54), ischaemic colitis (90 % positive staining, nine out of 
ten) and infectious colitis (79% positive staining, 11 out of 14), compared with 
inactive colitis (0 % positive expression, zero out of 67) and control tissues (0 
% positive expression, zero out of nine) (all P < 0.001; see Figure 3B). There 
are no significant differences in GRP78 expression between active CD and 
active UC or between inactive CD and inactive UC. In addition there were no 
differences in GRP78 expression in left- and right-sided colon biopsies taken 
from the same patient. We conclude that colonic inflammation is accompanied 
by the ER stress response, which is absent in the non-inflamed colon.
In the small bowel biopsies of active CD patients, there was increased 
GRP78 expression (29% positive expression, six out of 21) compared with 
inactive CD patients (0 % positive staining, zero out of nine) and controls 
(8% positive expression, two out of 25) (P<0.05; see Figures 3A and 3C). 
In all actively inflamed tissue samples, elevated GRP78 expression was 
evident, irrespective of disease type or location. ER stress during intestinal 
inflammation was further confirmed by measuring the mRNA expression of 
the ER-stress-associated gene CHOP in colonic biopsies. In biopsies taken 
from actively inflamed mucosa, a significant increase in CHOP mRNA 
expression was measured (P < 0.01; see Figure 2B). Moreover, an increased 
ratio of spliced XBP1 mRNA was detected in patients with active intestinal 
inflammation (Figure 2C). We conclude that activation of the unfolded protein 
response and intestinal inflammation are highly associated processes and we 
initiated experiments to investigate whether ER stress explains the down-
regulation of ABCG2 in intestinal inflammation.
Impaired ABCG2 function in ER-stressed cells
To investigate the effect of activated ER stress on ABCG2 protein 
expression and function, we created a GFP–ABCG2 fusion protein. To 
this end, ABCG2 cDNA was cloned into a pEGFP-C1 vector, which led to 
the production of GFP– ABCG2 after transfection (Figure 4A). The nitric 
oxide donor SNAP was used to ascertain whether nitric oxide was able to 
induce ER stress in 293t-AB (GFP–ABCG2-transfected HEK- 293T) cells. 
The Griess assay revealed that SNAP application induced robust increases 
in nitrate concentration, a good proxy measure for nitric oxide production 
Figure 3. Increased GRP78 expression in actively inflamed intestinal biopsies
(A) Representative images of intestinal biopsies stained for GRP78. Colon, ctr: colon biopsy from healthy 
individual. Colon, IA: colon biopsy from an IBD patient in remission. Colon, A: colon biopsy from an 
IBD patient with active inflammation. Colon, ISC: colon biopsy from a patient with ischaemic colitis. 
Colon, IFC: colon biopsy from a patient with infectious colitis. SB Ctr: small bowel biopsy from a healthy 
individual. SB, IA: small bowel biopsy from a CD patient in remission. SB, A: small bowel biopsy from 
a CD patient with active inflammation. Expression of GRP78 is detected as red/brown colour and is 
present in the cytoplasm of IECs and mononuclear cells in the lamina propria. Original magnification is 
×400. (B) Increase in the IEC fraction of colonic biopsies with elevated GRP78 expression during active 
inflammation. *P < 0.001. (C) Actively inflamed small bowel displays elevated GRP78 expression. *P < 
0.05. (B and C) The biopsies were double blindly examined as positive, moderate or negative according 
the amount of positive GRP78 immune reactivity. Mann–Whitney U tests and Kruskal–Wallis tests were 
used for statistical analysis.
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(see Figure 4B). The validity of the assay was demonstrated by experiments 
showing an increase in the ratio of unspliced XBP1 mRNA over spliced 
XBP1 mRNA 9 h after the application of 0.625 mM SNAP (see Figure 4C). In 
agreement with this, administration of tunicamycin, a well-established ER-
stress-response inducer, increased the XBP1 splicing ratio to approximately 
the same level as SNAP application (see Figure S1B). As is consistent with high 
ABCG2 transport activity, administration of Hoechst 33342 did not stain the 
nuclei of the 293t-AB cells (Figure 5A), also demonstrating the functionality 
of the ABCG2–GFP fusion protein in xenobiotic transport. Nevertheless, 
16 h after addition of the ER stress inducers SNAP or tunicamycin, the 
nuclei of 293t-AB cells became Hoechst 33342-positive (Figure 5A and 
Supplementary Movies S1, S2 and S3 at (http://www.BiochemJ.org/bj/441/
bj4410087add.htm). As shown in Figure 5(B), Hoechst 33342 also stained the 
nucleus blue in 293t-AB cells in the presence of the specific ABCG2 inhibitor 
Ko143 (see Supplementary Movie S4 at (http://www.BiochemJ.org/bj/441/
bj4410087add.htm). No altered GFP–ABCG2 protein function was found 
when SNAP or tunicamycin was added 48 h after transfection (see Figure 
S1C). Hence, in this overexpressing model system, ER stress provokes a very 
strong decrease in ABCG2 function, in agreement with a scheme in which 
inflammation-dependent induction of ER stress is causatively related to a 
reduced capacity to deal with xenobiotic challenge.
Figure 4. Nitric oxide-induced 
ER stress reduces ABCG2 protein 
expression and function
(A) Western blot analysis showing the 
expression of GFP–ABCG2 protein 
using the antibodies BXP-21 (anti–
ABCG2) and anti–GFP. Tubulin (Tub) 
and β-actin (b-Act) were used as 
loading control. MM is the molecular 
mass marker, with masses in kDa on 
the right-hand side. (B) SNAP induces 
increasing levels of nitrite, a stable 
derivative of nitric oxide, over time. 
Concentrations were measured from 
supernatants of 293t-AB cells. (C) 
After transfection with GFP–ABCG2, 
HEK-239T cells were stimulated with 
0.625 mM SNAP and XBP1 splicing 
was determined, and the ratio of 
un-spliced (U) and spliced (S) XBP1 
were plotted. Ctr depicts HEK-
239T cells only, 0 are GFP–ABCG2-
transfected cells without SNAP 
stimulation and other time points 
represents GFP–ABCG2-transfected 
cells with 0.625 mM SNAP. The gel 
picture is representative of three 
independent experiments, and the 
graph represents the mean+−S.D. of 
these three individual experiments.
In support for such a model, all images from 293t-AB cells with ER 
stress revealed a reduced apical membrane expression of GFP–ABCG2, with 
intracellular expression remaining. In order to ascertain whether GFP–
ABCG2 remained in the ER after stress induction, we stained the ER with 
ER–RFP. When ER stress was present, some GFP–ABCG2 co-localized with 
ER–RFP, whereas the majority was present in other cellular compartments 
(Figure 5C). As shown in Figure S2 the localization and expression of non-
ER-dependent GFP-tagged proteins GFP–β-catenin and GFP–H2B (histone 
2B) was not changed during ER stress conditions. Thus protein-folding 
difficulties seems incompatible with functional expression of ABCG2.
Figure 5. Reduced ABCG2 activity and membrane localization in ER-stressed cells
Hoechst 33342 (4 μM) DNA binding was measured to study the activity of ACBG2. (A) ABCG2-transfected 
cells were exposed to SNAP, tunicamycin or solvent for 16 h, after which Hoechst 33343 binding was 
studied. See Supplementary Movies S1–S3 (http://www.BiochemJ.org/bj/441/bj4410087add.htm). 
Original magnification ×400. (B) The specific inhibitor of ABCG2, Ko143 (2 μM), was added 12 min after 
Hoechst 33342 (4 μM), and was used as a positive control for ABCG2 activity. See Supplementary Movie 
S4. Original magnification ×400. (C) 293t-AB cells were stained with ER–RFP. ER stress was induced by 
addition of SNAP or tunicamycin 16 h before ER–RFP staining. All confocal images are representative of 
at least three independent experiments. Original magnification 400×.
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Figure S1. ER stress in control proteins and ER stress do not impede already correctly folded GFP–ABCG2
(A) To investigate whether overexpression of GFP–ABCG2 itself could affect protein folding, two other 
GFP fusion proteins were used as controls. The same methodology was used as described in Figure 
5(B) of the main text. For both GFP–β-catenin and GFP–H2B, a similar XBP1 mRNA splicing pattern was 
shown. (B) XBP1 splicing after tunicamycin stimulation. Tunicamycin is an inhibitor of N-glycosylation and 
thereby induces ER stress. XBP1 splicing was determined as described in Figure 5 (B) of the main text. An 
increased amount of spliced XBP1 was measured after addition of 2 mM tunicamycin for indicated time 
points. (C) The 293t-AB cells were cultured for 48 h after transfection before ER stress was introduced. 
Interestingly, functional ABCG2 was measured in SNAP and tunicamycin ER-stressed cells. This indicates 
that ABCG2, which was folded in the incubation time without ER stress, was not impeded by the later 
introduced ER stress. Apparently, only newly formed ABCG2 is affected by ER stress. All confocal images 
are representative of at least three independent experiments. Original magnification ×400.
Figure S2. Non-ER-dependent proteins are not affected by 
ER stress
To investigate whether non-ER-dependent proteins were 
affected by ER stress, GFP–H2B and GFP–β-catenin expression 
and cellular location were measured. The same methodology 
was used as in Figure 5(A) of the main text. SNAP and 
tunicamycin did not impede the fusion protein localization of 
GFP–H2B or GFP–β-catenin or affect nuclear Hoechst 33342 
accumulation. Original magnification ×400.
Discussion
The results shown in the present study are consistent with a model 
in which intestinal inflammation drives an epithelial misfolded protein 
response, which in turn interferes with the ABCG2 expression and function, 
leading to a diminished capacity of the epithelial compartment to cope with 
xenobiotic stress. Colonic and small bowel biopsies from IBD patients with 
active disease and those from patients with ischaemic and infectious colitis all 
show reduced apical ABCG2 expression in IECs compared with controls and 
IBD patients in remission. The decline of ABCG2 expression in the presence 
of active inflammation in IBD patients corresponds with the findings of two 
studies done exclusively on UC patients7,22. In addition, we found that ABCG2 
expression is not affected by medication use, patient age or location of the 
inflammation.
Expression of ABCG2, similar to that of many other proteins, can 
be regulated at various levels. In addition to a decline in ABCG2 protein 
expression, others have described a reduction in ABCG2 mRNA expression 
in actively inflamed intestine7,22. We corrected the ABCG2 mRNA expression 
to villin to prevent an underestimation of ABCG2 expression, since both 
genes are specific for IECs. Our results show no reduction of ABCG2 mRNA 
expression in biopsies with active mucosal inflammation. However, since 
the sample size used in the present study is smaller than those in previous 
studies, we cannot completely rule out the contribution of reduced mRNA 
expression to the decline in ABCG2 protein expression. As such, our findings 
merely imply that the decline in mRNA expression probably does not solely 
account for the complete loss of ABCG2 protein expression discernable on 
our immunohistochemistry images and that post-transcriptional mechanisms 
must be involved. The observation that unfolded protein responses are 
both general and specific to intestinal inflammation suggest a causal link 
between ER stress and diminished apical ABCG2 levels. Indeed, ABCG2 is 
a ‘half ’ transporter, spanning the membrane six times, functionally critically 
dependent on homodimerization, N-linked glycosylation and various disulfide 
bonds and thus is probably an early victim of the ER stress responses18,19. 
Disrupted protein-folding mechanisms that can lead to ER stress during 
active inflammation have been linked to IBD16,23,24, and may well involve the 
reduced capacity of the IEC compartment to deal with the xenobiotic stress 
and thus in turn interfere with demanding regenerative responses that an 
adequate response to IBD-related intestinal challenges requires.
Our link from inflammation to unfolded protein responses remains unclear, 
but inflammatory responses are associated with an excessive production of 
nitric oxide, which in turn is predicted to disturb the function of redox-state 
sensitive disulfide-bonding chaperones such as PDIs that are necessary for 
proper protein folding25. In all biopsies with active inflammation (i.e. IBD 
and non-IBD related), the GRP78 expression is significantly higher than in 
the biopsies of IBD patients in remission and in those of healthy controls. 
Furthermore, expression of CHOP mRNA (an ER stress marker) is increased 
in biopsies with active mucosal inflammation. In addition to this, biopsies 
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with active inflammation reveal an increased amount of spliced XBP1 mRNA 
expression. Thus factors common to multiple types of inflammation must be 
involved here and, as nitric oxide production is one of the few cellular responses 
described to generally accompany inflammation, it is tempting to attribute an 
important role to excessive nitric oxide generation in inflammation-related 
induction of ER stress responses23,25– 27. Indeed, we observed elevated XBP1 
splicing16 following application of the nitric oxide donor, suggesting that nitric 
oxide can directly affect protein-folding mechanisms20 and induce ER stress. 
In the present study we show that the reduction in ABCG2 expression is 
associated with inflammation, which fits with the observations that ABCG2 
expression is reduced in IBD- unrelated inflammatory conditions in other 
organs10,12,28. Other IBD-associated proteins are also reduced in protein 
expression during active intestinal inflammation29–31. Further research is 
needed to investigate the role of impeded protein folding and the effect of this 
on cellular processes. Noteably, ABCG2-mediated efflux of toxic components 
is thought to protect the epithelium of the gut and the underlying tissue to 
xenobiotic challenges. Importantly, as xenobiotic stress is directly linked to 
genotoxicity, our results may also help to explain the still poorly understood 
relationship between intestinal inflammation and colorectal cancer32. 
Decreased ABCG2 expression may have other deleterious consequences as 
well. Sulfasalazine, a derivate of mesalazine 5-ASA (5-aminosalicylic acid) 
that is commonly used in the treatment of IBD patients, is actively excluded 
from the epithelial compartment by ABCG233. Rodents with reduced IEC 
ABCG2 expression have increased 5-ASA trough levels34. In addition to 
its anti-inflammatory effect, accumulation of sulfasalazine can be toxic for 
epithelial cells35,36. Thus reduced expression and function of ABCG2 may 
therefore greatly enhance the sensitivity of IECs to sulfasalazine and limit 
the use of this compound for the treatment of IBD. Hence understanding 
the mechanisms governing ABCG2 expression are highly relevant for efforts 
with respect to rational design of novel therapy.
In conclusion, IEC ABCG2 protein expression is decreased in the inflamed 
bowel, probably as a result of incorrect protein folding due to inflammation-
driven ER dysfunction. Thus a novel paradigm explaining xenobiotic stress 
during inflammation emerges in which intestinal inflammation activates the 
unfolded protein response, in turn abrogating the defences against xenobiotic 
challenge by impairing ABCG2 expression and function.
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Abstract 
Although genome wide association studies have largely uncovered the 
genetic basis of Crohn’s disease(CD), it remains a challenge to link the 
underlying genetic polymorphisms to functional intestinal phenotypes. 
Paneth cells are specialized epithelial cells with topographical restriction to 
the small-intestinal crypt-base where they have an antimicrobial action. We 
were interested whether genomic variations in the autophagy-related gene 
ATG16L1 would affect Paneth cell function. 
Genomic variation of ATG16L1(T300A, rs2241880) was determined 
in DNA isolated from 78 CD patients and 12 healthy controls. Paraffin-
embedded ileal biopsies of patients with genotype AA(n=17), GA(n=38) 
and patients with the GG allele(n=23) were stained for Alcian blue–
PAS and immunohistochemically for GRP78 and pEIF2a(ER stress), 
lysozyme(antimicrobial peptide), cleaved-Caspase 3(apoptosis), pHiston 
H3(proliferation), p65 and phospho-p38MAPK(active), and PHLDA1(human 
stem cell marker). Disease phenotype severity and progression was noted.   
In patients with quiescent disease but with a mutated ATG16L1 allele, the 
ER stress markers GRP78 and pEIF2a were highly expressed in the Paneth 
cell compartment. Other CD risk gene mutations did not correlate with 
Paneth cell ER stress. Functionally, the patients with ER stressed Paneth 
cells showed no distinct IEC proliferation or increased apoptosis in their 
crypt base. Also in these patients the total number of stem or Paneth cells did 
not differ. Similarly, no nuclear p65 expression or increased phospho-p38 is 
detected ER stressed Paneth cells. Phenotypically, patients with Paneth cell 
ER stress have relatively less colonic disease over ileal disease(-21% p=0.04, 
more fistulas(+21%, p=0.05), and need intestinal surgery more often(+38%, 
p=0.002). 
The ATG16L1 polymorphism defines a specific subtype of CD patients, 
distinctively characterized by Paneth cell ER stress even during quiescent 
disease. ATG16L1-linked Paneth cell ER stress is likely to corrupt 
antimicrobial functionality of this cell type and thus increase vulnerability to 
chronic bacterial insult. 
Introduction
Inflammatory bowel disease (IBD) is the result of a deregulated immune 
response to gut microbiota. Both genetic and environmental factors play an 
important role in the development of IBD. The most frequent forms of IBD are 
Crohn’s disease (CD) and ulcerative colitis. By identifying single nucleotide 
polymorphisms (SNPs) associated with an increased risk for developing CD, 
genome wide association studies (GWAS) have now largely uncovered the 
genetic basis of CD, resulting in the identification of more than 70 genetic 
locations in the human genome apparently linked to this disease1. The main 
challenge now is to link these mutations to altered functionality in SNP 
carrying individuals explaining their association with disease susceptibility. 
The Paneth cells are specialized intestinal epithelial cells that are found 
at the crypt base of the small intestine. They are characterised by large 
secretory granules and an extensive ER (endoplasmic reticulum). Initially 
described as cells specialised with respect to luminal exocytosis cells of 
antimicrobial products such as, lysosyme and defensins, Paneth cells have 
recently been suggested to constitute a cardinal component of the intestinal 
stem cell niche2. Thus Paneth cells contribute to controlling the luminal 
flora as well as repairing the intestinal barrier following an insult. It can 
be hypothesised that genomic alterations that impede the Paneth cell-
compartment functionality would increase the propensity to develop CD.
CD-linked SNPs that might affect Paneth cells include those in NOD2 
(CARD15), which have been associated with reduced intracellular microbial 
sensing, a decrease in Paneth cell-produced a -defensins and reduced an-
timicrobial defense3-5. Also, genetic variation in the XBP1 gene may lead 
to increased ER stress as a consequence of a defective unfolded protein re-
sponse (UPR) in highly secretory intestinal epithelial cells (IEC) like gob-
let and Paneth cells thereby affecting their function6. Finally, it is described 
that a SNP in the ATG16L1 gene (T300A, G is risk allele, rs2241880) may 
confer its risk for CD development by affecting Paneth cell morphology and 
function7. Overall, Paneth cells seem to be especially affected by a variety of 
SNPs strongly associated with CD, suggesting that the affected pathways, 
bacterial/viral sensing (NOD2), ER-stress (XBP-1, ORMDL3) and auto-
phagy (ATG16L1, IRGM) are of crucial importance for normal Paneth cell 
function in turn affecting. The latter is important for maintaining intestinal 
homeostasis2. This notion is further supported by mouse studies using epi-
thelial-specific deficiencies in these pathways, which show abnormal Paneth 
cell phenotype and function, and lead in some cases to spontaneous ileitis5-7. 
In contrast, although a recently study described activation of autophagy and 
crynophagy with concomitant reduced numbers of secretory granules in the 
Paneth cell compartment of CD patients, these features correlated neither 
to disease activity or ATG16L1 and IRGM genotype8. It is thus fair to say 
that the link between genotype and Paneth cell functionality in CD remains 
poorly understood.
An underexplored possible connection between the Paneth cell 
compartment, CD-linked genetic polymorphisms and intestinal inflammation 
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is ER stress. ER stress has been shown to induce autophagy as part of the 
unfolded protein response (UPR), and impairments in the autophagy pathway 
can lead to ER stress and the induction of the UPR9. Activation of NOD2 by 
its ligand MDP or bacteria induces NF-kB mediated induction of autophagy3, 
whereas autophagy has been shown to play an important role in the uptake 
and delivery of NOD2 signals4. We and others have recently shown that 
elevated ER stress negatively influences the normal IEC function6, 10, 11. The 
possible connection, however, between genotype and Paneth cell ER stress 
remains unclear.
For these reasons, we investigated whether evidence for the convergence 
of ER stress and inflammatory pathways could be detected in Paneth cells of 
CD patients and how these pathways would relate to genetic polymorphisms 
in CD. In this study we demonstrate that CD patients and healthy controls 
with at least one risk allele for ATG16L1 (T300A, rs2241880) constitute a 
specific subset of CD patients with elevated ER stress specifically in their 
Paneth cells. 
Table S1: Baseline characteristics of with Crohn’s disease patients and healthy controls by 
ATG16L1 genotype (rs2241880)
Allele: AA Allele: GA Allele: GG
CD Controls CD Controls CD Controls
Total number of patients 17 3 38 3 23 6
Mean age, yr (SD)
43 
(17)
42 (22)
36 
(13)
44 (7)
40 
(18)
44 (11)
Sex (M/F) 6/11 1/2 20/18 1/2 8/15 3/3
Mean duration of disease, yr (SD)
11 
(13)
- 12 (9) -
12 
(11)
-
Smoking? (%Yes) 41 § 29 § 65 §
Familiar link to IBD? (%Yes) 35 - 32 - 26 -
Concomitant medication:
- none 6 * - 4 - 1 -
- aminosalicylates 6 - 22 - 9 -
- corticosteroids 5 - 6 - 7 -
- immunosuppressives 5 - 9 - 9 -
- biologicals 1 - 4 - 1 -
*CD patients with the ATG16L1 (rs2241880) AA allele take significantly less medication than CD patient 
with the GA of GG allele. p<0.05
§ smoking behaviour unknown
Methods
Patient material
Formalin-fixed paraffin-embedded (FFPE) small intestine biopsies were 
collected from the pathology archive from in total 78 patients with CD: 17 
with ATG16L1 (T300A) allele AA, 38 with the GA allele, and 23 with the GG 
allele and 12 healthy controls: 3 with ATG16L1 (T300A) allele AA, 3 with 
the GA allele, and 6 with the GG allele. Healthy individuals have no medical 
or familiar history in IBD. The CD patients were genotyped using genomic 
DNA isolated from peripheral blood mononuclear cells using Wizard Genome 
DNA purification kit (Promega Benelux B.V.) The healthy individuals were 
genotyped using genomic DNA isolated from FFPE biopsies. Detailed protocol 
is described below. All obtained biopsies were endoscopic and histologically 
(Geboes criteria) examined as not actively inflamed. The demographic and 
disease specific characteristics were subtracted from electronic patient files 
according the Montreal classification12 and are presented in Tables S1 and S2. 
Table S2, characteristics of healthy controls and CD patients without or with ER-
stressed Paneth cells.  
ER stress (-) ER stress (+)
CD Controls CD Controls
Total number of patients 54 8 24 4
Mean age, yr (SD) 39 (15) 45  (15) 38 (15) 40 (6)
Sex (M/F) 26/28 3/5 8/16 3/1
Mean duration of disease, yr (SD) 11 (10) - 13 (9) -
Concomitant medication:
- none 8 - 3 -
- aminosalicylates 25 - 12 -
- corticosteroids 14 - 1 -
- immunosuppressives 17 - 3 -
- biologicals 6 - 0 -
Healthy control genotyping
Genomic DNA from FFPE biopsies was isolated using the Wizard® 
Genomic DNA purification Kit (Promega), according manufactures 
description. A 330bp fragment spanning the ATG16L1 (T300A) SNP was 
amplified using standard PCR (Phusion, Finnzymes, Oslo Finland). The 
following primers were used: fw-5’-TTGGAGTCCACAGGTTAG-3’ 
and rev-5’-CAGTAGCTGGTACCCTCACTTC-3’. The DNA fragment 
was isolated from a 1% agarose gel using the Invisorb fragment cleanup 
kit (Invitek, USA). The ATG16L1 T300A SNP was determent two SNP 
specific q-PCRs, one PXR for the non-risk allele and one PXR for the 
risk allele. Both PCR reactions were performed using a universal forward 
primer: fw-5’-CTAGAAGGACAGGCTATCAAC-3’. The non-risk allele 
(A) was determent by using the non-risk allele specific revers primer: rev-5’-
TTACCAGAACCAGGATGAGT-3’. 
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The risk allele (G) was determent by using the risk allele specific revers 
primer: rev-5’-TTACCAGAACCAGGATGAGG-3’. A standard q-PCR 
reaction was performed using the purified ATG16L1 fragment (1:10000(v/v) 
dilution) as template. The Tm was optimized (64.3oC) as only a fragment was 
created when there was a perfect match with the primer and the template. 
Thus, an individual with an AA genotype only shows a Ct value in the non-
risk allele PCR, an individual with GA shows Ct values in both PCRs, and an 
individual with GG reveals only a Ct in the risk allele PCR. For each PCR a 
validated AA, GA and GG patient was included as control. 
Genomic DNA analysis
Genomic DNA was isolated from CD patient blood and healthy control 
FFPE biopsies. The following genetic loci associated with IBD and ER stress 
were analysed: ATG16L1 (rs10210302)13, NOD2 (rs2066844, rs2066845, 
rs2066847)14, XBP1 (rs35873774)6 for all the patients using the genomic DNA 
samples. KBiosciences UK ltd, Hertfordshire, United Kingdom, performed 
the SNP analysis.
Histology
For this we used serial sections (4 mm) of intestinal FFPE tissue blocks. 
Paneth cells were stained using PAS - Alcian Blue staining. Alcian blue - PAS 
staining was performed as follows: slides were deparaffinised, stained with 
1% Alcian blue (Sigma-Aldrich) in 3% acetic acid solution for 15 min, washed 
in tap water, 5 min in 0.5% periodic acid solution, washed dH2O, 10 min in 
Schiff ’s Reagent (Merck, Darmstadt, Germany), washed 5 min tap water, 1 
min Haematoxylin (Merck), stained in tap water for 5 min, dehydrated and 
mounted. Paneth cell morphology was scored as described earlier7.
For immunohistochemistry all the primary antibodies are summarized 
in Table S3. For IHC the FFPE slides were; deparaffinised, endogenous 
peroxidises were blocked using 3% H2O2 in methanol, treated for antigen 
retrieval, incubated o/n at 4oC with primary antibody, incubated for 1 h at 
RT with DAKO EnvisionTM + System-HRP (DAKO, Glostrup, Denmark) 
after which the antibody complex was detected by 3-amino-9-ethylcarbazol 
(DAB, Sigma-Aldrich, St Louis, MO). As a negative control, the primary 
antibody was replaced by an equivalent IgG (DAKO, Glostrup, Denmark). 
The slides were examined in a blinded fashion by light microscopy (Zeiss, 
Axioskop, Oberkochen, Germany). Intestinal biopsies with high numbers 
of GRP78- and pEIF2a-positive Paneth cells were scored as positive and 
biopsies with basal levels of GRP78- and pEIF2a- stained Paneth cells as 
negative. Representative examples of negative and positive score samples are 
represented in Figure S1. Positive cleaved-Caspase 3 and pHiston 3H cells 
of at least 20 intestinal crypts per biopsy were counted. Paneth cell specific 
lysozyme, p65, phospho-p38, and stem cell specific PHLDA1 staining were 
examined by immune reactivity intensity. 
Figure S1: GRP78 score
Representative images of Paneth cells scored as GRP78 positive and GRP78 negative. Original 
magnification 200x. 
Chapter VII |   125 124   | Chapter VII
ATG16L1(T300A) induces Paneth cell specific ER stress
VII
Back to Index
Cell culture and beta-Catenin reporter assay
Wnt3a producing (Wnt3a) and control cells (L-cells) were kindly pro-
vided by Dr. R. Smits (Erasmus MC, Rotterdam, The Netherlands). Cells 
were stimulated for 18 h with 2mM Tunicamycin to induce ER stress, and the 
conditioned medium was used in a beta-Catenin reporter assay as previously 
described15. XBP1 mRNA splicing, GRP78 mRNA and CHOP mRNA ex-
pression were measured as ER stress indicators10. 
Statistics and software
Statistical analyses were performed using the SPSS 11.0 software package 
for Windows. Data on different patient groups were compared using the 
Mann-Witney U test, chi-square test, Fisher exact test, and the McNemar’s 
test. Multivariate analyses relating ER-stress to different genotypes are 
performed using SPSS 11.0. A two-tailed P value <0.05 was accepted as 
statistically significant. Images were composed using Adobe Photoshop CS6.
Ta
bl
e 
S3
: A
nti
bo
di
es
 u
se
d 
fo
r 
IH
C.
 
A
nti
bo
dy
 t
ar
ge
t
Ca
ta
lo
gu
e 
nu
m
be
r
A
nti
bo
dy
 t
yp
e
M
an
uf
ac
tu
re
r
D
ilu
ti
on
A
nti
ge
n 
Re
tr
ie
va
l
Bi
P(
G
RP
78
)
31
77
Ra
bb
it
 
m
on
oc
lo
na
l
Ce
ll 
Si
gn
al
in
g 
Te
ch
no
lo
gy
1:
40
0
10
 m
in
 b
oi
l i
n 
10
m
M
 C
it
ra
te
Ly
so
zy
m
e
A
00
99
02
Ra
bb
it
 
po
ly
cl
on
al
D
ak
o
1:
80
0
10
 m
in
 R
T 
10
ug
/m
L 
Pr
ot
K
Ph
os
ph
o-
EI
F2
a
35
97
Ra
bb
it
 
po
ly
cl
on
al
Ce
ll 
Si
gn
al
in
g 
Te
ch
no
lo
gy
1:
50
10
 m
in
 b
oi
l i
n 
10
m
M
 C
it
ra
te
PH
LD
A
1 
(T
D
A
G
51
)
SC
23
86
6
M
ou
se
 
m
on
oc
lo
na
l
Sa
nt
a 
Cr
uz
 
Bi
ot
ec
hn
ol
og
y
1:
10
0
20
 m
in
 b
oi
l i
n 
10
m
M
 T
RI
S
Cl
ea
ve
d-
Ca
sp
as
e 
3
96
61
Ra
bb
it
 
m
on
oc
lo
na
l
Ce
ll 
Si
gn
al
in
g 
Te
ch
no
lo
gy
1:
40
0
10
 m
in
 b
oi
l i
n 
10
m
M
 C
it
ra
te
Ph
os
ph
o-
p3
8
45
11
Ra
bb
it
 
m
on
oc
lo
na
l
Ce
ll 
Si
gn
al
in
g 
Te
ch
no
lo
gy
1:
10
0
10
 m
in
 b
oi
l i
n 
10
m
M
 C
it
ra
te
N
F-
kB
 p
65
47
64
Ra
bb
it
 
m
on
oc
lo
na
l
Ce
ll 
Si
gn
al
in
g 
Te
ch
no
lo
gy
1:
10
0
10
 m
in
 b
oi
l i
n 
10
m
M
 C
it
ra
te
pH
is
to
n 
3H
06
-5
70
Ra
bb
it
 
po
ly
cl
on
al
M
ill
ip
or
e
1:
10
00
10
 m
in
 b
oi
l i
n 
10
m
M
 C
it
ra
te
Results
Increased ER stress in Paneth cells of ATG16L1 mutated patients  
To investigate the relationship between genetic polymorphisms and ER 
stress in Paneth cells, cross-sections of terminal ileum biopsies from patients 
with quiescent CD, where stained with multiple histological markers. Only in 
patients with an ATG16L1 risk allele an association with GRP78 positivity 
(ER stress) in the Paneth cell compartment was detected (Figure 1). GRP78 
staining extended to all Paneth cells of the entire biopsy in 37% of the CD 
patients carrying one risk allele (GA) and to 44% of those carrying two risk 
alleles (GG), whereas no GRP78+ Paneth cells were observed in patients 
without any risk allele (AA) (Figures 1A and 1D). Furthermore, in 43% of the 
ATG16L1 risk allele carriers (GA and GG) also pEIF2a positive Paneth cells 
were observed and not in the non-risk allele CD patients (AA) (Figure 1B and 
1E). No histological differences were detected between the three different 
ATG16L1 genotypes using the PAS - Alcian Blue and lysozyme staining 
(Figure 1C). The Paneth cell morphology was not different in respect to 
ATG16L1 genotype (Figure 2A) or presence of Paneth cell specific ER stress 
(Figure S2A).
Several CD-associated gene mutations can (in-) directly affect autophagy 
and Paneth cell function6, 7. As such, this might explain the subgroup of 
patients with ER stress positive Paneth cells in the ATG16L1 mutants. 
However, excluding the patients with NOD2 (rs2066844, rs2066845), XBP1 
(rs11175593) and IRGM (rs13361189) mutations did not affect the percentage 
of patients with GRP78+ Paneth cells (Figure 2B). In addition, multivariate 
analysis on the patients with GRP78+ Paneth cells regarding the ER stress 
associated genes did not reveal significant associations other than ATG16L1 
(rs2241880, p<0.002, Table S4). 
To establish whether the presence of GRP78+ Paneth cells was a local 
phenomenon or a constitutive property of the entire small intestine, biopsies 
from the duodenum and jejunum were investigated as well. CD patients with 
a terminal ileal GRP78+ Paneth cell phenotype, also presented with a thus 
affected duodenum and jejunum  (Figure 2C). 
Table S4, Results multivariate analysis 
(ER stressed Paneth cells vs ER stress related SNPs).  
SNP number p-value*
rs2241880 (ATG16L1) 0.002
rs2066844 (NOD2) 0.129
rs2066845 (NOD2) 0.229
rs2066847 (NOD2) 0.134
rs13361189 (IRGM) 0.466
rs35873774 (XBP1) 0.802
*Corrected for multiple testing
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Figure 1: Intestinal crypt characterisation of inactive CD patients with the ATG16L1 (T300A) GA or GG 
risk allele. 
(A) Representative images of small intestinal cross sections of inactive CD patients IHC stained for 
GRP78. The red-brown colour indicates a positive GRP78 staining. Original magnification 1000x. 
(B) Representative images of small intestinal cross sections of inactive CD patients IHC stained for 
pEIF2a. Red-brown colour indicates positive pEIF2a staining. Original magnification 1000x. 
(C) Identical cross sections as in A now stained for PAS - Alcian blue and lysozyme. The blue colour 
indicates mucus, and the crypt based pink-red colour represents granulomas present in Paneth cells. 
For the lysozyme staining the immune reactivity in cells at the crypt base indicates the Paneth cells. 
Original magnification 1000x.
(D) GRP78 immune reactivity scored and presented in graph. The graph represents the percentage 
biopsies with GRP78 positive and negative Paneth cells per genotype. The tissue specimens where 
blinded scored as positive or negative according the presence of GRP78 immune-reactivity. *** p<0.001
(E) pEIF2a immune reactivity scored and presented in graph. The graph represents the percentage 
biopsies with GRP78 positive and negative Paneth cells per genotype. The tissue specimens where 
blinded scored as positive or negative according the presence of pEIF2a immune-reactivity. ** p<0.01
Figure 2: Paneth cell morphology and ATG16L1 specificity 
(A) Paneth cell morphology. The small intestinal crypt bases were scored exactly as described before7. The 
percentage per phenotypic group was divided by the ATG16L1 T300A genotype. Error bar is SD. 
(B) Other ER stress related genes excluded. Same graph as in (Figure 1D), excluded the patients with 
mutations in NOD2 (rs2066844, rs2066845), XBP1 (rs11175593) and IRGM (rs13361189). *** P<0.001
(C) GRP78 staining in other part of the small intestine. Tissue specimen stained for GRP78 from the same 
GG patient as used in (Figure 1A), now originate from the duodenum and jejunum. Original magnification 
1000x.
(D) Colonic CD excluded. Same graph as (B), excluded the patients with primary colonic CD. *** P<0.001
The disease location could provide yet another factor that may be related 
to the GRP78+ Paneth cell phenotype. Stratifying our data based on disease 
location (small intestine vs. colonic CD), we observed that GRP78+ Paneth 
cells are a feature that is more associated with small intestine CD (Figure 2D 
and Table 1).
To determine if the ER-stressed Paneth cells is specific for CD patients, 
we also stained small intestinal biopsies of healthy controls. Both proteins, 
GRP78 and pEIF2a, were increased in expression in controls with the 
ATG16L1 risk allele (Figure 3A). The GRP78 expression is solely increased 
in 60% of the controls with the GG allele (p<0.01, Figure 3B). In 33% of 
the controls with the GA allele and 50% with the GG allele have increased 
pEIF2a protein expression (p<0.05, Figure 3C). 
Overall, a subset of the quiescent CD patients and healthy individuals 
with the ATG16L1 GA or GG risk allele, have ER stressed Paneth cells in 
their small intestine. Paneth cells are important in regulating the intestinal 
stem cell niche2 and have a clear antimicrobial function. As such, we further 
investigated the biological effects of the ER stress phenotype in the Paneth 
cells of CD patients.
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Figure S2: Paneth cell morphology and intestinal stem cell count. 
(A) Paneth cell phenotype divided in ER stress (+) and ER stress (-). This graph represents the same 
scored Paneth cells as in Figure 2A, however now divided in ER stress (+) and ER stress (-). 
(B) Number of Paneth cells. The graph represents the number of Paneth cells per crypt. All Paneth 
cells from at least 20 crypts of each tissue specimen were counted. AA(-): ATG16L1 (T300A) AA allele 
without ER stressed Paneth cells, GA(-): GA allele without ER stressed Paneth cells, GA(+): GA allele with 
ER stressed Paneth cells, GG(-): GG allele without ER stressed  Paneth cells, GG(+): GG allele with ER 
stressed Paneth cells. The graphs represent the mean +\- S.D. and n.s. is not significant. 
(C) Number of Paneth cells. The graph represents the number of Paneth cells per crypt divided in ER 
stress (-) and ER stress (+) patients. 
(D) Number of Stem cells. The graph represents the number of Stem cells per crypt divided in ER stress 
(-) and ER stress (+) patients. 
(A-D) ER stress (-) indicates biopsies without ER-stressed Paneth cells and ER stress (+) indicates biopsies 
with ER-stressed Paneth cells. The graphs represent the mean +\- S.D.
Table 1: Disease characteristics
ER stress (-)
N (%)
ER stress (+)
N (%)
p-Value
Total number of patients 54 (100) 24 (100)
Montreal classification: location
L1; ileal 16 (30) 6 (25) =0.675
L2; colonic 21 (38) 4 (17) =0.044
L3; ileocolonic 16 (30) 11 (46) =0.165
L4; upper disease 1 (2) 3 (12) =0.084
Montreal classification: behaviour 
B1; no stenosis, no fistula 22 (41) 6 (25) =0.210
B2; stenosis, No fistula 6 (11) 6 (25) =0.117
B3; Fistula 11 (20) 10 (41) =0.050
p; Perianal disease 17 (31) 8 (33) =0.872
Extra-intestinal manifestations 13 (24) 7 (29) =0.637
Intestinal surgery 29 (54) 22 (92) =0.002
Figure 3: Paneth cell ER stress in healthy controls. 
(A) Representative images of small intestinal cross sections of healthy controls IHC stained for GRP78 
and pEIF2a. Red-brown participate indicate positive GRP78 staining. Original magnification 1000x.
(B) GRP78 expression score. GRP78 expression was similarly scores as in Figure 1. The GRP78 score is 
presented per ATG16L1 genotype. 
(C) pEIF2a expression score. pEIF2a expression was similarly scores as in Figure 1. The pEIF2a score is 
presented per ATG16L1 genotype.
ER stress in Paneth cell is not associated with NF-kB activation
A distinctive subset of quiescent CD patients characterised by ATG16L1 
risk allele-restricted Paneth cell ER stress, warrants further exploration 
of the exact characteristics of this phenotype. Activation of Paneth cells by 
bacterial ligands may enhance the demand of secretory antimicrobial peptides, 
potentially leading to ER stress16 thus it is possible that the ER stress in 
the Paneth cells results from constitutive subclinical inflammation in the 
affected patients. To investigate this we stained and screened all the biopsies 
for the sentinel inflammatory transcription factor NF-kB using its nuclear 
localisation as an activation marker and the general cellular stress regulator 
phospho-p38MAPK. No nuclear or cytoplasmic p65 expression or increased 
phospho-p38 levels were found in Paneth cells of either ER-stressed or 
apparently normal Paneth cells (Figures 4A and 4C), thus the Paneth cell ER 
stress is not a secondary consequence of an on-going inflammatory reaction, 
but probably represents an intrinsic property of the Paneth cell compartment 
in ATG16L1 risk allele patients. Interestingly however, increased cytoplasmic 
p65 expression is seen in the stem cells and the cells of the trans-amplifying 
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domain from biopsies with ER stressed Paneth cells (p<0.05, Figure 4B), 
suggesting that the decreased Paneth cell functionality, as a consequence of 
ER stress, leads to increased inflammation elsewhere in the small intestinal 
crypt.
ER-stressed Paneth cells do not affect the intestinal stem cell 
compartment 
Recently, it becomes clear that the Paneth cell is an important component 
of the intestinal stem cell niche through e.g. Wnt3a production. To see if ER 
stress could affect the expression and excretion of these growth factors, we 
chemically induced ER stress in Wnt3a producing L-cells. L-cells stimulated 
for 18 h with 2mM Tunicamycin showed increased XBP1 mRNA splicing 
(+150%), as well as elevated levels of GRP78 (15 fold) and CHOP mRNA 
(10 fold), indicating ER stress in these cells (see Figures 5A and 5B). Using 
the beta-catenin reporter assay, we detected high levels of active Wnt3a in 
the supernatant of the Wnt3a-expressing L-cells (Figure 5C). However, 
Tunicamycin-induced ER-stress significantly reduced the levels of Wnt3a 
in the supernatant by 10 fold (P<0.001) (Figure 5C). Hence, we provide 
mechanistic evidence that ER stress can affect production of growth factors 
needed for stem cell homeostasis. To investigate the effect of ER-stressed 
Paneth cells on the intestinal stem cell compartment in patients, the aamount 
of stem cells (PHDLA1+ cells) and the number of Paneth cells per crypt 
were measured (Figure 4). The number of stem cells per crypt did not differ 
between the groups, AA(-) 4.0; GA(-) 3.4; GA(+) 4.0; GG(-) 3.6; GG(+) 3.2; 
P=0.79. (Figure 4D) Furthermore, the amount of Paneth cells per crypt was 
also not affected by either ATG16L1 mutation, or ER stress+ Paneth cells, 
AA(-) 6.2; GA(-) 6.5; GA(+) 6.6; GG(-) 6.7; GG(+) 5.6; P=0.92 (Figure S2B). In 
the same way, the amount of Paneth or stem cells is similar when selecting for 
biopsies without ER stressed Paneth cells or with ER-stressed Paneth cells 
(Figures S2C and S2D). From these data we conclude that the ER-stressed 
Paneth cells do not affect the small-intestinal stem cell compartment and 
thus the effects seen on crypt inflammation most likely can be attributed to 
diminished antimicrobial activity of the Paneth cell, whereas the effects on 
stem cell niche function are less important. 
No difference in IEC apoptosis or proliferation in patients with ER-
stressed Paneth cells
In apparent agreement with this notion were experiments in which we 
investigated the functional effects of the observed ER-stressed Paneth cells 
in vivo. We first determined the amount of apoptotic (cleaved-caspase 3) and 
proliferating (pHiston 3H) IEC per crypt. No cleaved-caspase 3 was detected 
in the crypts of any of the biopsies, irrespective of ER-stressed Paneth cells 
(Figure 6A). In all the biopsies, again irrespective of the presence of ER-
stressed Paneth cells, identical numbers of cleaved-Caspase 3 positive cells 
were detected at the top of the villi (Figure 6B). 
Figure 4: NF-kB (p65) IHC and detection of intestinal stem cells 
(A) Cross-sections as used in Figure 1A, now stained for NF-kB subunit p65, phospho-p38MAPK, and 
PHLDA1. The red-brown immune reactivity represents positive expression. Original magnification 
1000x.
(B) Overall p65 immunereactivity presented in a graph. All tissue specimens were scored in a blinded 
fashion as basal, mild increased, increased, or strong increased according the amount of positive p65 
immune reactivity. The graph represents the percentages of tissue samples in with a particular score, 
subdivided into samples without ER stressed Paneth cells (ER stress (-)) and samples with ER stressed 
Paneth cells (ER stress (+)). ** P<0.01
(C) Phospho-p38 immunereactivity presented in a graph. All tissue specimens were scored as percentage 
positive cells per crypt. The graph represents the average parentage per group, error bar is SEM. ER 
stress (-) and samples with ER stressed Paneth cells ER stress (+).
(D) Amount of stem cells per crypt. All crypts base PHLDA1 positive cells from at least 20 crypts of 
each tissue specimen were counted. AA(-): ATG16L1 (T300A) AA allele without ER stressed Paneth cells, 
GA(-): GA allele without ER stressed Paneth cells, GA(+): GA allele with ER stressed Paneth cells, GG(-): 
GG allele without ER stressed  Paneth cells, GG(+): GG allele with ER stressed Paneth cells. The graphs 
represent the mean +\- S.D. and n.s. is not significant. 
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Figure 5: In-vitro Wnt3a production in L-cells with and without ER stress
(A) XBP1 mRNA splicing. From L-cells and Wnt3a producing L-cells, un-stimulated, stimulated with 
DMSO, or with 2mM Tunicamycin for 18 h, XBP1 mRNA splicing was determined. The ratio un-spliced 
(U) spliced (S) XBP1 were plotted. Ctr depicts un-stimulated cells, DMSO are cells stimulated with the 
same concentration DMSO as the Tunicamycin stimulated cells. The gel is a representative image of 
two independent experiments and the graph represents the mean +/- S.D. band-intensity of the two 
independent experiments. 
(B) GRP78 and CHOP mRNA expression. The same mRNA samples as used in (A) were used to measure 
the mRNA expression of GRP78, CHOP and Wnt3a by quantitative RT-PCR. N.D. is not determinable. 
(C) Wnt3a protein production. Conditioned medium from the cells as used in (A) was used in the 
b-Catenin reporter assay. b-Catenin reporter activity is measured and presented in a graph as relative 
fluorescence units (RFU). ***P<0.001
The amount of pHiston 3H positive cells per crypt did not significantly 
differ between the geno- and phenotypes (AA(-) 1.3; GA(-) 1.1; GA(+) 1.2; 
GG(-) 1.5; GG(+) 0.9; p=0.84, see Figures 6C and 6D). These results 
show that the ER-stressed Paneth cells are not apoptotic themselves nor 
do they seem to affect apoptosis or proliferation of other IEC in the crypt 
and demonstrate that intrinsic defects in Paneth cell functionality probably 
underlie the ATG16L1 SNP phenotype.
Clinical differences in patients with ER stressed Paneth cells  
Although no obvious cellular differences were detected between the 
biopsies without ER-stressed Paneth cells (ER stress (-)) and the biopsies 
with ER-stressed Paneth cells (ER stress (+)), this does not rule out possible 
enhanced susceptibility for developing CD or disease severity in these 
patients, due to impeded Paneth cell function. The clinical characteristics of 
78 patients with inactive disease were analysed, 54 ER stress (-) CD patients 
and 24 ER stress (+) CD patients. In general the demographic characteristics 
were not significantly different between the two patient groups (Table S2). To 
investigate the clinical disease severity we collected the patient characteristics 
according to the Montreal classification (Tables 1A and 1B). As mentioned 
above colonic CD occurred less often in ER stress (+) (17%) than ER stress 
(-) CD patients (38%, P=0.044) (Figure 1F and Table 1). We also observed a 
significant difference in the number of fistula between the ER stress (-) (20%) 
and ER stress (+) (41%) CD patients (P=0.050). In addition, far less ER stress 
(-) patients underwent intestinal surgery (54%) than the ER stress (+) (92%) 
CD patients (P=0.002), irrespective of the disease duration (Table S3). Hence, 
we can concluded that the ER-stressed Paneth cell phenotype is associated 
with a generally more complicated disease course, occurring predominantly 
in the small intestine, and requiring surgery more often. 
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Figure 6: IEC apoptosis and proliferation.
(A) Cleaved-caspase 3 as apoptosis marker. Cross-sections as used in Figure 1A, now stained for cleaved-
caspase 3. ER stress (-) represents the CD patient group without ER-stressed Paneth cells and ER stress 
(+) represents the CD patient group with ER-stressed Paneth cells. Original magnification 1000x. 
(B) Apoptosis, only in the villi tips. The same tissue specimens as used in (A) are presented. Immune 
reactivity represents apoptotic cells, cleaved-caspase 3. Original magnification 200x, magnification of 
enlarged section 400x. 
(C) Proliferation in the trans-amplifying cells. Cross-sections as used in Figure 1A, now stained for 
pHiston 3H. Original magnification 1000x. 
(D) Quantification of crypt cell proliferation. All pHiston 3H positive and negative cells from 20 crypts of 
each tissue specimen were counted. AA(-): ATG16L1 (T300A) AA allele without ER stressed Paneth cells, 
GA(-): GA allele without ER stressed Paneth cells, GA(+): GA allele with ER stressed Paneth cells, GG(-): 
GG allele without ER stressed Paneth cells, GG(+): GG allele with ER stressed Paneth cells. The graph 
represents the mean +\- S.D. * p<0.05
Discussion 
Various SNPs strongly associated with CD seem to affect bacterial/viral 
sensing (NOD2), ER stress (XBP1, ORMDL3) and autophagy (ATG16L1, 
IRGM) all of which are of crucial importance to normal Paneth cell function. 
In this study we provide in vivo evidence for the convergence of these different 
pathways by the detection of ER stress in Paneth cell in a subset of the CD 
patients carrying the ATG16L1 T300A risk allele (G). 
A previous study performed in seven GG allele CD patients reported 
earlier that the ATG16L1 mutant genotype coincided with a particular 
Paneth cells phenotype, comprising of granule abnormalities7. Autophagy 
has been implicated as a crucial part of normal ER function and homeostasis, 
helping the ER recover from stress17. Autophagy can provide an additional 
degradation pathway for misfolded proteins or degrade damaged parts of 
the ER itself. This intimate relationship between autophagy and ER stress 
suggests that defects in autophagy may induce ER stress directly or hamper 
the recovery from stress. In the current study we show the occurrence of ER 
stress in Paneth cells in a subset of the patients and healthy controls carrying 
an ATG16L1 risk allele (G). Of note, we have recently demonstrated that 
histological assessment of ER stress by using the GRP78 protein marker, is 
a sustainable methodology to determine modulation in the protein folding 
machinery10. Our ER stressed Paneth cell finding was not linked to SNPs 
in other possible ER stress-associated genes such as, XBP1, NOD2, and 
IRGM, nor to active inflammation induced ER stress10, 18, 19. Therefore we 
hypothesised that the ER stress observed in Paneth cells results from a 
hampered recovery from stress or the increased demand for (antimicrobial) 
proteins downstream of NF-kB activation16, 20. Paneth cells stained negative 
for nuclear NF-kB subunit p65. Since ER stress pathways can also activate 
the NF-kB pathway (reviewed in21), our data suggest that this pathway is 
not activated in the ER stressed Paneth cells. This conclusion was further 
strengthened by the lack of increased nuclear phospho-p38 expression. In 
addition the ER stressed Paneth cells from the healthy controls also indicate 
that the ER stress is independent of subclinical inflammation. The overall 
p65 intensity was significantly higher in the crypts with ER-stressed Paneth 
cells, despite the fact that all our biopsies were histologically inactive. This 
can indicate that either the ER stressed Paneth cells excrete more pro-
inflammatory cytokines or due to decreased antimicrobial Paneth cells 
function more microbial ligands reach the crypts22. 
The function and differentiation of highly secretory cells such as Paneth 
cells and goblet cells depend strongly on a tight basal ER stress balance6, 7, 11, 
23. Genetic variations (e.g. NOD2, XBP1, and ATG16L1) and environmental 
conditions such as inflammation and ischemia can easily disturb this balance, 
what can result in cellular dysfunction and even apoptosis5-7, 24. Mutations 
in the NOD2 gene, one of the other important pathways in Paneth cell 
function, are associated with decreased defensin production5. In addition, 
in Paneth cells of severely obese individuals lower levels of defensins and 
lysozyme were found, which was associated with enhanced ER stress25. 
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Using immunohistochemistry no obvious difference in lysozyme expression 
was detected in the ER-stressed Paneth cells. The lack of low levels of 
inflammation that is associated with severe obesity may be one of several 
explanations for this difference. If there are differences in the amount of 
defensins or lysozyme at all, the abundant lysozyme expression could make it 
difficult to detect the subtle differences. Furthermore, the ER stress response 
may be part of the high translational activity in the cell and thereby not 
affecting the protein expression and function. Unfortunately, faecal sampling 
was not part of this study and we can therefore not report on any potential 
shift in microbial compositions previously associated with Paneth cells defects 
and Crohn’s disease26, 27. 
Activated ER stress pathways can initiate apoptosis (reviewed in11, 24, 
28). Moreover, intestinal-ischemia activated ER stress induces Paneth cell 
specific apoptosis24. However, no apoptotic (cleaved-caspase 3) cells could be 
found in our biopsies with or without ER-stressed Paneth cells, and similar to 
the results in obese patients with ER-stressed Paneth cells, we also detected 
no differences in Paneth cell numbers25. This suggests that either the ER-
stressed Paneth cells are able to cope with certain ER stress levels, or other 
environmental factors influence whether ER stress can lead to cell death11, 25. 
Recently Paneth cells have been described as important growth factor-
producing cells29, which maintain the intestinal crypt base structure by 
influencing stem cell homeostasis2. As we show that ER stress strongly 
reduced the Wnt3a production in vitro we hypothesised that ER-stressed 
Paneth cells could affect the intestinal stem cell population. Using a recently 
described human stem cell marker30 we could detect slim cylinder-shaped 
cells at the crypt base. However, no difference in amount of stem cells was 
detected between the different patient groups. This indicates that the ER-
stressed Paneth cells are mildly affected, since severe Paneth cells dysfunction 
leads to intestinal growth malfunctions31 and spontaneous enteritis6. Biopsies 
with ER-stressed Paneth do not have a different amount of proliferating 
cells (pHiston 3H) compared to biopsies without ER-stressed Paneth cells. 
Since the stem cells divide slowly, we may not have been able to pick up 
any differences. Furthermore, the majority of the pHiston 3H positive cells 
are IEC part of the trans-amplifying domain. These cells are not in direct 
contact with the Paneth cells, and therefore likely not or less affected by the 
ER-stressed Paneth cells. The ER-stressed Paneth cells do not hamper the 
intestinal epithelium in inactive CD patients, which corresponds with the 
normal crypt structures in our non-active patients. 
So, although no major histological differences could be detected between 
the tissue samples with or without ER-stressed Paneth cells, we found distinct 
clinical differences between the patient groups. The ER stress (+) CD patients 
have less colonic disease than the ER stress (-) CD patients, which is in line 
with the observation that XBP1-/- mice develop spontaneous inflammation in 
their ileum, due to impeded Paneth cell function6. The ER stress (+) patients 
have more fistulas than the ER stress (-) patients. Since microbes seem to 
be involved in the aetiology of these fistulas32, our observation reveal an 
impeded anti-microbial function of the Paneth cells in the ER stress (+) CD 
patients. Finally, ER stress (+) CD patients more often required intestinal 
surgery. Interestingly, a resent publication also associates a mutation in 
IRGM, another autophagy related gene, with an increased need for intestinal 
surgery in risk allele carrying CD patients33. 
Together our data provide in vivo evidence for the interrelationship 
between autophagy and ER stress in Paneth cells of CD patients. The lack 
of crypt abnormalities combined with the on average more complicated 
course of disease suggest that ER stress is probably sensitizing the Paneth 
cells for further insults and may hamper recovery to normal function after 
inflammation. As such, ER stress resolution or prevention should carefully be 
considered as CD therapy. Recent studies with a specific ER stress inhibitor 
have demonstrated an effect in ER-stressed IEC34. However, future research 
is needed to explore the possibilities of ER stress inhibitors as therapeutic 
target for CD patients with the ATG16L1 risk allele. 
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Letter to the Editor
We read with interest the paper from Muise et al. in which they describe a 
rare variant in the NCF2 gene, which demonstrates a diminished RAC2 binding 
capacity.1 The NCF2 encoded protein p67phox is one of the components of 
the NADPH oxidase complex which drives the production of reactive oxygen 
species (ROS) during the bactericidal response of innate immune cells. 
Output of disturbed granulocytic ROS as a result of impaired functioning 
of this enzyme complex has been shown in a number of diseases, including 
myelodysplasia (MDS) and chronic granulomatous disease.2,3 As Muise and 
colleagues point out, these diseases have been linked to development of a 
colitis resembling that seen in Crohn’s disease (CD), suggesting a potential 
role for impaired ROS production in CD pathology.
Genome-wide association studies (GWAS) are a promising tool to 
identify genetic variants of genes linked to an increased risk of developing 
CD. Amongst the single nucleotide polymorphisms (SNPs) identified so far 
is a T to C substitution in intron 1 of NCF4, encoding the p40phox NADPH 
protein. Association of this SNP, rs4821544, with ileal CD was confirmed by 
Muise et al. However, although in general much is made of the importance 
of GWAS-identified risk- conferring SNPs in patients, it remains as yet 
unclear how these SNPs affect patient cell function, as functional studies 
are mostly lacking. Although Muise and colleagues very clearly show that a 
non-synonymous mutation in NCF2 affects its interaction with RAC2, their 
paper provides no direct proof that this affects granulocytic ROS production. 
Although making a good case, the fact that the c.113 G/A mutation is so rare 
(they were only able to measure ROS in one patient bearing this mutation), 
impedes conclusions about its general role in CD occurrence.
To further examine the potential of SNP variants in NADPH oxidase 
genes to confer a functional consequence in CD, we have investigated 
granulocyte ROS production in patients with CD bearing either the NCF4 
risk allele (C), or patients homozygous for the non-risk allele (T). Patient 
characteristics (age, treatment, disease location, gender, fistulisation) were 
identical between the two groups (not shown). We observed no differences 
in N-formyl-methionyl-leucyl-phenylalanine (fMLP)-triggered intracellular 
ROS production between carriers and non-carriers of the risk allele. However, 
fMLP-induced ROS production was significantly lower in granulocyte-
macrophage colony-stimulating factor-primed neutrophils from patients 
with CD with an NCF4 mutation (figure 1). These results are consistent with 
previous studies, showing that p40phox is important for intracellular ROS 
production in response to certain triggers such as phagocytosis, but plays 
a smaller role in phorbol myristate acetate-induced or fMLP-induced ROS 
production.3 We observed no differences in granulocyte respiratory burst 
when patients were stratified according to ATG16L1 (rs10210302, rs2241880), 
IRGM (rs13361189) or NOD2 (rs2066844, rs2066845, rs2066847) SNP 
variants (data not shown).
As Muise and colleagues point out, the association between NCF4 and 
CD is not found in all GWAS studies. However, the rs4821544 SNP may 
define a subgroup of patients who develop CD in part as consequence of 
defective granulocyte ROS production. This may also explain why some 
studies find impaired ROS production in patients with CD, whereas others do 
not; none of these studies have stratified their patients according to genetic 
risk factors. Obviously, carrying the rs4821544 cannot be the only factor 
involved in development of CD, as healthy people also bear this mutation. 
However, impaired bacterial clearance in patients carrying this risk allele 
may contribute to the risk of getting CD.
Our results demonstrate for the first time that risk-conferring SNPs 
within the NADPH oxidase machinery lead to functional alterations in 
granulocyte ROS production in patients with CD. These data also show that 
although many of the SNPs found to be linked to CD, including rs4821544, 
are synonymous, they may nevertheless convey functional consequences.
 
Acknowledgements: The authors thank all participating patients.
Figure 1. fMLP-stimulated ROS production is decreased in GM-CSF-primed neutrophils from CD 
patients bearing the NCF4 risk allele (C:T). Freshly isolated granulocytes were pretreated with 5 ng/
mL GM-CSF and stimulated with 1 μM fMLP for 30 minutes. Intracellular ROS production was measured 
by Dihydro-rhodamine 123 assay as described4 and the increase in intracellular ROS as result of 
stimulation was presented as a percentage of control (unstimulated cells). The mean ± SEM values of C:T 
heterozygous (n=10) and T:T homozygous (n=8) CD patients is shown. Mann-Whitney test for unpaired 
samples was performed. Significant differences were also observed when GM-CSF-primed cells were 
stimulated with fMLP for 15 minutes (not shown). 
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Summary and Conclusions 
The intestinal epithelial cells (IEC) are indispensable factors in the host 
protection against the harmful luminal content. In this thesis we aimed 
to gain further insight in the role of  IEC in the IBD aetiology, since it is 
an important mediator between the already known factors that give onset 
of  IBD1. The importance of  this single cell layer in health and disease 
is summarised in Chapter II. In short, direct links between the innate 
immune system and IEC are described. Genetic predispositions in genes 
associated with IBD can have modulatory effects on IEC function. Various 
environmental factors such as diet, intoxications, drugs and pathogens have a 
direct effect on the IEC barrier function. These changes are closely related to 
the microbial composition in the gut, which also modulates the IEC function. 
We concluded from this review that the function of  IEC in the IBD aetiology 
is of  utmost importance and that proper IEC function is needed to prevent 
disease flares. This latter suggests that manipulation of  certain pathways 
may be interested targets of  therapy to get actively inflamed IBD patients 
in remission.
To investigate the IEC involvement in IBD we stimulated freshly isolated 
biopsies from CD patients with PXR ligands (rifampicin2, IEC specific) to 
inhibit the NF-kB (inflammatory key regulator3) signalling (Chapter III). 
Recently it was shown that in CD patients with quiescent disease PXR 
activation can reduce LPS-induced NF-kB activity in human IEC4. As such 
artificial inflammation induced by LPS stimulation may not necessarily relate 
to NF-kB signalling in active IBD. To investigate this we assessed the anti-
inflammatory effects of  activated PXR in active IBD by measuring NF-kB 
activity in freshly isolated biopsies. The expression of  NF-kB regulated 
cytokines was lower in our rifampicin-stimulated biopsies than in the non-
stimulated biopsies. However, further analysis of  the data uncovered that 
the presence of  PXR was more important than the actual PXR activation 
to inhibit the NF-kB activity. This observation was confirmed in in vitro 
experiments using stable PXR knock down cell lines. Complete reduction 
of  NF-kB signalling is fatal for IEC5, so delegate repression of  the NF-kB 
pathway is required. Hence, compounds that increase the PXR expression 
to safely inhibit the inflammatory NF-kB activity in IEC could be seen as a 
novel therapeutic approach.  
It becomes increasingly clear that the function of  PXR goes beyond its 
primary function in the xenobiotic detoxification pathways. As such, PXR 
also has a modulatory function in the proliferation and apoptosis of  intestinal 
cancers. However, there are no conclusive results about the expression of  PXR 
in cancers and its exact role in proliferation and apoptosis6-9. To investigate 
the expression of  PXR and its function in cancer cell growth, we measured 
the expression of  PXR in biopsies from IBD and IBD-CRC (Chapter 
IV). We found high PXR expression present exclusively in the neoplastic 
intestinal epithelium, whereas no PXR protein could be detected in normal 
or inflamed intestinal tissue. In vitro experiments uncovered that this high 
PXR expression reduces the growth speed of  the cells but increases the high 
cell density survival. Thus, the high PXR expression found in the biopsies 
could give the cells an advantage in surviving high cell densities. A common 
given chemotherapy for intestinal cancer is 5-FU. Despite the specificity of  
5-FU the response rate to this compound, if  given as first line therapy, is 
only 10-15% and decreases even further in severe metastatic disease10. We 
hypothesised that the cancer cells without PXR expression would respond 
better to the 5-FU treatment, since highly proliferative cells are more 
sensitive to 5-FU10. However, we found no difference in survival between the 
cells that express PXR and its PXR knock down counterpart by using 5-FU 
stimulation. This lack in difference may be a consequence of  the induced 
expression of  multi-drug resistance proteins such as, ABCG211, 12. Indeed 
the expression of  multi-drug resistance proteins was increased in these cells, 
irrespective of  PXR activation. In conclusion, PXR is abundantly expressed 
in human intestinal cancers irrespective of  the cancer origin or intestinal 
location. High PXR expression reduces cancer cell proliferation, improves 
high cell density survival, but in our in vitro models PXR expression is not 
influencing the chemotherapy resistance. With respect to the PXR mediated 
reduced cell survival, a therapeutic approach to inhibit the PXR expression 
in intestinal cancer is a promising area for further investigation. 
Thus, proper cellular responses to xenobiotic insults go beyond the 
simple induction of  detoxification enzymes but also include the modulation 
of  pathways associated with further damage (e.g. the generation of  cytokines) 
and the facilitation of  regenerative responses to repair tissue damage.
IEC and their protein folding problems 
Proper functioning IEC are depending on correctly folded and expressed 
proteins. Secreted and membrane bound proteins are mainly synthesised and 
folded in the endoplasmic reticulum (ER). Folding difficulties of  these proteins 
leads to accumulation of  unfolded proteins inside the ER, which activates 
the ER associated degradation (ERAD) pathways. Activation of  autophagy, 
engulfment and degradation of  cellular components is part of  the ERAD 
pathway. Several factors can provoke protein misfolding, e.g. toxins, reactive 
oxygen species (ROS), cytokines and genetic mutations. In IBD patients 
with active intestinal inflammation increased levels of  cytokines en ROS 
are measured. The consequence of  these increased levels on ER depending 
protein folding is discussed in Chapter V. In this chapter we postulated a 
plausible explanation why some ER-dependent proteins, are decreased in 
expression during active inflammation, with ABCG2 as an example. The 
ABCG2 protein function and membrane localisation is dependent on post-
translational protein modifications inside the ER, such as disulphide bridges13 
and n-glycosylation14. The creation of  these modifications is sensitive to 
high ROS levels. Hence, we hypothesised that the decreased expression of  
ABCG2 during active IBD might be due to the impeded protein folding by 
the high levels of  ROS. This hypothesis was tested in Chapter VI. Firstly, we 
confirmed that the ABCG2 membrane expression is decreased during active 
intestinal inflammation irrespective of  intestinal location and disease type. 
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This decrease in expression correlated with an increase in GRP78 expression, 
a histological marker for ER stress, in the IEC. Secondly, we functionally 
supported our hypothesis by stimulating GFP-ABCG2 expressing cells 
with nitric oxide (NO), an ER stress inducer and major component of  the 
inflammation produced ROS. These NO-stimulated cells have ER stress 
and reduced membrane bound ABCG2 expression and function. Thus, ER-
dependent proteins are impeded in their expression and function due to 
elevated ROS production during active inflammation. 
Another possible factor that can provoke protein folding problems are 
genetic mutations in genes involved in (XBP115) and ERAD (NOD216, 17, 
ATG16L118, IRGM19, ) pathways. A single nucleotide polymorphism (SNP) 
in an autophagy related gene (ATG16L1, T300A, rs2241880) is associated 
with an increased risk for developing CD18. A modulated Paneth cell 
morphology was found in mice, genetically modified to express the human 
ATG16L1 risk allele in their IEC specifically,  and human in IBD patients 
with the  ATG16L1 (T300A) SNP20. Autophagy has been implicated as a 
crucial part of  normal ER function and homeostasis, helping the ER recover 
from stress21. Autophagy can provide an additional degradation pathway 
for misfolded proteins or degrade damaged parts of  the ER itself. This 
intimate relationship between autophagy and ER stress suggests that defects 
in autophagy may induce ER stress directly or hamper the recovery from 
stress. In Chapter VII we showed the occurrence of  ER stress in Paneth 
cells in a subset of  the patients carrying an ATG16L1 risk allele (G). As 
discussed in Chapter II, Paneth cells are protective cells located in the small 
intestine at the crypt base. These cells produce anti-microbial substances 
such as defensins and lysozyme, but also produce growth factors that are 
indispensable for the intestinal stem cell niche22-24. Hence, we hypothesised 
that these ER stressed Paneth cells are deficient in producing ER depending 
proteins such as lysozyme and growth factors. Although, we were enable to 
detect any histological difference in the patients with ER stressed Paneth 
cells, these patients with ER stressed Paneth cells tend to have a more 
severe disease course. Together our data provide in vivo evidence for the 
interrelationship between autophagy and ER stress in Paneth cells of  CD 
patients. The lack of  crypt abnormalities combined with the on average more 
complicated course of  disease suggest that ER stress is probably sensitizing 
the Paneth cells for further insults and may hamper recovery to normal 
function after inflammation. Together, our data provide in vivo evidence for 
the interrelationship between autophagy and ER stress in Paneth cells of  
CD patients. 
To further explore the role of  SNP in CD patients we investigated 
in our final chapter (Chapter VIII) the role of  a synonymous SNP in the 
NCF4 gene (rs482154425) in the ROS production. Excessive mucosal ROS 
production can lead to impeded ER-dependent protein folding (Chapter V 
and VI), on the other hand diminished ROS production can lead to impaired 
bacterial clearance resulting in mucosal inflammation26. Interestingly, both 
scenarios are CD-associated, thus proper ROS production is essential for 
a normal gut homeostasis. As such, we measured the ROS production in 
granulocytes of  CD patients with and without the risk allele. Activated 
granulocytes from CD patients with the NCF4 risk allele have lower ROS 
production than the non-risk allele carriers. Our results demonstrate for the 
first time that risk-conferring SNPs within the NADPH oxidase machinery 
lead to functional alterations in granulocyte ROS production in patients with 
CD. These data also show that although many of  the SNPs found to be linked 
to CD, including rs4821544, are synonymous, they may nevertheless convey 
functional consequences.
Future perspectives
The IEC have an indispensable role in the aetiology of  IBD. However, 
further research is needed to completely understand their exact mechanism 
of  action. Although, we show that the presence of  PXR can inhibit the NF-
kB activity, it will be of  great interest to find other NR family members that 
also can modulate the NF-kB function. If  this process is better understood 
possible novel therapies could be implicated. However, certain notice should 
be taken in account since PXR expression also enhances high cell density 
survival. Thus, better understanding of  the function of  PXR in IEC is 
essential for possible further clinical implication. 
We have shown in this thesis that inflammatory compounds, such as ROS, 
can modulate the expression of  the membrane bound protein ABCG2. It will 
be of  great value to verify the expression of  other ER-depending proteins 
such as defensins, mucus, growth factors, and bacterial ligand receptors in 
this respect during active intestinal inflammation. Especially since recent 
studies already describe a modulated expression pattern of  these proteins 
during active IBD.   
GWAS associated many genomic variations to a higher risk for 
developing IBD, however experimental evidence to show a causal relation is 
majorly lacking. Thus, future IBD research should and probably will focus 
on the biological consequence of  these SNP linked to IBD. In this thesis we 
already linked two SNPs to two new specific phenotypes, e.g. ATG16L1 and 
NCF4. As there was no other histological correlation with the ER stressed 
Paneth cell in ATG16L1 T300A patients, detailed expression profiles of  the 
Paneth cells and a prospectively followed patient cohort should uncover the 
biological consequence of  the ER stressed Paneth cells. 
In conclusion
Overall we conclude that, the intestinal epithelium has a distinct 
function in the aetiology of  IBD patients on many disease-associated factors. 
This thesis justifies the extensive investigation of  IEC driven therapeutic 
approaches for IBD patients. To even better understand the gut-modulatory 
function of  IEC, further research should focus on the function of  IEC during 
the early stage of  the disease. 
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De enkelvoudige cellaag tussen de darminhoud en mucosa (intestinale 
epitheel cellen, IEC) spelen een onmisbare rol in het ontstaan en de 
behandeling van patiënten met IBD. Het doel van ons onderzoek, zoals 
beschreven in dit proefschrift, was om een duidelijker beeld te krijgen van 
de functie van IEC in de etiologie van IBD. Uit eerder onderzoek is gebleken 
dat IBD kan voortkomen als de volgende factoren samenkomen: genomische 
variaties, intestinale microbiome, overactief  immuunrespons en ongunstige 
omgevingsfactoren. Een belangrijke tussenspeler in deze factoren zijn de 
IEC. Het belang van de IEC bij IBD hebben wij samengevat in Chapter 
II. In dit hoofdstuk beschrijven wij o.a. de rol van IEC bij immunologische 
processen, de consequentie van genetische mutaties op het functioneren van 
IEC, het effect van dieet en omgevingsveranderingen op IEC en het effect van 
bacteriën op IEC. Naar aanleiding van dit review kunnen wij concluderen dat 
gezonde IEC onmisbaar zijn voor een goed werkend maag- en darmkanaal. 
In Chapter III beschrijven wij een alternatieve functie voor de nucleaire 
receptor, de Pregnane X Receptor (PXR), in IEC uit verse darmbiopten 
van Crohn’s disease (CD) patiënten. PXR staat bekend als receptor voor de 
detectie van toxische stoffen. Daarnaast heeft recent onderzoek uitgewezen 
dat activatie van PXR kan leiden tot verlaging van de activiteit van NF-
kB (sleutelregulator bij cellulaire immuunreacties). Echter bleek uit onze 
experimenten dat niet de activatie van PXR, maar de aanwezigheid van 
PXR belangrijk is voor de verlaging van de NF-kB activiteit. Hieruit volgt 
dat het verhogen van de PXR expressie kan worden gezien als een nieuwe 
therapeutische mogelijkheid. Door onder meer dit hoofdstuk is het duidelijk 
dat de functie van PXR verder gaat dan zijn primaire detoxificatie taken. Als 
zodanig is er in de literatuur geen eenduidige conclusie over de functie van 
PXR bij kanker-celdeling (proliferatie) en celdood (apoptose). Daarom hebben 
we in Chapter IV de expressie en functie van PXR in IEC onderzocht tijdens 
de vorming van darmkanker, al dan niet gerelateerd aan IBD. In IEC van 
normaal of  ontstoken darmweefsel is geen PXR expressie detecteerbaar in 
zowel de dunne als de dikke darm. Alleen tijdens de vorming van darmkanker 
hebben we, al vanaf  een vroeg stadium (HGD), een hoge PXR expressie 
gemeten. Uit daaropvolgende in vitro experimenten bleek dat deze hoge PXR 
expressie de proliferatie iets vertraagd, maar wel de overleving van de cellen 
bevordert bij hoge celdichtheden. Uit de daaropvolgende chemoresistentie 
proeven bleek echter dat er geen verschil is in de chemo-overleving van 
de IEC met hogere PXR expressie. Hieruit kunnen we concluderen dat 
darmkankercellen een hoge PXR expressie hebben, welke zorgt voor een 
betere overleving bij hoge celdichtheden. Het verlagen van de PXR expressie 
in kankercellen zou hieruit volgend een nieuwe therapeutische mogelijkheid 
kunnen zijn. 
IEC en hun eiwit vouwingsproblemen
Goed functionerend darmepitheel hangt of  staat bij correct gevouwen 
eiwitten. Membraan gebonden en uitgescheiden eiwitten worden in 
het endoplasmatische reticulum (ER) gecreëerd en gevouwen. Bij 
eiwitvouwingsproblemen (ER stress) stapelen de niet (goed) gevouwen 
eiwitten op in het ER, waardoor het ER geassocieerde degradatie systeem 
(ERAD) wordt ingeschakeld. Een belangrijk onderdeel van de ERAD is het 
opnemen en afbreken van een gedeelte van het ER. Dit proces heet autophagy. 
Factoren, zoals toxines, zuurstofradicalen (ROS), cytokines, en genetische 
mutaties, kunnen leiden tot eiwitvouwingsproblemen. Tijdens actieve 
ontsteking in patiënten met IBD is er een verhoogde expressie van cytokines 
en ROS gemeten. De consequentie van deze verhoogde aanwezigheid op de 
eiwitvouwing in IEC is beschreven in Chapter V. In dit hoofdstuk beschrijven 
wij een mogelijk model waarom de expressie van ER afhankelijke eiwitten 
in IEC verlaagd is tijdens actieve ontsteking, bijvoorbeeld van ABCG2. De 
activiteit van de membraangebonden transporter, ABCG2, is afhankelijk 
van modificatie in het ER, zoals de n-glycosilatie en de vorming di-sulfiet 
bruggen. De vorming van deze eiwitmodificaties kan worden geremd 
door hoge ROS concentraties. Daardoor kwamen wij op de hypothese dat 
problemen met de eiwitvouwing zorgt voor de afwezigheid van ABCG2 
expressie tijdens actieve ontsteking in IBD patiënten. Deze hypothese hebben 
wij experimenteel onderbouwd in Chapter VI. Eerst hebben wij bevestigd 
dat er geen detecteerbare ABCG2 expressie is tijdens actieve ontsteking, 
zowel in de dunne als de dikke darm. Deze verlaging is gecorreleerd aan een 
verhoogde GRP78 expressie. Hoge GRP78 expressie staat voor ER stress. 
Daarna is met behulp van in vitro experimenten aangetoond dat de ABCG2 
expressie en zijn functie kan worden verhinderd door ROS geïnitieerde ER 
stress. Deze experimenten laten zien dat ER afhankelijke eiwitten gevoelig 
kunnen zijn voor hoge ROS concentraties met verminderde functie tot gevolg. 
Hieruit kunnen we concluderen dat de verlaagde ABCG2 eiwit expressie 
tijdens actieve darmontsteking mogelijk komt door de aanwezige hoge ROS 
concentraties. 
Een andere mogelijke factor die eiwitvouwing kan verhinderen 
zijn mutaties in genen die betrokken zijn in de ER stress (XBP1) of  
ERAD (ATG16L1, NOD2, IRGM) signaalroutes. Een enkelvoudige 
nucleotideverandering (single nucleotide polymorphism, SNP) in een 
autophagy gerelateerd gen (ATG16L1, T300A, rs2241880) is geassocieerd 
met een verhoogde kans op het krijgen van IBD. In een eerder onderzoek is 
een morfologische verandering in Paneth cellen beschreven van CD patiënten 
met een SNP in het ATG16L1 gen. Omdat er een belangrijke relatie bestaat 
tussen ER stress en autophagy hebben wij gekeken naar de expressie van 
ER stress markers (GRP78) in darmweefsel van CD patiënten met en 
zonder de ATG16L1 mutatie. De GRP78 expressie was verhoogd specifiek 
in de Paneth cellen van patiënten met de ATG16L1 mutatie. Er zijn geen 
verdere pathologische verschillen gekoppeld aan de ER gestreste Paneth 
cellen. Echter zijn er duidelijke aanwijzingen dat patiënten met ER gestreste 
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Paneth cellen een moeilijker te behandelen ziekte hebben. Het gebrek aan 
histologische afwijkingen gecombineerd met een moeilijkere te behandelen 
ziekte wijst erop dat de Paneth cellen gevoeliger zijn voor schade en dat ze 
daardoor de herstelfase na een ontsteking remmen. Samenvattend hebben wij 
met dit hoofdstuk experimenteel bewijs geleverd voor de relatie tussen ER 
stress en autophagy. 
In het laatste hoofdstuk (Chapter VIII) hebben wij de rol van SNP van 
CD patiënten verder onderzocht. In dit hoofdstuk onderzoeken wij het effect 
van mutatie in het NCF4 gen (rs4821544) op de ROS productie. Extreem 
hoge ROS productie kan leiden tot verminderde eiwitvouwing (Chapter 
V and VI), maar te lage ROS productie kan juist leiden tot verminderde 
verwijdering van bacteriën wat mogelijk resulteert in een ontsteking. Beide 
scenario’s zijn geassocieerd met CD, waaruit blijkt dat een normale ROS 
productie essentieel is voor een gezonde darm. Vanwege dit gegeven hebben 
wij de ROS productie gemeten in granulocyten van CD patiënten met en 
zonder de NCF4 mutatie. De geactiveerde granulocyten van CD patiënten 
met de NCF4 mutatie produceren minder ROS dan granulocyten van de 
niet-gemuteerde CD patiënten. Deze resultaten laten zien dat een SNP in 
de NADPH oxidatie mechanisme kan leiden tot een vermindering in de ROS 
productie bij CD patiënten. Daarnaast blijkt hieruit ook dat de synonymous 
(non-coding) SNP belangrijk kunnen zijn in de functie van een gen. 
De conclusie
Het wordt steeds duidelijker dat het darmepitheel op veel verschillende 
raakvlakken een erg belangrijke rol speelt in de etiologie van IBD patiënten. 
Daarnaast beschrijven wij in dit proefschrift ook enkele nieuwe mogelijke 
IEC gedreven therapieën voor IBD patiënten. Om waar mogelijk een nog 
beter beeld te krijgen van de darm modulerende functie van het darmepitheel 
moet de focus van toekomstig IBD onderzoek liggen bij het onderzoeken van 
darmweefsel van IBD patiënten vlak voor de klinische diagnose. 
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